date,username,to,replies,retweets,favorites,text,geo,mentions,hashtags,id,permalink
2020-03-06 19:37:34,GlobalMedEd,,0,1,2,"#Pimavanserin as an adjunct to #antidepressant therapy in major depressive disorder (MDD): Is it effective? http://bit.ly/21zY2Zp #nursepractitioner #mh #mhchat #psychiatry #primarycare #familymedicine #elderly #geriatrics #depression #anxiety #mentalhealth",,,#Pimavanserin #antidepressant #nursepractitioner #mh #mhchat #psychiatry #primarycare #familymedicine #elderly #geriatrics #depression #anxiety #mentalhealth,1236013071707054081,https://twitter.com/GlobalMedEd/status/1236013071707054081
2020-03-03 14:36:06,PaperbirdsN,,0,0,0,"New clinical trial: Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis http://link.paperbirds.me/RR8yzj #parkinsons #neurology",,,#parkinsons #neurology,1234850039828074496,https://twitter.com/PaperbirdsN/status/1234850039828074496
2020-03-02 00:35:03,RyznarMD,awaisaftab,4,0,3,"So Arvid Carlsson wanted everyone to know that zimelidine was discovered before fluoxetine. https://www-sciencedirect-com.proxy1.library.jhu.edu/science/article/pii/0924933896887049 This is also the history that Dr. Herbert Meltzer at @NMPsychiatry, of clozapine and pimavanserin fame, reported to me as well.",,@NMPsychiatry,,1234275993034031104,https://twitter.com/RyznarMD/status/1234275993034031104
2020-02-29 17:15:02,PCC_CNSDisord,,0,0,1,"The authors of this letter to the editor comment on a previously published report on #pimavanserin in The Primary Care Companion for CNS Disorders. http://bit.ly/2Pv4P53",,,#pimavanserin,1233802874603393025,https://twitter.com/PCC_CNSDisord/status/1233802874603393025
2020-02-27 04:24:02,stigmabase,,0,1,0,"Fighting stigma — ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results: ... study of pimavanserin for the treatment of dementia-related psychosis at the Clinical Trials on Alzheimer's Disease (CTAD) meeting on December 4, ... http://dlvr.it/RQqWqX",,,,1232884070218006528,https://twitter.com/stigmabase/status/1232884070218006528
2020-02-24 08:33:07,LC_Analysis,,0,0,0,"Analytical procedure development: Concept to application for chemometry based ultrafast LC estimation of pimavanserin in pharmaceuticals ",,,,1231859589659975681,https://twitter.com/LC_Analysis/status/1231859589659975681
2020-02-14 15:04:48,UpdatesPsy,,0,0,0,"""https://doi.org/10.1016/j.neuropharm.2020.108009 Suppression of Cocaine Relapse-Like Behaviors upon Pimavanserin and Lorcaserin Co-Administration (Anastasio et al.) Published: Feb 14, 2020 Neuropharmacology""",,,,1228334279920422914,https://twitter.com/UpdatesPsy/status/1228334279920422914
2020-02-09 16:58:51,NarcBrain,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression https://www.narcbrain.com/add-on-pimavanserin-promising-for-resistant-major-depression/",,,,1226551041551818752,https://twitter.com/NarcBrain/status/1226551041551818752
2020-02-02 17:27:04,ProfRobHoward,Suzanne04823062,2,3,23,"And, hopefully, ondansetron will turn out to have more convincing efficacy than pimavanserin in the treatment of hallucinations In Parkinson’s disease in the Top Hat trial. I’ll be playing my own small part in the study, running the Constipation Hot Line. Truly, living the dream! ",,,,1224021429492092929,https://twitter.com/ProfRobHoward/status/1224021429492092929
2020-02-02 06:36:19,realBioMassSpec,,0,0,0,"A Rapid, Simple and Highly Sensitive UPLC-MS/MS Method for Quantitation of Pimavanserin in Plasma and Tissues: Application to Pharmacokinetics and Brain Uptake Studies in Mice #JChromB",,,#JChromB,1223857661210505216,https://twitter.com/realBioMassSpec/status/1223857661210505216
2020-02-01 17:15:02,PCC_CNSDisord,,0,1,0,"The authors of this letter to the editor comment on a previously published report on #pimavanserin. ""Pimavanserin: A 2019 Clarification on the FDA Update:"" http://bit.ly/2Oci6ig",,,#pimavanserin,1223656011212435457,https://twitter.com/PCC_CNSDisord/status/1223656011212435457
2020-02-01 10:59:32,Suzanne04823062,cadoganhealthc1,0,5,12,"... just another point about ondansetron, the mechanism is different from pimavanserin, as 5HT3 receptor antagonists reduce excessive mesolimbic dopamine release and enhance cholinergic transmission in the hippocampus. Visual hallucinations are the primary focus of TOP HAT. ",,,,1223561513379733504,https://twitter.com/Suzanne04823062/status/1223561513379733504
2020-01-31 21:10:47,cadoganhealthc1,,2,1,6,"Ondansetron: 5HT-3A antagonist (looks like pimavanserin), appears to reduce VH's and paranoid ideas but RCT's needed. Rivastigmine may be useful in patient with PDP with and without dementia.",,,,1223352954981441537,https://twitter.com/cadoganhealthc1/status/1223352954981441537
2020-01-31 21:10:47,cadoganhealthc1,,1,0,5,"Pimavanserin: 5HT-2A inverse agonist licensed in US for PDP but not in Europe. Dose 34mg/d in divided doses. Takes 2-4 weeks to work. Reduce dose with CYP3A4 inhibitors.",,,,1223352953064521729,https://twitter.com/cadoganhealthc1/status/1223352953064521729
2020-01-28 11:03:18,ProfRobHoward,LonSchneiderMD,0,1,2,"Interesting (and a bit depressing) to see how Acadia present the results of this study to somehow make pimavanserin look like a credible treatment for psychosis in AD. Can’t be right to be so selective in data presentation and gives completely different impression from full set. ",,,,1222112913240088576,https://twitter.com/ProfRobHoward/status/1222112913240088576
2020-01-27 17:26:32,psychopharmacol,,0,0,0,"In patients with Parkinson’s sisease psychosis, pimavanserin was found to be effective and well-tolerated but its onset of benefit takes 4–6 weeks. Low doses of clozapine can provide benefit without worsening PD motor symptoms ",,,,1221846965622837249,https://twitter.com/psychopharmacol/status/1221846965622837249
2020-01-24 06:47:44,SaariTT,LonSchneiderMD,1,0,1,"Open questions regarding NPI's (and by proxy NPI-NH's) validity also contribute to difficulties in interpreting differences in scores between pimavanserin and placebo. Our preprint: ",,,,1220599043904212992,https://twitter.com/SaariTT/status/1220599043904212992
2020-01-23 23:09:35,LonSchneiderMD,,4,6,14,"@alhzheimerssoc @WheelerSimon @alzassociation Thought this is well-known. Pimavanserin was signif on NPI-psychosis at wk 6 (called the primary outcome). It was not signif at wk 2, 4, 9, &amp; 12, or on any secondary outcome. Note placebo worsening at wk 6. You decide @ACADIAPharma https://twitter.com/ProfRobHoward/status/1220029349027635202",,@WheelerSimon @alzassociation @ACADIAPharma,,1220483747327250433,https://twitter.com/LonSchneiderMD/status/1220483747327250433
2020-01-22 17:03:58,ProfRobHoward,WheelerSimon,1,1,9,"Simon - have you actually read the trial paper? Differences between pimavanserin and placebo at 6 weeks driven mainly by worsening in placebo arm. At later points, no differences between arms. Accompanying editorial by @LonSchneiderMD described trial as negative. And $30k/year.",,@LonSchneiderMD,,1220029349027635202,https://twitter.com/ProfRobHoward/status/1220029349027635202
2020-01-02 15:35:04,PCC_CNSDisord,,0,0,0,"The authors of this letter to the editor comment on a previously published report on pimavanserin in The Primary Care Companion for CNS Disorders. http://bit.ly/2tePzAZ @AtlantaVAMC @AvalonCuracao @TTUHSC @UofLMedicine",,@AtlantaVAMC @AvalonCuracao @TTUHSC @UofLMedicine,,1212759218371072002,https://twitter.com/PCC_CNSDisord/status/1212759218371072002
2019-12-28 03:50:13,dawso007,Da3dalusStephen,0,1,2,"The table is instructive. The atypicals have high to low (0.2-250) 5-HT2A antagonist affinity but also high to moderate D2 antagonist affinity (0.2-250). Pimavanserin has no D2 affinity but high 5-HT2A antagonist affinity. https://real-psychiatry.blogspot.com/2016/05/pimavanserin.html",,,,1210769898642608128,https://twitter.com/dawso007/status/1210769898642608128
2019-12-28 02:58:45,dawso007,DebiecJacek,1,0,5,"5-HT2A partial agonism is considered the likely initial mechanism for classic hallucinogens. Pimavanserin was the first antipsychotic approved that has no activity at D2 receptors and is a 5-HT2A anatagonist and possible inverse agonist.",,,,1210756944580923398,https://twitter.com/dawso007/status/1210756944580923398
2019-12-26 09:58:12,Dra_TeraizaMesa,,0,0,0,"RT @MDEdgePsych: Pimavanserin may also be helpful for #psychotic symptoms in #dementia patients. http://ms.spr.ly/6011TnAAZ #CTAD19",,@MDEdgePsych,#psychotic #dementia #CTAD19,1210137729322901505,https://twitter.com/Dra_TeraizaMesa/status/1210137729322901505
2019-12-26 01:00:01,MDEdgePsych,,1,7,10,"Pimavanserin may also be helpful for #psychotic symptoms in #dementia patients. http://ms.spr.ly/6011TnAAZ #CTAD19",,,#psychotic #dementia #CTAD19,1210002290175856640,https://twitter.com/MDEdgePsych/status/1210002290175856640
2019-12-21 21:17:36,ProfRobHoward,eturnermd1,0,7,25,"Really important reason for concern in dementia, with aducanumab and pimavanserin coming to FDA for approval in early 2020. ",,,,1208496767270035464,https://twitter.com/ProfRobHoward/status/1208496767270035464
2019-12-20 14:25:15,PeterDKramer,,0,0,2,"#Pimavanserin, an effective treatment for psychosis in #Parkinson's disease &amp; perhaps #Alzheimer's, shows promise for #depression, both as an add-on and as a primary treatment, in small, well-designed study. https://bit.ly/36YkTTk Med is v-expensive in the US, cheaper elsewhere.",,,#Pimavanserin #Parkinson #Alzheimer #depression,1208030608645066752,https://twitter.com/PeterDKramer/status/1208030608645066752
2019-12-18 09:45:03,AlzheimerEurope,,0,3,2,"Read more about @ACADIApharma’s presentation of topline results from the HARMONY trial of pimavanserin for #dementia-related psychosis @CTADconference #ClinicalTrials #CTAD2019 https://bit.ly/36SMh57",,@ACADIAPharma @CTADconference,#dementia #ClinicalTrials #CTAD2019,1207235316244975618,https://twitter.com/AlzheimerEurope/status/1207235316244975618
2019-12-18 05:10:01,Biotech2050,,0,0,4,"#Pimavanserin: A potentially safer alternative to #clozapine for refractory #hallucinations and #delusions $ACAD #nuplazid",,,#Pimavanserin #clozapine #hallucinations #delusions #nuplazid,1207166104117940224,https://twitter.com/Biotech2050/status/1207166104117940224
2019-12-18 03:43:13,RosyMar24604545,,0,0,0,"Pimavanserin drug used to reduce delusions in #Parkinson's disease patients does the same for patients with #Alzheimer's disease and other types of #dementia For details Visit:https://bit.ly/2pPKqtN #neurologicaldisorders #psychiatry",,,#Parkinson #Alzheimer #dementia #neurologicaldisorders #psychiatry,1207144258097934336,https://twitter.com/RosyMar24604545/status/1207144258097934336
2019-12-18 02:00:01,MDEdgeTweets,,0,0,0,"Pimavanserin may also be helpful for #psychotic symptoms in #dementia patients. http://ms.spr.ly/6010TnXvY #CTAD19",,,#psychotic #dementia #CTAD19,1207118286376374272,https://twitter.com/MDEdgeTweets/status/1207118286376374272
2019-12-17 21:00:01,MDEdgePsych,,0,1,3,"Pimavanserin may also be helpful for #psychotic symptoms in #dementia patients. http://ms.spr.ly/6011TnkL1 #CTAD19",,,#psychotic #dementia #CTAD19,1207042788019376128,https://twitter.com/MDEdgePsych/status/1207042788019376128
2019-12-17 21:00:01,MDedgeNeurology,,0,4,0,"Pimavanserin may also be helpful for #psychotic symptoms in #dementia patients. http://ms.spr.ly/6010TnkIG #CTAD19",,,#psychotic #dementia #CTAD19,1207042787876786177,https://twitter.com/MDedgeNeurology/status/1207042787876786177
2019-12-15 15:40:00,PsychCongress,,0,0,0,"Pimavanserin Reduces Risk of #Dementia-Related #Psychosis Relapse: http://bit.ly/2KgZjiW",,,#Dementia #Psychosis,1206237478287491072,https://twitter.com/PsychCongress/status/1206237478287491072
2019-12-14 18:01:12,RxSchool,,0,0,0,"If approved by regulators, pimavanserin could become the first drug offered specifically for treating dementia-related psychosis and would be the first new medicine for Alzheimer’s in nearly 20 years. ",,,,1205910626863919107,https://twitter.com/RxSchool/status/1205910626863919107
2019-12-14 15:00:37,morodog,,0,0,1,"#HackingNews #acadia ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia: SAN DIEGO–(BUSINESS WIRE)–Nov 25, 2019– ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD),… http://bit.ly/2LRtChF",,,#HackingNews #acadia,1205865180854272000,https://twitter.com/morodog/status/1205865180854272000
2019-12-14 05:11:41,ParkinsonismD,,0,1,0,"#pimavanserin #quetiapine #treatmentpsychosis #PD #LBD Log in to: https://doi.org/10.1016/j.parkreldis.2019.11.009",,,#pimavanserin #quetiapine #treatmentpsychosis #PD #LBD,1205716971095900161,https://twitter.com/ParkinsonismD/status/1205716971095900161
2019-12-13 20:00:00,ClinRev,,0,0,0,"Pimavanserin, a second-generation antipsychotic approved for hallucinations and delusions in patients with Parkinson’s disease, may also be helpful for psychotic symptoms in other dementia patients. Read more: https://www.mdedge.com/neurology/article/214241/alzheimers-cognition/pimavanserin-reduced-dementia-related-psychotic",,,,1205578135460368384,https://twitter.com/ClinRev/status/1205578135460368384
2019-12-13 16:57:00,neurology_live,,0,0,1,"In a Q&A with NeurologyLive, HARMONY study investigator Jeffrey Cummings, MD, ScD, @CleClinicMD, discussed the need for an effective treatment for Dementia-related psychosis and what makes #pimavanserin a unique treatment option. READ more ",,@CleClinicMD,#pimavanserin,1205532080161148934,https://twitter.com/neurology_live/status/1205532080161148934
2019-12-11 21:18:50,BoomerBaby54,,0,0,2,"Drug used to ease delusions for people with Parkinson's disease may be able to do the same for people with Alzheimer's... https://www.healthline.com/health-news/parkinsons-drug-ease-delusions-with-alzheimers #Parkinsons #AlzheimerDisease #Alzheimer #pimavanserin #delusions #parkinsondelusions #alzheimerdelusions",,,#Parkinsons #AlzheimerDisease #Alzheimer #pimavanserin #delusions #parkinsondelusions #alzheimerdelusions,1204873198640123904,https://twitter.com/BoomerBaby54/status/1204873198640123904
2019-12-11 00:25:04,PsychiatryAdv,,0,0,0,"Adjunctive treatment with #pimavanserin did not result in a statistically significant change from baseline in Positive and Negative Syndrome Scale total score in patients with #schizophrenia.",,,#pimavanserin #schizophrenia,1204557675658465280,https://twitter.com/PsychiatryAdv/status/1204557675658465280
2019-12-10 21:47:24,TodaysGeriMed,,0,0,0,"ACADIA Pharmaceuticals Presents Positive Top-Line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients With Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease Meeting https://www.todaysgeriatricmedicine.com/news/121019_news.shtml",,,,1204517999652360192,https://twitter.com/TodaysGeriMed/status/1204517999652360192
2019-12-08 20:00:01,byMattHoffman,,0,0,2,"HARMONY study investigator Jeffrey Cummings, MD, ScD, discussed the need for an effective treatment for DRP and what makes pimavanserin a unique treatment option. ",,,,1203766198392852480,https://twitter.com/byMattHoffman/status/1203766198392852480
2019-12-08 17:15:04,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Pati http://crweworld.com/article/news-provided-by-business-wire/1342947/acadia-pharmaceuticals-presents-positive-top-line-results-from-pivotal-phase-3-harmony-trial-of-pimavanserin-in-patients-with-dementia-related-psychosis-at-12th-clinical-trials-on-alzheimersn-disease-ctad-meeting",,,,1203724686393085952,https://twitter.com/CrweWorld/status/1203724686393085952
2019-12-08 17:15:00,neurology_live,,0,0,1,"In an interview with NeurologyLive, HARMONY study investigator Jeffrey Cummings, MD, ScD, discussed the need for an effective treatment for #DRP and what makes #pimavanserin a unique treatment option. https://www.neurologylive.com/clinical-focus/in-dementia-pimavanserin-significantly-reduces-psychosis-relapse",,,#DRP #pimavanserin,1203724670769516545,https://twitter.com/neurology_live/status/1203724670769516545
2019-12-08 16:55:27,Being_Patient_,,0,0,1,"A new drug called #pimavanserin has shown promise in treating delusions and hallucinations in #dementia. Read more here: http://bit.ly/2E9QeWN",,,#pimavanserin #dementia,1203719752721616897,https://twitter.com/Being_Patient_/status/1203719752721616897
2019-12-08 06:06:23,Artstrada,,0,0,0,"pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions. ",,,,1203556410598051840,https://twitter.com/Artstrada/status/1203556410598051840
2019-12-08 00:00:05,InsomniaData,,0,0,1,"New clinical trial for #insomnia: Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder https://medtally.com/post/pimavanserin-for-insomnia-in-veterans-with-posttraumatic-stress-disorder-551963",,,#insomnia,1203464226548797440,https://twitter.com/InsomniaData/status/1203464226548797440
2019-12-07 22:09:00,Medscape,,0,1,5,"Topline results from the HARMONY phase 3 study show that pimavanserin significantly reduces risk of relapse of psychosis in patients with dementia-related psychosis. ",,,,1203436272213282817,https://twitter.com/Medscape/status/1203436272213282817
2019-12-07 21:19:00,neurology_live,,0,0,0,"In an interview with NeurologyLive, HARMONY study investigator Jeffrey Cummings, MD, ScD, discussed the need for an effective treatment for #DRP and what makes #pimavanserin a unique treatment option. https://www.neurologylive.com/clinical-focus/in-dementia-pimavanserin-significantly-reduces-psychosis-relapse",,,#DRP #pimavanserin,1203423687334154247,https://twitter.com/neurology_live/status/1203423687334154247
2019-12-07 13:01:43,PatentAwards,,0,0,0,"Let us honor Stephen Abele for his patent 10,449,185 ""Formulations of Pimavanserin"". Learn more here! http://bit.ly/2OdLKCT Looking for some holiday gifts? Go here! http://bit.ly/2Uv6hbv",,,,1203298541143244800,https://twitter.com/PatentAwards/status/1203298541143244800
2019-12-06 21:30:49,Biotech2050,TheADDF,0,3,2,"$ACAD DRP pimavanserin approval in late 2020 according to KOL @DrJeffCummings",,@DrJeffCummings,,1203064276157685761,https://twitter.com/Biotech2050/status/1203064276157685761
2019-12-06 21:09:00,MedscapeNeuro,,0,3,2,"Topline results from the HARMONY phase 3 study show that #pimavanserin significantly reduces risk of relapse of psychosis in patients with dementia-related psychosis. http://ms.spr.ly/6015TVVx9",,,#pimavanserin,1203058783355887626,https://twitter.com/MedscapeNeuro/status/1203058783355887626
2019-12-06 20:42:57,Spanishcountry,,0,0,0,"Topline Results for Pimavanserin in Dementia-Related Psychosis https://www.medscape.com/viewarticle/922211?src=soc_tw_share via @medscape",,@Medscape,,1203052228984147968,https://twitter.com/Spanishcountry/status/1203052228984147968
2019-12-06 19:29:02,TheADDF,,0,16,26,"Live from #CTAD19 - @DrJeffCummings of @LouRuvoCenter shares topline results from the #HARMONY trial, which showed the drug #pimavanserin has promise for patients with dementia-related psychosis as well as their families and caregivers. ",,@DrJeffCummings @LouRuvoCenter,#CTAD19 #HARMONY #pimavanserin,1203033626419638275,https://twitter.com/TheADDF/status/1203033626419638275
2019-12-06 18:11:03,doctorsaad,,0,0,0,"Topline Results for Pimavanserin in Dementia-Related Psychosis http://dlvr.it/RKp7SW",,,,1203014003095531521,https://twitter.com/doctorsaad/status/1203014003095531521
2019-12-06 17:01:28,ALZ_GRVA,,0,0,1,"Clinical trial data at #CTAD19 shows pimavanserin may be effective in treating dementia-related psychosis. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions. http://wapo.st/2s33rNX #ENDALZ",,,#CTAD19 #ENDALZ,1202996489556905984,https://twitter.com/ALZ_GRVA/status/1202996489556905984
2019-12-06 17:01:13,alznorfolk,,0,0,1,"Clinical trial data at #CTAD19 shows pimavanserin may be effective in treating dementia-related psychosis. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions. http://wapo.st/2s33rNX #ENDALZ",,,#CTAD19 #ENDALZ,1202996428639014913,https://twitter.com/alznorfolk/status/1202996428639014913
2019-12-06 17:00:35,ALZNCA,,0,1,3,"Clinical trial data at #CTAD19 shows pimavanserin may be effective in treating dementia-related psychosis. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions. http://wapo.st/2s33rNX #ENDALZ",,,#CTAD19 #ENDALZ,1202996265774145536,https://twitter.com/ALZNCA/status/1202996265774145536
2019-12-06 14:55:17,Primal_Digest,LEAD_Coalition,0,0,1,"#AcadiaPharmaceuticals : Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on #AlzheimersDisease (CTAD) Meeting https://www.marketscreener.com/ACADIA-PHARMACEUTICALS-IN-8222/news/ACADIA-Pharmaceuticals-Presents-Positive-Top-line-Results-from-Pivotal-Phase-3-HARMONY-Trial-of-Pi-29683534/",,,#AcadiaPharmaceuticals #AlzheimersDisease,1202964734271803392,https://twitter.com/Primal_Digest/status/1202964734271803392
2019-12-06 13:09:00,MedscapePsych,,0,4,9,"Topline results from the HARMONY phase 3 study show that pimavanserin significantly reduces risk of relapse of psychosis in patients with dementia-related psychosis. http://ms.spr.ly/6015TVVxF",,,,1202937988122107910,https://twitter.com/MedscapePsych/status/1202937988122107910
2019-12-06 13:00:46,alzheimerssoc,,1,7,8,"'We know that antipsychotics can be prescribed inappropriately for people with dementia so robust regulation of use is essential.' @JamesPickett12 comments on news that pimavanserin, a drug used to treat Parkinson's, may relieve symptoms of dementia. ",,@JamesPickett12,,1202935917289230337,https://twitter.com/alzheimerssoc/status/1202935917289230337
2019-12-06 08:02:19,TrialBulletin,,0,0,0,"Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder: Status: Not yet recruiting, Condition Summary: Post-traumatic Stress Disorder; Insomnia ",,,,1202860810592235520,https://twitter.com/TrialBulletin/status/1202860810592235520
2019-12-06 07:57:28,amobeirne,wendyburn,1,0,0,"When I do a quick search it says Pimavanserin is an anti- psychotic. Which usually means major tranquilizer. Who are we fooling ? You can't really fool the people who were pumped with cocktails of drugs and escaped, while learning the truth ! @joannamoncrieff @DrDavidHealy",,@joannamoncrieff @DrDavidHealy,,1202859587227017217,https://twitter.com/amobeirne/status/1202859587227017217
2019-12-06 01:42:55,KristiTalmadge,latimes,0,0,0,"#Dementia #Alzheimers #ParkinsonsDisease ""The drug, #pimavanserin, is sold as #Nuplazid by #Acadia #Pharmaceuticals Inc. It was approved for Parkinson’s-related #psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions."" #MentalHealth",,,#Dementia #Alzheimers #ParkinsonsDisease #pimavanserin #Nuplazid #Acadia #Pharmaceuticals #psychosis #MentalHealth,1202765327651786753,https://twitter.com/KristiTalmadge/status/1202765327651786753
2019-12-06 00:30:20,BioCentury,,0,0,1,"Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster $ACAD",,,,1202747063810830336,https://twitter.com/BioCentury/status/1202747063810830336
2019-12-05 23:37:10,HoldenCCole,,0,0,1,"$ACAD said that its phase 3 trial of pimavanserin in patients with dementia-related psychosis met its main endpoint of reducing the risk of relapse. The trial also met its secondary goal of reducing risk of discontinuation. Shares rose 14.7% @CNBC @business @MarketWatch",,@CNBC @business @MarketWatch,,1202733685138763777,https://twitter.com/HoldenCCole/status/1202733685138763777
2019-12-05 23:34:36,MaisaCorp,,0,0,1,"$ACAD announced positive results of its drug Pimavanserin in a Phase 3 trial of patients with dementia-related psychosis.",,,,1202733038909739008,https://twitter.com/MaisaCorp/status/1202733038909739008
2019-12-05 22:12:30,Briefingcom,,0,0,0,"$SCANX: Mid cap notable movers of interest -- ACADIA Pharmaceuticals (ACAD) achieves new high following pimavanserin... http://bit.ly/2YimrEs",,,,1202712376602062848,https://twitter.com/Briefingcom/status/1202712376602062848
2019-12-05 21:56:06,SPKennelly,Clive_Ballard,0,0,10,"Promising news from CTAD19 on Pimavanserin for psychosis symptoms in dementia. Almost 1/3 people living with dementia develop these sx so an effective treatment would be a big breakthrough especially given poor side effect profile of current therapies . @alzheimersocirl @DNNIrl",,@alzheimersocirl @DNNIrl,,1202708248782090240,https://twitter.com/SPKennelly/status/1202708248782090240
2019-12-05 21:26:18,alzassociation,,1,31,55,"Acadia Pharmaceuticals shared clinical trial data at #CTAD19 showing pimavanserin may be effective in treating dementia-related psychosis. We encourage a rigorous review &amp; discussion of the data and potential side effects. http://wapo.st/2s33rNX #ENDALZ",,,#CTAD19 #ENDALZ,1202700750394183696,https://twitter.com/alzassociation/status/1202700750394183696
2019-12-05 21:15:04,_APCI,,0,0,0,"The study showed that Pimavanserin, sold as Nuplazid, targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse. | @AP http://ow.ly/8NY330pZkIq",,@AP,,1202697923374538752,https://twitter.com/_APCI/status/1202697923374538752
2019-12-05 21:05:27,dcweisman,matthewherper,1,0,0,"Dr Foff presented the pimavanserin for dementia psychosis trial last night. No one blinked.",,,,1202695500975108096,https://twitter.com/dcweisman/status/1202695500975108096
2019-12-05 20:59:09,fdadaily,,0,0,0,"Topline Results for Pimavanserin in Dementia-Related Psychosis, ,",,,,1202693918992818176,https://twitter.com/fdadaily/status/1202693918992818176
2019-12-05 20:44:02,InvestorIdeas,,0,2,0,"Biopharma Stock News: ACADIA Pharmaceuticals (Nasdaq: ACAD) Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer's Disease (CTAD)… http://dlvr.it/RKlC2M #Biotech",,,#Biotech,1202690111986515968,https://twitter.com/InvestorIdeas/status/1202690111986515968
2019-12-05 20:41:31,FeedHcp,,0,0,0,"Topline Results for Pimavanserin in Dementia-Related Psychosis,,https://www.hcpfeed.com/2019/12/05/topline-results-for-pimavanserin-in-dementia-related-psychosis/,",,,,1202689481616302080,https://twitter.com/FeedHcp/status/1202689481616302080
2019-12-05 20:38:33,Cirupla1,,0,0,1,"Topline Results for Pimavanserin in Dementia-Related Psychosis http://dlvr.it/RKlBSR",,,,1202688732035313665,https://twitter.com/Cirupla1/status/1202688732035313665
2019-12-05 20:36:00,WHSVnews,,0,1,0,"If regulators agree, pimavanserin, a daily pill, could become the first treatment specifically for dementia-related psychosis: https://www.whsv.com/content/news/Drug-can-curb-dementias-delusions-researchers-find-565815811.html",,,,1202688090172731393,https://twitter.com/WHSVnews/status/1202688090172731393
2019-12-05 20:22:24,AlzKYIN,,0,0,3,"Pimavanserin is FDA approved for people experiencing psychosis who are living w/ Parkinson’s &amp; a new study aims to expand the use in individuals living w/ dementia-related psychosis, including Alzheimer’s, frontotemporal, Lewy body, and vascular dementia. https://www.yahoo.com/news/drug-curb-dementia-delusions-researchers-213516443.html",,,,1202684667016728576,https://twitter.com/AlzKYIN/status/1202684667016728576
2019-12-05 20:18:50,PracticalNeuro,,0,3,3,"Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefold - Practical Neurology @ACADIAPharma #neurology #dementia #pimavanserin #parkinsonsdisease #Alzheimers",,@ACADIAPharma,#neurology #dementia #pimavanserin #parkinsonsdisease #Alzheimers,1202683771079839745,https://twitter.com/PracticalNeuro/status/1202683771079839745
2019-12-05 20:08:03,BrainSightsApp,,0,0,0,"Topline Results for Pimavanserin in Dementia-Related Psychosis - Medscape - Neurology via BrainSights for iOS http://www.medscape.com/viewarticle/922211?src=rss",,,,1202681058027868160,https://twitter.com/BrainSightsApp/status/1202681058027868160
2019-12-05 17:49:11,ONDRISTUDY,,0,1,2,"Study finds that a new drug controls delusions in #Parkinsons and #Alzheimers patients. http://bit.ly/2DQKHnK #research #pharmaceuticals #pimavanserin #Nuplazid",,,#Parkinsons #Alzheimers #research #pharmaceuticals #pimavanserin #Nuplazid,1202646112454217729,https://twitter.com/ONDRISTUDY/status/1202646112454217729
2019-12-05 17:36:12,ThePharmaLetter,,0,0,0,"Pimavanserin meets Ph III endpoints in dementia-related psychosis https://www.thepharmaletter.com/article/pimavanserin-meets-ph-iii-endpoints-in-dementia-related-psychosis #biotech",,,#biotech,1202642841706610688,https://twitter.com/ThePharmaLetter/status/1202642841706610688
2019-12-05 17:00:01,newswest9,,0,0,1,"If regulators agree, the drug -- pimavanserin -- could become the first new medicine for Alzheimer's in nearly two decades. ",,,,1202633737386762241,https://twitter.com/newswest9/status/1202633737386762241
2019-12-05 16:27:33,DrCarlForkner,,0,0,0,"ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting ",,,,1202625565548789760,https://twitter.com/DrCarlForkner/status/1202625565548789760
2019-12-05 16:18:05,StckPro,,0,0,0,"$ACAD NEW ARTICLE : Acadia Pharma up 16% on pimavanserin data in dementia psychosis https://dashboard.stck.pro/news.php?ticker=ACAD&amp;rowid=2327393 Get all the latest $ACAD related news here : https://dashboard.stck.pro/news.php?ticker=ACAD",,,,1202623182517223424,https://twitter.com/StckPro/status/1202623182517223424
2019-12-05 14:54:01,judyfr262,,0,0,1,"$ACAD Gap up on huge volume and upgrade by Leerink on positive topline results phase 3 trial of pimavanserin in patients w dementia-related ohyscosis",,,,1202602027005730816,https://twitter.com/judyfr262/status/1202602027005730816
2019-12-05 14:53:35,TheADDF,,0,2,8,"At #CTAD19, results from the HARMONY trial showed Pimavanserin, an anti-psychosis drug for patients with #Parkinsons, also showed promise for patients with #Alzheimers. #ADDF's @a_hfillit spoke with @MMarchioneAP of the @AP to discuss the implications: http://bit.ly/2DQ2lIg.",,@a_hfillit @MMarchioneAP @AP,#CTAD19 #Parkinsons #Alzheimers #ADDF,1202601919702654976,https://twitter.com/TheADDF/status/1202601919702654976
2019-12-05 14:11:04,dteb16,adamfeuerstein,0,1,1,"Science says pimavanserin doesn’t suck. $ACAD",,,,1202591218447929346,https://twitter.com/dteb16/status/1202591218447929346
2019-12-05 14:10:29,dteb16,adamfeuerstein,0,1,1,"$ACAD uses Science to produce positive Ph3 pimavanserin results. Bears cite misinterpreted Magic 8 Ball readout. ",,,,1202591073819938821,https://twitter.com/dteb16/status/1202591073819938821
2019-12-05 13:46:06,dteb16,adamfeuerstein,0,0,3,"But pimavanserin will. $ACAD",,,,1202584935854432258,https://twitter.com/dteb16/status/1202584935854432258
2019-12-05 13:16:25,Briefingcom,,0,0,2,"$ACAD: ACADIA Pharmaceuticals presents positive top-line results from pivotal phase 3 Harmony trial of pimavanserin... http://bit.ly/352ncUR",,,,1202577468676116480,https://twitter.com/Briefingcom/status/1202577468676116480
2019-12-05 12:52:51,psk2329,,0,0,2,"ACADIA Pharmaceuticals shares are trading higher after the company reported the results from its pivotal phase 3 HARMONY trial of pimavanserin in patients with dementia-related psychosis met the primary endpoint and key secondary endpoint. $ACAD",,,,1202571533840977920,https://twitter.com/psk2329/status/1202571533840977920
2019-12-05 12:28:51,cfromhertz,,0,3,3,"$ACAD ACADIA Says Phase 3 Trial of Pimavanserin in Patients With Dementia-Related Psychosis Meets Primary Endpoint $SAGE Plunges as Key Depression Study Fails to Show Benefit ‘Mountain’ study did not meet primary endpoint at day 15",,,,1202565497532887042,https://twitter.com/cfromhertz/status/1202565497532887042
2019-12-05 12:22:43,WallStEagle,,0,1,0,"$ACAD ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting",,,,1202563952040914944,https://twitter.com/WallStEagle/status/1202563952040914944
2019-12-05 12:08:38,IncredibleTrade,,0,0,2,"Acadia Pharma $ACAD Highlights Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin at CTAD 2019 Meetings GAP UP +10",,,,1202560406415392769,https://twitter.com/IncredibleTrade/status/1202560406415392769
2019-12-05 12:07:14,sp3cul8r,,0,0,4,"The Baker Bros continue to kill it! —-> ACADIA Pharma up 10% premarket on positive pimavanserin data $ACAD",,,,1202560055448608768,https://twitter.com/sp3cul8r/status/1202560055448608768
2019-12-05 11:38:24,Biotech2050,matthewherper,0,0,0,"Will you be issuing a report on pimavanserin's data release at #CTAD2019?",,,#CTAD2019,1202552801915817994,https://twitter.com/Biotech2050/status/1202552801915817994
2019-12-05 11:36:05,StckPro,,0,0,0,"$ACAD NEW ARTICLE : ACADIA Pharma up 10% premarket on positive pimavanserin data https://dashboard.stck.pro/news.php?ticker=ACAD&amp;rowid=2315287 Get all the latest $ACAD related news here : https://dashboard.stck.pro/news.php?ticker=ACAD",,,,1202552215258509312,https://twitter.com/StckPro/status/1202552215258509312
2019-12-05 10:38:28,fwpharma,,0,0,1,"Acadia details positive results from late-stage study of pimavanserin for dementia-related psychosis https://www.firstwordpharma.com/node/1685530 $ACAD #CTAD19",,,#CTAD19,1202537717726359554,https://twitter.com/fwpharma/status/1202537717726359554
2019-12-05 07:12:09,kkmaggon,,0,0,0,"ACADIA Pharma Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disea... http://sco.lt/5ZXmkq",,,,1202485797380902913,https://twitter.com/kkmaggon/status/1202485797380902913
2019-12-05 04:45:59,Biotech2050,,1,1,6,"$ACAD revenue guidance for 2019 is circa $320M on a #pimavanserin market penetration of circa 15% in #parkinsons #psychosis #PDP (Gross $2B) The #dementia related psychosis market is x10 PDP. Gross for both DRP + PDP is..... staggering for a $7B MC co!",,,#pimavanserin #parkinsons #psychosis #PDP #dementia,1202449013527760896,https://twitter.com/Biotech2050/status/1202449013527760896
2019-12-05 04:04:27,Biotech2050,,0,0,4,"#Parkinson's treatment shows promise in treating #dementia, clinical trials show $ACAD #Alzheimers #pimavanserin ",,,#Parkinson #dementia #Alzheimers #pimavanserin,1202438561414422528,https://twitter.com/Biotech2050/status/1202438561414422528
2019-12-05 03:05:44,neurology_live,,0,8,7,"Breaking: Top-line results from phase 3 #HARMONY trial of #pimavanserin in #dementia related psychosis show significant reduction in relapse risk vs placebo. Jeffrey Cummings of @CleClinicMD spoke with us about the results presented at #CTAD",,@CleClinicMD,#HARMONY #pimavanserin #dementia #CTAD,1202423784118083584,https://twitter.com/neurology_live/status/1202423784118083584
2019-12-05 02:52:36,ForTheRecord01,,1,2,4,"$ACAD Pimavanserin reduced psychotic symptoms in the DRP study by over 75%: ",,,,1202420477668409344,https://twitter.com/ForTheRecord01/status/1202420477668409344
2019-12-05 02:39:54,sabaribaba,,0,0,0,"@CTADconference pleased to hear positive results of Pimavanserin study. Could be very useful for Dementia patients with psychotic experiences. Reassured with the data and study design.",,@CTADconference,,1202417282737004549,https://twitter.com/sabaribaba/status/1202417282737004549
2019-12-05 02:12:07,otcdynamics,,0,0,0,"$ACAD ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin https://www.otcdynamics.com/acad-acadia-pharmaceuticals-presents-positive-top-line-results-from-pivotal-phase-3-harmony-trial-of-pimavanserin-in-patients-with-dementia-related-psychosis-at-12th-clinical-trials-on-alzheimer/?utm_campaign=twitter&amp;utm_medium=twitter&amp;utm_source=twitter",,,,1202410289993601029,https://twitter.com/otcdynamics/status/1202410289993601029
2019-12-05 02:09:54,Clive_Ballard,,0,1,7,"Ps fantastic phase 3 pimavanserin results make the hard work of our 2028 Lancet Neurol phase 2 trial with pimavanserin worth the hard work! #exeterdementia #CTAD19",,,#exeterdementia #CTAD19,1202409731937062912,https://twitter.com/Clive_Ballard/status/1202409731937062912
2019-12-05 02:08:13,Clive_Ballard,,5,50,103,"Stunning phase 3 study of pimavanserin for psychosis in people with dementia ... 65% reduction in decline compared to placebo over 6 months with excellent safety. This will revolutionise treatment of psychosis in dementia compared to #exeterdementia #CTAD19",,,#exeterdementia #CTAD19,1202409308379435010,https://twitter.com/Clive_Ballard/status/1202409308379435010
2019-12-05 01:51:55,syinvesting,,1,10,14,"$ACAD announces results from pivotal Ph 3 HARMONY trial of pimavanserin in patients with dementia-related psychosis. #CTAD19 #Alzheimers Met primary endpoint by significantly reducing risk of relapse of psychosis by 2.8x (HR=0.353, one-sided p=0.0023).",,,#CTAD19 #Alzheimers,1202405205544964096,https://twitter.com/syinvesting/status/1202405205544964096
2019-12-05 01:50:56,brunovellas,,0,4,7,"Large efficacy for Pimavanserin versus placebo in Alzheimer patient with psychosis #ctad San Diego",,,#ctad,1202404959393701890,https://twitter.com/brunovellas/status/1202404959393701890
2019-12-05 01:48:57,newsfilterio,,0,0,1,"ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia.. $ACAD https://newsfilter.io/articles/acadia-pharmaceuticals-presents-positive-top-line-results-from-pivotal-phase-3-harmony-trial-of-pima-5a348b3815ad2c82b3f5aeb0d876d860",,,,1202404458975481858,https://twitter.com/newsfilterio/status/1202404458975481858
2019-12-04 23:57:30,scooperpr,,0,1,4,"Getting locked in at #CTAD19 in San Diego where ACADIA pharmaceuticals $ACAD (client) will be presenting phase 3 results of HARMONY trial evaluating pimavanserin in dementia-related psychosis (DRP) in the opening LBCT session. #dementia #Alzheimers #CNS",,,#CTAD19 #dementia #Alzheimers #CNS,1202376411257827328,https://twitter.com/scooperpr/status/1202376411257827328
2019-12-02 14:54:05,Clive_Ballard,,1,2,16,"San Diego Marina looking great ahead of CTAD. Looking forward. To hearing more about the phase 3 trial of pimavanserin for psychosis in people with dementia today! #exeterdementia",,,#exeterdementia,1201514882438270976,https://twitter.com/Clive_Ballard/status/1201514882438270976
2019-12-01 17:57:03,NateNs5,,0,0,0,"$ACAD investor event 12/4 ... Phase3 Harmony results ... pimavanserin as treatment for dementia related psychosis",,,,1201198540808216576,https://twitter.com/NateNs5/status/1201198540808216576
2019-12-01 13:12:46,Biotech2050,Clive_Ballard,0,0,1,"Keep us posted on pimavanserin on DRP. Hope it brings great news for #Alzheimer’s patients",,,#Alzheimer,1201126997260419072,https://twitter.com/Biotech2050/status/1201126997260419072
2019-12-01 12:11:30,Clive_Ballard,,3,2,17,"Just heading to CTAD t SAN Diego .. should be exiting meeting with full oresentations of the new pimavanserin and aducanamab data!!! Was also looking forward to the treat of a business class flight .. but BA overbooked so downgraded grrr #exeterdementia",,,#exeterdementia,1201111576260042752,https://twitter.com/Clive_Ballard/status/1201111576260042752
2019-11-30 23:58:25,maher275,,0,0,1,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia ",,,,1200927090670997504,https://twitter.com/maher275/status/1200927090670997504
2019-11-29 23:07:18,HansBangen,,0,0,0,"NUPLAZID TV Commercial, 'Seeing Things' - https://www.ispot.tv/ad/dvSu/nuplazid-seeing-things #ispottv #Nuplazid #Pimavanserin #Psychopharmakon",,,#ispottv #Nuplazid #Pimavanserin #Psychopharmakon,1200551840670257153,https://twitter.com/HansBangen/status/1200551840670257153
2019-11-29 18:15:13,TrialsiteN,,0,0,0,"#AcadiaPharma Reports #PositiveData from Phase 2 #ADVANCE Trial #Pimavanserin for Negative Symptoms of #Schizophrenia https://www.trialsitenews.com/acadia-pharma-reports-positive-data-from-phase-2-advance-trial-pimavanserin-for-negative-symptoms-of-schizophrenia/ @acadiapharma #negativesymptoms #clinicaltrials #healthcare",,@ACADIAPharma,#AcadiaPharma #PositiveData #ADVANCE #Pimavanserin #Schizophrenia #negativesymptoms #clinicaltrials #healthcare,1200478336754962432,https://twitter.com/TrialsiteN/status/1200478336754962432
2019-11-28 04:40:01,newsfilterio,,0,0,0,"ACADIA Pharmaceuticals slips 2% after the results from its ADVANCE study of pimavanserin as a treatment for negative symptoms of schiz.. $ACAD",,,,1199910795536027649,https://twitter.com/newsfilterio/status/1199910795536027649
2019-11-27 02:16:15,cmencke,,0,1,0,"AwesomeCapital: Acadia’s Pimavanserin Narrowly Hits Primary Endpoi... https://awesomecapital.blogspot.com/2019/11/acadias-pimavanserin-narrowly-hits.html?spref=tw",,,,1199512228963246085,https://twitter.com/cmencke/status/1199512228963246085
2019-11-27 02:08:24,maher275,,0,0,0,"Pimavanserin Improves Negative Symptoms of Schizophrenia in Trial ",,,,1199510250186932224,https://twitter.com/maher275/status/1199510250186932224
2019-11-26 23:38:37,maher275,,0,0,0,"Acadia’s Pimavanserin Narrowly Hits Primary Endpoint in Schizophrenia Study ",,,,1199472559626084353,https://twitter.com/maher275/status/1199472559626084353
2019-11-26 19:33:04,BioCalifornia,,0,0,0,"Acadia’s Pimavanserin Narrowly Hits Primary Endpoint in Schizophrenia Study http://bit.ly/2KWRiRD",,,,1199410761258242048,https://twitter.com/BioCalifornia/status/1199410761258242048
2019-11-26 15:05:51,semodough,,0,3,5,"RBC $ACAD Pimavanserin’s Perpetual Promise: Positive ADVANCE Topline, CTAD, PDP; Assuming Coverage PT 60",,,,1199343516935000067,https://twitter.com/semodough/status/1199343516935000067
2019-11-26 11:20:40,GlobalMedEd,,0,1,2,"#Pimavanserin (#Nuplazid) showed efficacy in treating negative symptoms of #schizophrenia, a great unmet need in #psychiatry. http://bit.ly/2qKP2FW #nursepractitioner #mhchat #psychiatry #primarycare #familymedicine #mentalhealth",,,#Pimavanserin #Nuplazid #schizophrenia #psychiatry #nursepractitioner #mhchat #psychiatry #primarycare #familymedicine #mentalhealth,1199286844367745024,https://twitter.com/GlobalMedEd/status/1199286844367745024
2019-11-26 01:53:32,into_AI,,0,0,0,"Acadia Pharma (ACAD) Reports Top-line Results from ADVANCE Trial of Pimavanserin as … - https://into.ai/blog/news-stories/acadia-pharma-acad-reports-top-line-results-from-advance-trial-of-pimavanserin-as/ #neuroscience #intoAInews",,,#neuroscience #intoAInews,1199144121870561280,https://twitter.com/into_AI/status/1199144121870561280
2019-11-25 23:43:34,cmencke,,0,1,0,"AwesomeCapital: ACADIA -2% after mixed pimavanserin results https://awesomecapital.blogspot.com/2019/11/acadia-2-after-mixed-pimavanserin.html?spref=tw",,,,1199111417422602241,https://twitter.com/cmencke/status/1199111417422602241
2019-11-25 23:00:37,maher275,,0,0,1,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia https://www.digitalmunition.me/acadia-pharmaceuticals-announces-positive-top-line-results-from-advance-trial-of-pimavanserin-as-treatment-for-negative-symptoms-of-schizophrenia/",,,,1199100606809554944,https://twitter.com/maher275/status/1199100606809554944
2019-11-25 22:35:07,NateNs5,,0,0,0,"ACADIA -2% after mixed pimavanserin results $ACAD",,,,1199094189050548232,https://twitter.com/NateNs5/status/1199094189050548232
2019-11-25 22:34:11,StckPro,,0,0,0,"$ACAD NEW ARTICLE : ACADIA -2% after mixed pimavanserin results https://dashboard.stck.pro/news.php?ticker=ACAD&amp;rowid=1748047 Get all the latest $ACAD related news here : https://dashboard.stck.pro/news.php?ticker=ACAD",,,,1199093954274299911,https://twitter.com/StckPro/status/1199093954274299911
2019-11-25 22:23:24,newsfilterio,,0,0,0,"ACADIA -2% after mixed pimavanserin results $ACAD https://newsfilter.io/articles/acadia--2-after-mixed-pimavanserin-results-f18dfd6e41bc209bf9f5b7da5efa1c36",,,,1199091241738096640,https://twitter.com/newsfilterio/status/1199091241738096640
2019-11-25 22:20:22,MarketCurrents,,0,0,1,"$ACAD - ACADIA -2% after mixed pimavanserin results https://seekingalpha.com/news/3521943-acadia-minus-2-percent-mixed-pimavanserin-results?source=feed_f&amp;utm_campaign=twitter_automated&amp;utm_content=news&amp;utm_medium=social&amp;utm_source=twitter",,,,1199090478932606978,https://twitter.com/MarketCurrents/status/1199090478932606978
2019-11-25 21:40:51,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negat http://crweworld.com/article/news-provided-by-business-wire/1329633/acadia-pharmaceuticals-announces-positive-top-line-results-from-advance-trial-of-pimavanserin-as-treatment-for-negative-symptoms-of-schizophrenia",,,,1199080531578671104,https://twitter.com/CrweWorld/status/1199080531578671104
2019-11-25 21:36:13,Home_Remedy_Res,,0,0,0,"New post (ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia) has been published on Home Remedy Resource - ",,,,1199079366774231040,https://twitter.com/Home_Remedy_Res/status/1199079366774231040
2019-11-25 21:24:45,otcdynamics,,0,0,1,"$ACAD ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment https://www.otcdynamics.com/acad-acadia-pharmaceuticals-announces-positive-top-line-results-from-advance-trial-of-pimavanserin-as-treatment-for-negative-symptoms-of-schizophrenia/?utm_campaign=twitter&amp;utm_medium=twitter&amp;utm_source=twitter",,,,1199076480644464641,https://twitter.com/otcdynamics/status/1199076480644464641
2019-11-25 21:23:37,MichaelMOTTCM,,1,0,1,"$acad this is important sentence imo ... A greater improvement in the NSA-16 total score compared to placebo was observed in the 53.8% of patients (n=107) who received the highest pimavanserin dose of 34 mg (-11.6 vs. -8.5; unadjusted p=0.0065, effect size = 0.34).",,,,1199076194886529024,https://twitter.com/MichaelMOTTCM/status/1199076194886529024
2019-11-25 21:20:12,ForTheRecord01,,0,0,3,"$ACAD This is the 7th clinical trial in which Nuplazid (pimavanserin) has been shown to be both safe &amp; effective.",,,,1199075335863590912,https://twitter.com/ForTheRecord01/status/1199075335863590912
2019-11-25 21:16:24,Biotech2050,,0,1,6,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of #Schizophrenia $ACAD",,,#Schizophrenia,1199074380271280130,https://twitter.com/Biotech2050/status/1199074380271280130
2019-11-25 21:15:52,syinvesting,,0,3,3,"$ACAD announces results from ADVANCE trial of pimavanserin in #schizophrenia. - Stat sig improvement in primary endpoint of NSA-16 total score (-10.4 vs -8.5, albeit p=0.043) - Better effect in high dose - No separation from pbo on secondary endpoint https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-announces-positive-top-line-results?field_nir_news_date_value[min]=",,,#schizophrenia,1199074245050957824,https://twitter.com/syinvesting/status/1199074245050957824
2019-11-25 21:14:00,MaisaCorp,,0,0,1,"$ACAD Plans to Commence Second Pivotal Study With 34 Mg Dose of Pimavanserin in 1H of 2020",,,,1199073774118813696,https://twitter.com/MaisaCorp/status/1199073774118813696
2019-11-25 21:12:24,newsfilterio,,0,0,1,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Sc.. $ACAD",,,,1199073373684240384,https://twitter.com/newsfilterio/status/1199073373684240384
2019-11-25 21:12:18,Picante_Media,,0,0,0,"ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia https://picante.today/technology/2019/11/25/118225/acadia-pharmaceuticals-announces-positive-top-line-results-from-advance-trial-of-pimavanserin-as-treatment-for-negative-symptoms-of-schizophrenia/",,,,1199073349055533060,https://twitter.com/Picante_Media/status/1199073349055533060
2019-11-25 21:07:03,pnani456,,0,1,1,"$ACAD ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as ... https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-positive-top-210300824.html?soc_src=social-sh&amp;soc_trk=tw via @YahooFinance",,@YahooFinance,,1199072028084592640,https://twitter.com/pnani456/status/1199072028084592640
2019-11-25 21:06:32,psk2329,,0,1,3,"ACADIA Pharma Reports Top-Line Results From ADVANCE Trial Of Pimavanserin As Treatment For Negative Symptoms Of Schizophrenia; Will Initiate Second Pivotal Study In H1'20 $ACAD",,,,1199071895037075457,https://twitter.com/psk2329/status/1199071895037075457
2019-11-25 21:04:01,_B_I_O_T_E_C_H_,,0,5,7,"$ACAD ACADIA PHARMACEUTICALS INC - PIMAVANSERIN DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT ON STUDY'S PRIMARY ENDPOINT COMPARED TO PLACEBO",,,,1199071265119715328,https://twitter.com/_B_I_O_T_E_C_H_/status/1199071265119715328
2019-11-25 21:03:25,sfef84,,0,1,1,"$ACAD 49.05 DJ ACADIA Pharmaceuticals Announces Positive Top-line Results From ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia",,,,1199071110530248704,https://twitter.com/sfef84/status/1199071110530248704
2019-11-24 00:24:58,dingfriesdun,realDonaldTrump,0,0,0,"Maybe you should take @Pimavanserin to help with your delusions. – at Apple",,@Pimavanserin,,1198397059310718977,https://twitter.com/dingfriesdun/status/1198397059310718977
2019-11-22 21:49:58,KingFranklinIV,usonainstitute,0,0,1,"Huge news. Between MDMA and psilocybin, psychedelics are the *only* drugs to be given this designation by the FDA to date. Pimavanserin doesn’t count as it’s only for Parkinson’s-related psychosis. ",,,,1197995663918862336,https://twitter.com/KingFranklinIV/status/1197995663918862336
2019-11-22 11:00:36,PaperbirdsN,,0,0,0,"New article: Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. http://dlvr.it/RJrPYB #parkinsons #neurology",,,#parkinsons #neurology,1197832244934479872,https://twitter.com/PaperbirdsN/status/1197832244934479872
2019-11-22 04:36:03,Biotech2050,,0,1,3,"""Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of #Schizophrenia (ADVANCE)"" $ACAD will announce results soon for this trial and on 12/04 will release additional data on #dementia related #psychosis #DRP #Alzheimers",,,#Schizophrenia #dementia #psychosis #DRP #Alzheimers,1197735471008366592,https://twitter.com/Biotech2050/status/1197735471008366592
2019-11-21 18:03:59,PananthattilR,,0,0,1,"It's good news #pimavanserin which is a #serotonin 2A receptor partial agonist is found to be useful in #dementia related #psychosis/ #schizophrenia&amp;psychotic #depression apart from #Parkinsons related psychosis&amp;it's not a dopamine antagonist like other #antipsychotics #nuplazid https://twitter.com/JClinPsychiatry/status/1197536401283338240",,,#pimavanserin #serotonin #dementia #psychosis #schizophrenia #depression #Parkinsons #antipsychotics #nuplazid,1197576406785392640,https://twitter.com/PananthattilR/status/1197576406785392640
2019-11-21 15:25:01,JClinPsychiatry,,0,5,15,"The use of atypical #antipsychotics as adjunctive treatment for nonresponsive #depression is limited by side effects. This study explores whether #pimavanserin can be both an efficacious and tolerable adjunctive treatment for major depressive disorder. http://bit.ly/2KDnHMF",,,#antipsychotics #depression #pimavanserin,1197536401283338240,https://twitter.com/JClinPsychiatry/status/1197536401283338240
2019-11-17 04:14:04,Ingentium_PD,,0,1,1,"Study to Evaluate Safety and Daytime Sedation in Subjects With #ParkinsonsDisease #PD With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine http://dlvr.it/RJRdd3",,,#ParkinsonsDisease #PD,1195917999628111872,https://twitter.com/Ingentium_PD/status/1195917999628111872
2019-11-16 00:00:05,DepressionData,,0,0,1,"New clinical trial for #depression: Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) https://medtally.com/post/study-to-evaluate-the-efficacy-and-safety-of-adjunctive-pimavanserin-in-major-depressive-disorder-clarity-549354",,,#depression,1195491694881341440,https://twitter.com/DepressionData/status/1195491694881341440
2019-11-14 01:14:00,neurology_live,,1,2,3,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage #PsychosisSymptoms.",,,#pimavanserin #PsychosisSymptoms,1194785518183014400,https://twitter.com/neurology_live/status/1194785518183014400
2019-11-13 23:33:31,MizzouPatriot,,0,0,0,"@EveningEdit @LizMacDonaldFOX @FoxBusiness @Pimavanserin The guy on the otherwise very well done Nuplazid commercial is Jeffrey Epstein’s doppelgänger. Just sayin’.",,@EveningEdit @LizMacDonaldFOX @FoxBusiness @Pimavanserin,,1194760230153805825,https://twitter.com/MizzouPatriot/status/1194760230153805825
2019-11-12 23:14:00,neurology_live,,0,1,0,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage #PsychosisSymptoms. https://www.neurologylive.com/journals/neurologylive/2019/october-2019/managing-psychosis-in-parkinson-disease-challenges-and-opportunities",,,#pimavanserin #PsychosisSymptoms,1194392931282505729,https://twitter.com/neurology_live/status/1194392931282505729
2019-11-12 07:18:31,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1194152476213219329,https://twitter.com/BrainSightsApp/status/1194152476213219329
2019-11-11 21:08:57,Tony1518,UsAgainstAlz,0,0,0,"The way Alzheimer is approached the cure is an illusion Oligomannate pretend to""improve""cognitive function which is, subjective, meaning, not necessary. Aducanumab totally useless Pimavanserin treat psychosis,1 is dissociative the other is degenerative, where is the common ground",,,,1193999075517095939,https://twitter.com/Tony1518/status/1193999075517095939
2019-11-11 16:29:23,UsAgainstAlz,,1,4,7,"It’s been an exciting few weeks in the Alzheimer’s world. All of the activity has raised a lot of questions around the progress toward a cure. A new blog from our COO @RussPaulsen answers some questions about oligomannate, aducanumab, and pimavanserin. ",,@RussPaulsen,,1193928717879386118,https://twitter.com/UsAgainstAlz/status/1193928717879386118
2019-11-05 17:51:10,geridrugho,geridrugho,0,0,3,"Who said geri clin pharm was not exciting? Pimavanserin's pharmacology, and comparative risks and benefits. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207318Orig1s000MedR.pdf #gerimedrisk",,,#gerimedrisk,1191774973603520513,https://twitter.com/geridrugho/status/1191774973603520513
2019-11-05 17:08:21,geridrugho,GeriMedRisk,1,0,6,"Excited to learn about benefits and risks of pimavanserin, newly featured on the updated beers @AGardhouse @camilla_wong",,@AGardhouse @camilla_wong,,1191764196645593090,https://twitter.com/geridrugho/status/1191764196645593090
2019-11-04 19:10:07,CLRI_LTC,,0,1,1,"Register for tomorrow's @GeriMedRisk webinar Geriatric Clinical Pharmacology Rounds ""Pimavanserin: 5HT2, eh?"" Tuesday, November 5th, 12:00-1:00pm. Learn more: http://ow.ly/Uqjs50wPRud #meded #safeprescribing #educationforprescribers #webinar",,@GeriMedRisk,#meded #safeprescribing #educationforprescribers #webinar,1191432454428594176,https://twitter.com/CLRI_LTC/status/1191432454428594176
2019-11-04 15:33:40,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1191377983807856640,https://twitter.com/BrainSightsApp/status/1191377983807856640
2019-11-04 13:39:00,neurology_live,,0,0,1,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage #psychosis symptoms.",,,#pimavanserin #psychosis,1191349124983087104,https://twitter.com/neurology_live/status/1191349124983087104
2019-11-03 18:23:02,Anton_Pearce,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression http://dlvr.it/RHXYBT",,,,1191058218404859905,https://twitter.com/Anton_Pearce/status/1191058218404859905
2019-11-03 16:28:00,neurology_live,,0,1,1,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage #psychosis symptoms. https://www.neurologylive.com/journals/neurologylive/2019/october-2019/managing-psychosis-in-parkinson-disease-challenges-and-opportunities",,,#pimavanserin #psychosis,1191029267137617921,https://twitter.com/neurology_live/status/1191029267137617921
2019-11-01 16:47:00,neurology_live,,0,1,0,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms. https://www.neurologylive.com/journals/neurologylive/2019/october-2019/managing-psychosis-in-parkinson-disease-challenges-and-opportunities",,,#pimavanserin,1190309273085108226,https://twitter.com/neurology_live/status/1190309273085108226
2019-11-01 02:37:28,semodough,,0,2,6,"$ACAD two key remaining events in 2019 detailed interim Phase 3 data for pimavanserin in dementia- related psychosis (DRP) at CTAD, December 4th in San Diego; and (2) results for the Phase 2 study in schizophrenia negative symptoms in 4Q19.",,,,1190095483466911746,https://twitter.com/semodough/status/1190095483466911746
2019-10-31 04:30:03,SiteFocusHQ,,0,0,0,"$ACAD Earnings Intelligence Analysis of recent earnings identified ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) business focus on (mdd,positive), (pimavanserin,trofinetide), (fda,pimavanserin,post-marketing) https://www.sitefocus.com/cif/cifqbainq?ajencparm=Y0ngTYu0J%2Fb32MkFbLYScCWGCHJkQeQwxnWemWWTInmvuQKbpLkLgb1SSXPTKVsE0wmmJPrZq5TNsgZ1dgBrEXO8PgRF",,,,1189761426224627713,https://twitter.com/SiteFocusHQ/status/1189761426224627713
2019-10-31 01:05:00,neurology_live,,0,1,0,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms. https://www.neurologylive.com/journals/neurologylive/2019/october-2019/managing-psychosis-in-parkinson-disease-challenges-and-opportunities",,,#pimavanserin,1189709823413239810,https://twitter.com/neurology_live/status/1189709823413239810
2019-10-30 11:38:00,neurology_live,,0,1,2,"Although the indication of #pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage #psychosis symptoms. https://www.neurologylive.com/journals/neurologylive/2019/october-2019/managing-psychosis-in-parkinson-disease-challenges-and-opportunities",,,#pimavanserin #psychosis,1189506734861291521,https://twitter.com/neurology_live/status/1189506734861291521
2019-10-29 15:38:04,GeriMedRisk,,1,1,1,"We are looking forward to upcoming GeriMedRisk rounds “Pimavanserin: 5HT2, eh?” presented by Jack Bodkin (RPh, BCGP). Join us online Nov 5 at 12pm EDT by registering to attend: https://gerimedrisk.us17.list-manage.com/track/click?u=583aeb76b54728de6549236cd&amp;id=ebb9a14b36&amp;e=8ebfd8ee12 #meded #atypicalantipsychotic #parkinson’s",,,#meded #atypicalantipsychotic #parkinson,1189204761981149184,https://twitter.com/GeriMedRisk/status/1189204761981149184
2019-10-29 14:01:03,OnLTCC,,0,0,0,"https://www.gerimedrisk.com OBJECTIVES: - pharmacology of pimavanserin and atypical antipsychotics - pimavanserin in the treatment of psychosis in Parkinson's disease, efficacy and safety - other treatments of psychosis in PD - current research directions @geridrugho",,@geridrugho,,1189180348686577664,https://twitter.com/OnLTCC/status/1189180348686577664
2019-10-26 16:16:43,haru_spex0,markwwilsonmd,0,0,0,"Anything about Pimavanserin? I’ve got a lady with TR psychosis. She’s failed clozapine. Worth considering?",,,,1188127324283133952,https://twitter.com/haru_spex0/status/1188127324283133952
2019-10-23 21:33:53,LarissaMVLopez,dcweisman,0,0,0,"Many negative trials for citalopram for neuropsych symptoms. Pimavanserin kills patients with dementia just like with other antipsychotics. Suvorexant hasn't been studied against other hypnotics, only placebo so no way of knowing if it is more effective.",,,,1187119980992716801,https://twitter.com/LarissaMVLopez/status/1187119980992716801
2019-10-23 14:25:02,JClinPsychiatry,,0,3,9,"The use of atypical #antipsychotics as adjunctive treatment for nonresponsive #depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious &amp; tolerable adjunctive treatment for #MDD. http://bit.ly/31n0ljW #TRD",,,#antipsychotics #depression #MDD #TRD,1187012055053848583,https://twitter.com/JClinPsychiatry/status/1187012055053848583
2019-10-20 11:06:26,BlancFrdric7,,0,0,1,"Pimavanserin is so effective against behavioural disorders in dementia (Alzheimer's, dementia with Lewy bodies) that the therapeutic trial has been stopped. Quick, we need this treatment in Europe and France ",,,,1185874911547592704,https://twitter.com/BlancFrdric7/status/1185874911547592704
2019-10-18 18:20:48,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1185259451160371201,https://twitter.com/BrainSightsApp/status/1185259451160371201
2019-10-17 06:20:51,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1184715881122881536,https://twitter.com/BrainSightsApp/status/1184715881122881536
2019-10-15 02:28:00,neurology_live,,0,0,1,"#ICYMI: Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with #Parkinsons disease with depressive symptoms in an 8-week, open-label study.",,,#ICYMI #Parkinsons,1183932504740253696,https://twitter.com/neurology_live/status/1183932504740253696
2019-10-14 17:13:00,neurology_live,,0,0,1,"Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with #Parkinsons disease with depressive symptoms in an 8-week, open-label study. https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#Parkinsons,1183792834664681472,https://twitter.com/neurology_live/status/1183792834664681472
2019-10-12 19:00:33,PFheartland,,0,1,1,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis https://buff.ly/2ldPF8u",,,,1183095125058228226,https://twitter.com/PFheartland/status/1183095125058228226
2019-10-12 06:51:02,RobertXJohn,NikkieVel,1,0,0,"Mag risperidone ka or pimavanserin pills to counter hallucinations ",,,,1182911535296868353,https://twitter.com/RobertXJohn/status/1182911535296868353
2019-10-11 11:56:21,jackperlov,,0,0,0,"Pimavanserin: A potentially safer alternative to clozapine for refractory hallucinations and delusions ",,,,1182625984953995264,https://twitter.com/jackperlov/status/1182625984953995264
2019-10-11 11:42:26,jackperlov,,0,0,0,"Pimavanserin Improves Sexual Function in Patients With MDD ",,,,1182622483804872706,https://twitter.com/jackperlov/status/1182622483804872706
2019-10-10 03:17:18,SeeFisch,,0,14,34,"Quetiapine is the anti-psychotic medication with the smallest amount of extrapyramidal symptoms which is another way of saying Parkinsonism. Pimavanserin is an anti-psychotic medication that does not inhibit dopamine. LEARN IT ALL HERE: ",,,,1182132972822110208,https://twitter.com/SeeFisch/status/1182132972822110208
2019-10-08 01:14:49,hgabrielpj,,0,0,0,"Pimavanserin could be used in Parkinson. Only if there is psychosis though.",,,,1181377372748169216,https://twitter.com/hgabrielpj/status/1181377372748169216
2019-10-07 20:48:39,MaisaCorp,,0,0,0,"$ACAD said a secondary analysis of its Phase 2 CLARITY study evaluating pimavanserin showed the drug has the potential to improve the symptoms of sexual dysfunction in patients with major depressive disorder, or MDD.",,,,1181310391961505793,https://twitter.com/MaisaCorp/status/1181310391961505793
2019-10-07 15:05:31,Briefingcom,,0,0,0,"$ACAD: ACADIA Pharmaceuticals says adjunctive pimavanserin showed the potential to improve symptoms of sexual... http://bit.ly/2AS8CSm",,,,1181224039336955904,https://twitter.com/Briefingcom/status/1181224039336955904
2019-10-07 13:20:54,Biotech2050,,0,1,2,"$ACAD Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major #Depressive Disorder at 2019 Psych Congress",,,#Depressive,1181197712772993024,https://twitter.com/Biotech2050/status/1181197712772993024
2019-10-07 13:15:49,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunct http://crweworld.com/article/news-provided-by-business-wire/1265077/acadia-pharmaceuticals-presents-additional-positive-data-from-the-phase-2-clarity-study-with-pimavanserin-in-adjunctive-major-depressive-disorder-at-2019-psych-congress",,,,1181196431543025664,https://twitter.com/CrweWorld/status/1181196431543025664
2019-10-07 03:05:32,Ingentium_PD,,0,1,1,"Study Finds Pimavanserin May Effectively Treat #ParkinsonsDisease #PD Psychosis",,,#ParkinsonsDisease #PD,1181042846834413568,https://twitter.com/Ingentium_PD/status/1181042846834413568
2019-10-05 06:36:42,deedeeb8,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression ",,,,1180371216453914625,https://twitter.com/deedeeb8/status/1180371216453914625
2019-10-04 18:02:51,bridge_insights,,0,0,0,"ACADIA Pharmaceuticals announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinic…https://lnkd.in/fGEtyUb https://lnkd.in/fXwtq8A",,,,1180181503009071105,https://twitter.com/bridge_insights/status/1180181503009071105
2019-10-04 03:39:11,Biotech2050,,0,2,5,"$ACAD Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in #Dementia-Related #Psychosis at the Clinical Trials on #Alzheimer’s Disease (CTAD) 2019 Meeting #CTAD19",,,#Dementia #Psychosis #Alzheimer #CTAD19,1179964154611929089,https://twitter.com/Biotech2050/status/1179964154611929089
2019-10-03 22:58:46,Briefingcom,,0,1,2,"$ACAD: ACADIA Pharmaceuticals announces late-breaking oral presentation of Phase 3 HARMONY pimavanserin data at CTAD... http://bit.ly/2M9oTHH",,,,1179893585828646912,https://twitter.com/Briefingcom/status/1179893585828646912
2019-10-03 21:25:27,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dem http://crweworld.com/article/news-provided-by-business-wire/1262323/acadia-pharmaceuticals-announces-late-breaking-oral-presentation-of-the-phase-3-harmony-study-of-pimavanserin-in-dementia-related-psychosis-at-the-clinical-trials-on-alzheimers-disease-ctadn-2019-meeting",,,,1179870100213526528,https://twitter.com/CrweWorld/status/1179870100213526528
2019-10-03 20:59:38,NedPagliarulo,,1,1,0,"$ACAD will present pimavanserin results from HARMONY study in dementia-related psychosis at CTAD on Dec. 4. https://www.businesswire.com/news/home/20191003005841/en/ACADIA-Pharmaceuticals-Announces-Late-Breaking-Oral-Presentation-Phase",,,,1179863604566413314,https://twitter.com/NedPagliarulo/status/1179863604566413314
2019-10-03 12:02:00,neurology_live,,0,0,0,"Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with #Parkinson disease with depressive symptoms in an 8-week, open-label study.",,,#Parkinson,1179728302799495172,https://twitter.com/neurology_live/status/1179728302799495172
2019-10-02 18:07:10,PracticalNeuro,,0,0,0,"Pimavanserin Also Effective as Adjunct Treatment for Major #Depressive Disorder - Practical Neurology #PD #psychosis #MDD #AcadiaPharm",,,#Depressive #PD #psychosis #MDD #AcadiaPharm,1179457812205899781,https://twitter.com/PracticalNeuro/status/1179457812205899781
2019-10-02 12:22:30,neurology_live,,0,0,0,"Results of an interim efficacy analysis have led Acadia Pharmaceuticals to halt its phase 3 HARMONY trial of pimavanserin (Nuplazid) after demonstrating a highly statistically significant reduction in relapse in patients with dementia-related psychosis. ",,,,1179371073516818432,https://twitter.com/neurology_live/status/1179371073516818432
2019-10-01 21:41:00,MedscapePharm,,0,4,2,"Pimavanserin, a novel antipsychotic, may improve resistant major depressive disorder symptoms. ",,,,1179149237046644739,https://twitter.com/MedscapePharm/status/1179149237046644739
2019-10-01 19:03:00,MDMagazine,,0,1,1,"“Pimavanserin demonstrated robust efficacy in patients with MDD and an inadequate response to an SSRI or SNRI,” authors of a new phase 2 study wrote. “Tolerability was consistent with previous experience.” ",,,,1179109475124252672,https://twitter.com/MDMagazine/status/1179109475124252672
2019-10-01 18:46:02,NNTonthefly,,0,0,0,"New NNT→Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. http://bit.ly/2zdfxX4",,,,1179105205704482817,https://twitter.com/NNTonthefly/status/1179105205704482817
2019-10-01 12:15:25,jerod23,MedscapePsych,1,1,0,"As an add-on. Just like most antipsychotics. Although pimavanserin is pretty damn novel in its mechanism of action, so it might be worth considering as an add-on before other APs. ",,,,1179006905169133569,https://twitter.com/jerod23/status/1179006905169133569
2019-10-01 12:03:00,MedscapePsych,,0,6,4,"Pimavanserin may improve resistant major depressive disorder symptoms. http://ms.spr.ly/6019TuvwW",,,,1179003778659491840,https://twitter.com/MedscapePsych/status/1179003778659491840
2019-10-01 11:20:10,MNCAssociates,,0,0,0,"Pimavanserin may improve resistant major depressive disorder symptoms. @MedscapePsych http://ms.spr.ly/6015TuvZb",,@MedscapePsych,,1178992999142957062,https://twitter.com/MNCAssociates/status/1178992999142957062
2019-09-30 19:38:54,Spanishcountry,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression https://www.medscape.com/viewarticle/919096?src=soc_tw_share via @medscape",,@Medscape,,1178756122645270530,https://twitter.com/Spanishcountry/status/1178756122645270530
2019-09-30 17:46:00,neurology_live,,0,0,1,"#ICYMI last week: The removal of pregnancy contraindications from 2 interferon-beta therapies for #MS; positive data on oral tavapadon in early-stage Parkinson disease; and data on pimavanserin for #depression in patients with Parkinson disease.",,,#ICYMI #MS #depression,1178727709528084481,https://twitter.com/neurology_live/status/1178727709528084481
2019-09-30 16:55:23,geropsych,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression https://www.medscape.com/viewarticle/919096",,,,1178714973947625472,https://twitter.com/geropsych/status/1178714973947625472
2019-09-30 15:04:11,EDesapriya,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression https://www.medscape.com/viewarticle/919096?src=soc_tw_share via @medscape",,@Medscape,,1178686989479989249,https://twitter.com/EDesapriya/status/1178686989479989249
2019-09-30 00:03:00,MedscapePsych,,0,8,15,"Pimavanserin may improve resistant major depressive disorder symptoms. http://ms.spr.ly/6015TuvZb",,,,1178460197003694081,https://twitter.com/MedscapePsych/status/1178460197003694081
2019-09-29 13:26:00,neurology_live,,0,1,0,"This week on #NNN: The removal of pregnancy contraindications from 2 interferon-beta therapies for #MS; positive data on oral tavapadon in early-stage Parkinson disease; and data on pimavanserin for #depression in patients with Parkinson disease. WATCH: https://www.neurologylive.com/clinical-focus/ema-removes-pregnancy-contraindications-from-ms-drugs-oral-tavapadon-effective-in-earlystage-parkinson-disease-pimavanserin-reduces-depression-in-pd",,,#NNN #MS #depression,1178299890218291201,https://twitter.com/neurology_live/status/1178299890218291201
2019-09-29 11:30:35,neurologis,,0,0,1,"EMA Removes Pregnancy Contraindications From MS Drugs, Oral Tavapadon Effective in Early-Stage Parkinson Disease, Pimavanserin Reduces Depression in PD https://www.neurologylive.com/clinical-focus/ema-removes-pregnancy-contraindications-from-ms-drugs-oral-tavapadon-effective-in-earlystage-parkinson-disease-pimavanserin-reduces-depression-in-pd?eKey=ZHJpc2FhYy5tb3NxdWVyYUBnbWFpbC5jb20= vía @neurology_live",,@neurology_live,,1178270846902820869,https://twitter.com/neurologis/status/1178270846902820869
2019-09-28 21:26:59,eturnermd1,,2,2,8,"Next step was to look up the speaker in Open Payments https://openpaymentsdata.cms.gov, which showed that this KOL has received megabucks from Acadia Pharma. Guess which company makes pimavanserin?",,,,1178058547747123205,https://twitter.com/eturnermd1/status/1178058547747123205
2019-09-28 21:26:59,eturnermd1,,1,1,2,"Email back to (the very lg group). Talk objectives: (1) role of serotonin, specifically (2) 5-HT2A receptor in causing (3) psychotic sx in patients with (4) Parkinson's disease. Pimavanserin checks all 4 boxes. AND it's the only drug FDA-approved for this indication. ",,,,1178058545981358080,https://twitter.com/eturnermd1/status/1178058545981358080
2019-09-28 21:20:00,neurology_live,,0,1,1,"#ICYMI: Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with #Parkinson disease with depressive symptoms in an 8-week, open-label study. https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#ICYMI #Parkinson,1178056788329058304,https://twitter.com/neurology_live/status/1178056788329058304
2019-09-28 18:18:15,Rx_Ed,,0,2,5,"For DECADES, we had no new therapy for Parkinson’s disease. In the last 2 years only, we came up with PIMAVANSERIN (for Parkinson’s associated psychosis) and ISTRADEFYLLINE (for on/off phenomenon). Isn’t this a miracle? I’m HIGH on life and I have so much LOVE to give! @SeeFisch",,@SeeFisch,,1178011052316991492,https://twitter.com/Rx_Ed/status/1178011052316991492
2019-09-28 12:10:00,neurology_live,,0,0,0,"This week on #NNN: The removal of pregnancy contraindications from 2 interferon-beta therapies for #MS; positive data on oral tavapadon in early-stage Parkinson disease; and data on pimavanserin for #depression in patients with Parkinson disease. WATCH: https://www.neurologylive.com/clinical-focus/ema-removes-pregnancy-contraindications-from-ms-drugs-oral-tavapadon-effective-in-earlystage-parkinson-disease-pimavanserin-reduces-depression-in-pd",,,#NNN #MS #depression,1177918376259121154,https://twitter.com/neurology_live/status/1177918376259121154
2019-09-28 03:26:00,neurology_live,,0,0,2,"Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with #Parkinson disease with depressive symptoms in an 8-week, open-label study.",,,#Parkinson,1177786507429580802,https://twitter.com/neurology_live/status/1177786507429580802
2019-09-27 17:35:24,somsirsa,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression – Medscape ",,,,1177637880807727104,https://twitter.com/somsirsa/status/1177637880807727104
2019-09-27 15:44:36,somsirsa,,0,0,0,"Add-On Pimavanserin Promising for Resistant Major Depression – Medscape https://somsirsac.wordpress.com/2019/09/27/add-on-pimavanserin-promising-for-resistant-major-depression-medscape/",,,,1177609994667208706,https://twitter.com/somsirsa/status/1177609994667208706
2019-09-26 15:49:16,psychopharmacol,,0,0,1,"Pimavanserin (a 5-hydroxytryptamine-2A antagonist and inverse receptor agonist) demonstrated efficacy in patients with MDD and an inadequate response to an SSRI or SNRI [At week 5, LS mean (SE) difference vs placebo on the HDRS-17 = −4.0 [1.09] (P=.0003) https://www.psychiatrist.com/JCP/article/Pages/2019/v80/19m12928.aspx",,,,1177248782901227534,https://twitter.com/psychopharmacol/status/1177248782901227534
2019-09-26 15:40:00,neurology_live,,0,0,0,"New phase 2 results suggest that investigational pimavanserin treatment, as monotherapy or adjunct to SSRI or SNRI therapy, is associated with an improvement in patients with #Parkinson disease who have depressive symptoms https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#Parkinson,1177246448766898177,https://twitter.com/neurology_live/status/1177246448766898177
2019-09-26 14:07:18,Neuropsychophar,,1,1,12,"Congrats to @IMunetaArrate on winning a Travel Award @ECNPtweets #ecnp2019 #Neuropsichopharmacologylab #5HT2A #Pimavanserin ",,@IMunetaArrate @ECNPtweets,#ecnp2019 #Neuropsichopharmacologylab #5HT2A #Pimavanserin,1177223119259537408,https://twitter.com/Neuropsychophar/status/1177223119259537408
2019-09-26 02:40:00,neurology_live,,0,1,2,"New phase 2 results suggest that investigational pimavanserin treatment, as monotherapy or adjunct to SSRI or SNRI therapy, is associated with an improvement in patients with #Parkinson disease who have depressive symptoms https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#Parkinson,1177050155637305344,https://twitter.com/neurology_live/status/1177050155637305344
2019-09-25 20:39:00,neurology_live,,0,1,1,"#ICYMI at #MDS2019: Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study. https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#ICYMI #MDS2019,1176959306840723456,https://twitter.com/neurology_live/status/1176959306840723456
2019-09-25 15:57:19,ForTheRecord01,,0,0,2,"It is a shame that somebody claiming to be a professor should inoculate himself from scrutiny, as the absurd @AF_biotech has done with me. Those interested in pimavanserin's importance in depression should see Dr. Fava's article: https://www.psychiatrist.com/JCP/article/Pages/2019/v80/19m12928.aspx $ACAD",,@AF_biotech,,1176888419227598848,https://twitter.com/ForTheRecord01/status/1176888419227598848
2019-09-25 15:54:51,ForTheRecord01,,0,0,3,"$ACAD ""Pimavanserin demonstrated robust and clinically meaningful efficacy in MDD patients with inadequate response to antidepressant therapy,"" writes Harvard's Maurizio Fava in The Journal of Clinical Psychiatry.",,,,1176887800932651009,https://twitter.com/ForTheRecord01/status/1176887800932651009
2019-09-25 14:39:00,byMattHoffman,,0,1,2,"#ICYMI at #MDS2019: Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study. https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#ICYMI #MDS2019,1176868709949825024,https://twitter.com/byMattHoffman/status/1176868709949825024
2019-09-25 14:25:02,JClinPsychiatry,,1,2,4,"Just Published: ""A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With #MDD and an Inadequate Response to Therapy (CLARITY)"". http://bit.ly/2lsvPpS #TRD #depression @MassGeneralNews @harvardmed @PennMedicine @UTSWNews",,@MassGeneralNews @harvardmed @PennMedicine @UTSWNews,#MDD #TRD #depression,1176865195530104832,https://twitter.com/JClinPsychiatry/status/1176865195530104832
2019-09-25 14:19:23,neurology_live,,0,0,0,"#MDS2019: Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study. https://www.neurologylive.com/conferences/mds-2019/pimavanserin-improves-parkinson-disease-depressive-symptoms",,,#MDS2019,1176863774726397952,https://twitter.com/neurology_live/status/1176863774726397952
2019-09-25 01:33:03,feed_stocks,,0,0,0,"ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder ",,,,1176670919936233472,https://twitter.com/feed_stocks/status/1176670919936233472
2019-09-24 23:05:01,mrdphd,,0,0,0,"Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the in under the trade name NUPLAZID. #MSL #medicalaffairs #neurodegeneration #parkinsons",,,#MSL #medicalaffairs #neurodegeneration #parkinsons,1176633664718946310,https://twitter.com/mrdphd/status/1176633664718946310
2019-09-24 22:13:01,Briefingcom,,0,0,0,"$ACAD: ACADIA Pharmaceuticals reports that positive ph 2 CLARITY results were published for pimavanserin as... http://bit.ly/2mr03d8",,,,1176620580910448640,https://twitter.com/Briefingcom/status/1176620580910448640
2019-09-24 20:42:03,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder - https://sdbn.org/san-diego-biotech-news/2019/09/24/acadia-pharmaceuticals-announces-that-the-journal-of-clinical-psychiatry-publishes-positive-phase-2-clarity-results-for-pimavanserin-as-adjunctive-treatment-for-patients-with-major-depressive-disorder/ #biotech #news",,,#biotech #news,1176597686734266368,https://twitter.com/sdbn/status/1176597686734266368
2019-09-24 20:17:32,Pediatrics_Bio,,0,1,0,"ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder: Pimavanserin as an adjunctive treatment for patients… http://bioportfol.io/RDpGSd",,,,1176591517009317888,https://twitter.com/Pediatrics_Bio/status/1176591517009317888
2019-09-24 07:52:01,AlzheimerEurope,,0,2,3,"ACADIA Pharmaceuticals announces that its HARMONY Phase III of #pimavanserin met its primary endpoint in people with #dementia-related psychosis https://bit.ly/2lhb3cJ",,,#pimavanserin #dementia,1176403903539273728,https://twitter.com/AlzheimerEurope/status/1176403903539273728
2019-09-23 22:58:30,PsychopharmInst,,0,0,2,"Psychosis in Parkinson's Disease: Clozapine, Quetiapine, and Pimavanserin This presentation covers the workup, management strategies, and medications used for psychosis in Parkinson's disease, including the recent FDA-approved drug pimavanserin. https://psychopharmacologyinstitute.com/section/psychosis-in-pd-management-strategies-2353-4560?utm_source=Twitter&amp;utm_medium=Twitter&amp;utm_campaign=[Twitter]1707",,,,1176269638122053632,https://twitter.com/PsychopharmInst/status/1176269638122053632
2019-09-23 22:17:40,DataTrials,,0,0,0,"$ACAD Phase 2 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)…NCT02970305. Estimated Primary Completion Date - 10/2019",,,,1176259360542134277,https://twitter.com/DataTrials/status/1176259360542134277
2019-09-23 20:15:21,MaisaCorp,,0,1,1,"$ACAD presenting positive data from phase II testing of its pimavanserin drug candidate in patients with Parkinson's disease and depressive symptoms, showing significant improvement in symptoms as soon as two weeks after treatment began",,,,1176228580138913796,https://twitter.com/MaisaCorp/status/1176228580138913796
2019-09-23 15:08:45,Briefingcom,,0,0,1,"$ACAD: ACADIA Pharmaceuticals presents ""positive"" data from Parkinson's disease patients treated with pimavanserin... http://bit.ly/2mb5tbT",,,,1176151423303573505,https://twitter.com/Briefingcom/status/1176151423303573505
2019-09-23 13:58:14,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders - https://sdbn.org/san-diego-biotech-news/2019/09/23/acadia-pharmaceuticals-presents-new-data-on-pd-patients-treated-with-pimavanserin-for-depression-at-the-2019-international-congress-of-parkinsons-disease-and-movement-disorders/ #biotech #news",,,#biotech #news,1176133676343672833,https://twitter.com/sdbn/status/1176133676343672833
2019-09-23 13:49:16,syinvesting,,0,0,0,"$ACAD presents new data on #Parkinsons patients treated with pimavanserin for #depression. On Friday, the company closed a secondary offering for $287.5M in gross proceeds (full shoe exercised). Meanwhile, Cantor maintains OW and raised PT to $56/share. http://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-new-data-pd-patients-treated?field_nir_news_date_value%5Bmin%5D=",,,#Parkinsons #depression,1176131420705579008,https://twitter.com/syinvesting/status/1176131420705579008
2019-09-23 13:27:17,MatteoNecci,,0,1,0,"$ACAD ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders | Business Wire https://www.businesswire.com/news/home/20190923005157/en/ACADIA-Pharmaceuticals-Presents-New-Data-PD-Patients#.XYjHvfJAMBY.twitter",,,,1176125887126704128,https://twitter.com/MatteoNecci/status/1176125887126704128
2019-09-23 13:17:56,Biotech2050,,0,0,0,"$ACAD Presents New Data on PD Patients Treated with Pimavanserin for #Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders cc @Clive_Ballard @UofE_Research http://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-new-data-pd-patients-treated?field_nir_news_date_value[min]=",,@Clive_Ballard @UofE_Research,#Depression,1176123534990594048,https://twitter.com/Biotech2050/status/1176123534990594048
2019-09-23 13:08:34,MrZackMorris,,1,0,0,"$ACAD ACADIA Pharmaceuticals presents ""positive"" data from Parkinson's disease patients treated with pimavanserin for depression",,,,1176121178936750080,https://twitter.com/MrZackMorris/status/1176121178936750080
2019-09-23 05:01:25,ForTheRecord01,,1,1,3,"$ACAD Nuplazid (pimavanserin) was found to be effective in a phase 2 Parkinson's depression trial. Data to be presented at Parkinson's conference on Sept. 23, 2019. ",,,,1175998583394275329,https://twitter.com/ForTheRecord01/status/1175998583394275329
2019-09-22 13:11:28,AndyMcKenzie,,0,0,0,"A Phase 3 trial of pimavanserin met its primary endpoint early of delaying relapse to psychosis in people with all-cause dementia. Atypical trial design - participants started on the med, then responders were randomized to the med or placebo. https://www.alzforum.org/news/research-news/phase-3-trial-suggests-pimavanserin-assuages-psychosis-dementia",,,,1175759519105933312,https://twitter.com/AndyMcKenzie/status/1175759519105933312
2019-09-21 20:56:26,MarketChmln,,0,0,0,"$ACAD upcoming event September 23: Open-Label Study of Pimavanserin in Patients With Comorbid Parkinson https://marketchameleon.com/Overview/ACAD/OptionChain/?e=1860_20190927",,,,1175514145040605184,https://twitter.com/MarketChmln/status/1175514145040605184
2019-09-21 09:32:21,Biotech2050,mattdoc1982,1,0,1,"not before pimavanserin trials shows success in DRP; depression; and whatever they have in Phase 3 so that then $ACAD can apply for all in EU in one go whilst they are getting staggered approvals in US. Its for their patent expiry protection in EU.",,,,1175341989166014464,https://twitter.com/Biotech2050/status/1175341989166014464
2019-09-21 09:24:32,Biotech2050,Clive_Ballard,0,0,1,"Video: Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis https://www.youtube.com/watch?v=UX-ZtAoNBxo&amp;feature=youtu.be Dr Ballard your comment ""spectacularly good"" still echoes in my mind. $ACAD pimavanserin",,,,1175340023014711296,https://twitter.com/Biotech2050/status/1175340023014711296
2019-09-20 00:14:53,MedsOptADRD,,0,0,0,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis | BioSpace https://www.biospace.com/article/releases/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/?TrackID=16 #jobs",,,#jobs,1174839310144561152,https://twitter.com/MedsOptADRD/status/1174839310144561152
2019-09-19 18:11:15,Biotech2050,Clive_Ballard,1,1,1,"Listen to a key opinion leader @matthewherper on $ACAD pimavanserin. Any chance you interview @Clive_Ballard?",,@matthewherper @Clive_Ballard,,1174747799096832002,https://twitter.com/Biotech2050/status/1174747799096832002
2019-09-19 17:27:46,Clive_Ballard,,9,36,98,"Great to see press release that the phase 3 clinical trial of pimavanserin for treating psychosis in people with Alz Dis (following on from our phase 2 trial) has been stopped early because of CLEAR BENEFIT. Look forward to seeing the full results!! #exeterdementia",,,#exeterdementia,1174736854169587713,https://twitter.com/Clive_Ballard/status/1174736854169587713
2019-09-19 13:24:12,Biotech2050,,0,1,3,"$ACAD to present Nuplazid as a viagra equivalent for depression patients having sexual dysfunction (basically all of them) ""Poster Number 137:Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin presented on October 4""",,,,1174675560284524546,https://twitter.com/Biotech2050/status/1174675560284524546
2019-09-19 13:08:05,cro_bio,,0,0,0,"ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings: New data presented at the International Congress of Parkinsons Disease and Movement Disorders will highlight treatment benefit of pimavanserin in… ",,,,1174671503880646661,https://twitter.com/cro_bio/status/1174671503880646661
2019-09-19 10:48:04,NFLObjectors,,0,0,0,"Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia https://www.alzforum.org/news/research-news/phase-3-trial-suggests-pimavanserin-assuages-psychosis-dementia",,,,1174636267671302144,https://twitter.com/NFLObjectors/status/1174636267671302144
2019-09-19 02:28:09,brunovellas,,0,6,5,"Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia | ALZFORUM https://www.alzforum.org/news/research-news/phase-3-trial-suggests-pimavanserin-assuages-psychosis-dementia",,,,1174510459497713664,https://twitter.com/brunovellas/status/1174510459497713664
2019-09-18 20:30:28,i_zekel,,0,0,0,"Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia",,,,1174420444834750464,https://twitter.com/i_zekel/status/1174420444834750464
2019-09-18 18:46:31,alzforum,,0,0,0,"Phase 3 pimavanserin trial ends early, claiming drug reduced psychosis in people with dementia. http://ow.ly/d81850wfpDy",,,,1174394284826669057,https://twitter.com/alzforum/status/1174394284826669057
2019-09-18 02:17:18,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1174145342209712129,https://twitter.com/BrainSightsApp/status/1174145342209712129
2019-09-17 11:01:08,PsychiatryAdv,,0,0,1,"A phase 3 trial evaluating pimavanserin for the treatment of #dementia-related #psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.",,,#dementia #psychosis,1173914781994102784,https://twitter.com/PsychiatryAdv/status/1173914781994102784
2019-09-16 19:09:44,semodough,,0,1,6,"Stifel - nice note on $ACAD today FLASH NOTE Summary Acadia Pharmaceuticals, Inc. ACAD– NASDAQ September 13, 2019 Biotechnology KOL Call Recap: A Bull/Bear on Pimavanserin, Though Both Agree on the Size and Realness of the DRP Oppty",,,,1173675354243944448,https://twitter.com/semodough/status/1173675354243944448
2019-09-13 15:09:24,PracticalNeuro,,0,2,3,"Pimavanserin Efficacy for #Dementia-Related Psychosis Leads to Early Discontinuation of Pivotal Phase 3 Trial - Practical Neurology #Neurology #MovementDisorders #Alzheimers #DLB #PD #Parkinsons #AcadiaPharm @ClevelandClinic",,@ClevelandClinic,#Dementia #Neurology #MovementDisorders #Alzheimers #DLB #PD #Parkinsons #AcadiaPharm,1172527707034439680,https://twitter.com/PracticalNeuro/status/1172527707034439680
2019-09-13 14:59:39,tribui,JD4myfab4,1,0,0,"ACAD HARMONY was a Phase 3 study of pimavanserin.The trial was designed to assess the potential of pimavanserin as a potential option for patients with dementia-related psychosis. About 45 million people have dementia-related psychosis. If we extract $1000 or $10000 for 20% ",,,,1172525253236445185,https://twitter.com/tribui/status/1172525253236445185
2019-09-13 02:34:00,neurology_live,,0,1,0,"Results of an interim efficacy analysis have led Acadia Pharmaceuticals to halt its phase 3 HARMONY trial of pimavanserin (Nuplazid) after demonstrating a highly statistically significant reduction in relapse in patients with dementia-related psychosis. ",,,,1172337603095474176,https://twitter.com/neurology_live/status/1172337603095474176
2019-09-12 16:25:00,MDMagazine,,0,0,0,"Could pimavanserin break ground on a dementia-associated psychosis indication? ",,,,1172184343323635719,https://twitter.com/MDMagazine/status/1172184343323635719
2019-09-12 13:22:31,CindyBirck,,0,1,1,"ACADIA Pharmaceuticals announces pivotal Phase III HARMONY trial stopped early for positive efficacy as Pimavanserin meets the primary endpoint in people with #dementia-related psychosis https://www.biospace.com/article/releases/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/?TrackID=16 #jobs",,,#dementia #jobs,1172138421516754945,https://twitter.com/CindyBirck/status/1172138421516754945
2019-09-12 11:20:34,BrainSightsApp,,0,0,0,"Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Findings - Neurology Advisor via BrainSights for iOS https://www.neurologyadvisor.com/topics/alzheimers-disease-and-dementia/trial-investigating-pimavanserin-for-dementia-related-psychosis-stopped-early-due-to-positive-findings/",,,,1172107732750495744,https://twitter.com/BrainSightsApp/status/1172107732750495744
2019-09-12 11:16:33,BrainSightsApp,,0,0,0,"Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Findings - Neurology Advisor via BrainSights for iOS https://www.neurologyadvisor.com/topics/alzheimers-disease-and-dementia/trial-investigating-pimavanserin-for-dementia-related-psychosis-stopped-early-due-to-positive-findings/",,,,1172106722296696833,https://twitter.com/BrainSightsApp/status/1172106722296696833
2019-09-12 09:53:07,brunovellas,,0,2,2,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis | BioSpace https://www.biospace.com/article/releases/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/",,,,1172085723173924865,https://twitter.com/brunovellas/status/1172085723173924865
2019-09-12 06:14:42,Biotech2050,Biotech2050,0,0,1,"In your pimavanserin trials have you noticed the improvement mentioned below on your #dementia trial patients @Clive_Ballard @UofE_Research @ExeterMed or is this only applicable to #depression patients ? Appreciate your thoughts. (Quote from $ACAD CEO webcast at Morgan Stanley)",,@Clive_Ballard @UofE_Research @ExeterMed,#dementia #depression,1172030759168892930,https://twitter.com/Biotech2050/status/1172030759168892930
2019-09-12 02:50:35,JWhelanRN,,0,0,0,"Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Findings https://www.empr.com/home/news/drugs-in-the-pipeline/trial-investigating-pimavanserin-for-dementia-related-psychosis-stopped-early-due-to-positive-findings/",,,,1171979390160445440,https://twitter.com/JWhelanRN/status/1171979390160445440
2019-09-11 17:48:00,MDMagazine,,0,0,0,"Approximately 2.4 million US patients suffer from dementia-associated psychosis. Could pimavanserin become the first drug indicated for this population? https://www.mdmag.com/medical-news/pimavanserin-psychosis-phase-3-results",,,,1171842843020673024,https://twitter.com/MDMagazine/status/1171842843020673024
2019-09-11 17:17:45,SurgingEarnings,,0,0,0,"Acadia Pharmaceuticals jumped 70% after pleasantly surprising analysts with blockbuster potential for pimavanserin in dementia psychosis. The news was well received given a $25,000 annual charge and 1.2 million potential patients ( and a TAM $30bn) $ACAD",,,,1171835231759937538,https://twitter.com/SurgingEarnings/status/1171835231759937538
2019-09-11 14:14:00,MDMagazine,,0,2,0,"Following promising phase 3 results which concluded the HARMONY trial early, pimavanserin may be aligned to become the first drug indicated for dementia-related psychosis. https://www.mdmag.com/medical-news/pimavanserin-psychosis-phase-3-results",,,,1171788988421591041,https://twitter.com/MDMagazine/status/1171788988421591041
2019-09-11 05:50:04,fundswift,,0,0,0,"New post (ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - 'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis) has been published on FUNDSWIFT - http://www.fundswift.com/2019/09/11/acadia-pharmaceuticals-inc-nasdaqacad-pleasantly-surprised-acadia-analysts-see-blockbuster-potential-for-pimavanserin-in-dementia-psychosis/",,,,1171662172004519944,https://twitter.com/fundswift/status/1171662172004519944
2019-09-11 02:21:05,bita137,NIMHDirector,0,2,8,"Correct that Pimavanserin is an inverse agonist but good opportunity to point out some pharmacology trivia : a partial agonist, depending on dose, can function as an antagonist Bottom line: Pimavanserin is reducing tonic 5HT2A activity",,,,1171609576422010880,https://twitter.com/bita137/status/1171609576422010880
2019-09-11 01:59:05,NIMHDirector,NIMHDirector,1,0,11,"CORRECTION:Good news for patients & families struggling with dementia-related psychosis. Studies are ongoing for this serotonin 2A receptor inverse agonist in schizophrenia. #pimavanserin #BasicToBedside",,,#pimavanserin #BasicToBedside,1171604042423910400,https://twitter.com/NIMHDirector/status/1171604042423910400
2019-09-10 22:59:04,GiDunham,,0,0,0,"$ACAD after positive results from its ‘pimavanserin’ in dementia-related psychosis. H.C.Wainwright &amp;Co. analyst Andrew Fein reiterates a Buy w/ a $60 price target. Canaccord Genuity analyst Sumant Kulkarny upgraded the stock from Hold to Buy raising price target to $50 #biotech",,,#biotech,1171558740816015360,https://twitter.com/GiDunham/status/1171558740816015360
2019-09-10 20:11:45,Artstrada,,0,0,1,"ACADIA Surges on Early Success of Nuplazid Dementia Study https://finance.yahoo.com/news/acadia-surges-early-success-nuplazid-154103825.html ACADIA Pharmaceuticals Inc. ACAD announced that Nuplazid (pimavanserin) met the primary endpoint by showing statistically significant superiority over placebo",,,,1171516632218259456,https://twitter.com/Artstrada/status/1171516632218259456
2019-09-10 19:18:00,InvestorIdeas,,0,0,0,"September 10, 2019 (http://Investorideas.com Newswire) Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoi.. ",,,,1171503105722085376,https://twitter.com/InvestorIdeas/status/1171503105722085376
2019-09-10 15:09:25,neurology_live,,0,0,0,"Results of an interim efficacy analysis have led Acadia Pharmaceuticals to halt its phase 3 HARMONY trial of pimavanserin (Nuplazid) after demonstrating a highly statistically significant reduction in relapse in patients with #dementia-related psychosis.",,,#dementia,1171440548508393472,https://twitter.com/neurology_live/status/1171440548508393472
2019-09-10 14:05:24,NIMHDirector,NewsFromBW,3,5,12,"Good news for patients & families struggling with dementia-related psychosis. Studies are ongoing for this serotonin 2A receptor partial agonist in schizophrenia. #pimavanserin #BasicToBedside",,,#pimavanserin #BasicToBedside,1171424436475453441,https://twitter.com/NIMHDirector/status/1171424436475453441
2019-09-10 05:39:58,ForTheRecord01,ForTheRecord01,0,0,0,"3) Pimavanserin has been shown not to worsen cognition in Alzheimer's patients. 4) The FDA will ask, ""Do the benefits of the drug in DRP outweigh the risks?"" The answer will be very clearly ""yes"".",,,,1171297241727819776,https://twitter.com/ForTheRecord01/status/1171297241727819776
2019-09-10 05:37:08,ForTheRecord01,ForTheRecord01,1,0,0,"Comparisons of the risperidone trial with pimavanserin/DRP trial are problematic: 1) The former trial was for psychosis &amp; agitation; the latter, just for psychosis. 2) Pimavanserin's safety profile is much cleaner than risperidone's. This will be key in FDA approval.",,,,1171296529644048384,https://twitter.com/ForTheRecord01/status/1171296529644048384
2019-09-10 05:34:38,Biotech2050,PRB51,1,0,0,"Matthew have you considered interviewing @Clive_Ballard and/ or someone at @ExeterMed @UofE_Research to get their views on Pimavanserin?",,@Clive_Ballard @ExeterMed @UofE_Research,,1171295898011394048,https://twitter.com/Biotech2050/status/1171295898011394048
2019-09-10 04:01:20,LonSchneiderMD,matthewherper,1,0,6,"Re: #pimavanserin, $ACAD, &amp; the Harmony trial: 1 They didn't give the info needed to make inferences; a p value is not an effect size 2. A withdrawal trial is not an efficacy trial 3. To understand the issues see Devanand's risperidone withdrawal trial https://www.nejm.org/doi/full/10.1056/NEJMoa1114058",,,#pimavanserin,1171272418448424960,https://twitter.com/LonSchneiderMD/status/1171272418448424960
2019-09-10 03:14:10,Macro_Markets,,0,0,0,"#Acadia shares spiked +63% today in response to the news that #pimavanserin (aka #Nuplazid) hit its primary endpoint in a Phase 3 trial known as #Harmony. The Harmony trial was designed to evaluate pimavanserin as a treatment for #dementia-related psychosis. #stockstowatch",,,#Acadia #pimavanserin #Nuplazid #Harmony #dementia #stockstowatch,1171260548803174400,https://twitter.com/Macro_Markets/status/1171260548803174400
2019-09-10 02:15:07,SWLifeSciences,,0,0,0,"ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results: http://ow.ly/QFa350w3IQj The Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. $ACAD #biotech #pharma #healthcare #stocks",,,#biotech #pharma #healthcare #stocks,1171245690640637952,https://twitter.com/SWLifeSciences/status/1171245690640637952
2019-09-10 02:15:03,SWReports,,0,0,0,"ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results: http://ow.ly/Ippi50w3IRj The Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. $ACAD #biotech #pharma #healthcare #stocks",,,#biotech #pharma #healthcare #stocks,1171245671720071168,https://twitter.com/SWReports/status/1171245671720071168
2019-09-09 23:38:13,sudha_md,,2,6,5,"Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis; ..nice to have early cessation for 'efficacy' even though it is for a drug that only resolves symptoms, does not modify disease course",,,,1171206202727944192,https://twitter.com/sudha_md/status/1171206202727944192
2019-09-09 23:33:25,jeff_cranmer,,0,0,5,"Ph 3 data bolster $ACAD's chances to expand pimavanserin's label to include dementia-related psychosis, an indication that afflicts a 10x greater population than the one for which Nuplazid is already approved @BioCentury's @iBonanos reports",,@BioCentury,,1171204997167501312,https://twitter.com/jeff_cranmer/status/1171204997167501312
2019-09-09 23:33:20,wjdeardorff,,0,0,1,"ACADIA announces that the Phase 3 HARMONY trial of pimavanserin (Nuplazid) in dementia-related psychosis was stopped early for positive efficacy - Get the popcorn ready, gonna be a good FDA advisory committee meeting 1,2. https://www.businesswire.com/news/home/20190909005286/en/ACADIA-Pharmaceuticals-Announces-Pivotal-Phase-3-HARMONY 3. https://endpts.com/positive-efficacy-signal-allows-acadia-to-halt-dementia-study-testing-controversial-nuplazid-early/",,,,1171204976280047616,https://twitter.com/wjdeardorff/status/1171204976280047616
2019-09-09 23:19:50,ForTheRecord01,ForTheRecord01,0,0,1,"The big advantage of pimavanserin in DRP is that it doesn't worsen cognition, doesn't give patients tardive dyskinesia (Seroquel does), doesn't cause agranulocytosis (clozapine does). If Matteis were a better analyst he'd know these things.",,,,1171201576473481217,https://twitter.com/ForTheRecord01/status/1171201576473481217
2019-09-09 23:01:11,vitojdisibio,,0,0,0,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint ",,,,1171196885236944896,https://twitter.com/vitojdisibio/status/1171196885236944896
2019-09-09 21:37:05,stocksharks_,,0,0,0,"The company said pimavanserin achieved ""robust statistical superiority"" over placebo, with longer time to relapse of psychosis with pimavanserin compared with placebo. Acadia said the study will be stopped early based on the study's findings. ",,,,1171175721038860289,https://twitter.com/stocksharks_/status/1171175721038860289
2019-09-09 21:35:07,stocksharks_,,0,0,0,"ACADIA Pharmaceuticals (NASDAQ:ACAD) is up 68% premarket on increased volume in reaction to successful results in a Phase 3 clinical trial, HARMONY, evaluating lead drug NUPLAZID (pimavanserin) for the treatment of dementia-related psychosis. ",,,,1171175223384690688,https://twitter.com/stocksharks_/status/1171175223384690688
2019-09-09 21:20:47,DataTrials,,0,0,0,"$ACAD ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis.",,,,1171171618183417856,https://twitter.com/DataTrials/status/1171171618183417856
2019-09-09 20:03:01,GlobalMedEd,,0,1,3,"#Pimavanserin ( #Nuplazid) showed robust efficacy for #dementia related #psychosis. Poised to be first FDA approved drug for a great unmet need. http://bit.ly/2kckz0s #nursepractitioner #psychiatry #mh #mhchat #psychiatry #primarycare #mhsm #familymedicine #depression",,,#Pimavanserin #Nuplazid #dementia #psychosis #nursepractitioner #psychiatry #mh #mhchat #psychiatry #primarycare #mhsm #familymedicine #depression,1171152045258215425,https://twitter.com/GlobalMedEd/status/1171152045258215425
2019-09-09 17:55:24,MrJeffKarp,,0,0,0,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint - treatment for dementia-related psychosis https://www.yahoo.com/finance/m/559a39d3-bc24-3510-bed9-5dbfb46fbc25/acadia-pharmaceuticals-stock.html?.tsrc=fauxdal",,,,1171119929476734979,https://twitter.com/MrJeffKarp/status/1171119929476734979
2019-09-09 16:28:08,DrCarlForkner,,0,0,0,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis https://picante.today/business-wire/2019/09/09/85080/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/",,,,1171097970881835010,https://twitter.com/DrCarlForkner/status/1171097970881835010
2019-09-09 16:07:15,NFLObjectors,,0,0,0,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint https://on.mktw.net/2ZP6NUQ #NFLPA #dementia",,,#NFLPA #dementia,1171092713695060000,https://twitter.com/NFLObjectors/status/1171092713695060000
2019-09-09 15:47:32,medtechy,,0,1,0,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis $ACAD |",,,,1171087750814150661,https://twitter.com/medtechy/status/1171087750814150661
2019-09-09 15:05:27,syinvesting,,1,2,0,"$ACAD (+65% intraday) announced pivotal Phase 3 HARMONY trial stopped early for positive efficacy as pimavanserin meets the primary endpoint in patients with dementia-related psychosis. ",,,,1171077162536853504,https://twitter.com/syinvesting/status/1171077162536853504
2019-09-09 14:38:28,bita137,zenbrainest,1,0,1,"Wasn’t this expected? Pimavanserin already used for PD and other psychoses.",,,,1171070371367243777,https://twitter.com/bita137/status/1171070371367243777
2019-09-09 14:28:15,worldnews911,,0,0,1,"Acadia Pharma up 68% premarket on positive pimavanserin data – Seeking Alpha https://news.islamic-id.com/acadia-pharma-up-68-premarket-on-positive-pimavanserin-data-seeking-alpha/",,,,1171067799604801543,https://twitter.com/worldnews911/status/1171067799604801543
2019-09-09 14:14:00,SlingshotCtlyst,,0,0,0,"Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis Stopped Early $ACAD",,,,1171064212807999489,https://twitter.com/SlingshotCtlyst/status/1171064212807999489
2019-09-09 14:07:39,PRB51,,1,0,2,"Just a clarification I do not expect pimavanserin ALONE in schizophrenic patients But adjunctive to some other conventional antipsychotic? This hypothesis is being tested in a P3 with data before the end of 2019 With this morning data suggest it is quite possible",,,,1171062616820781058,https://twitter.com/PRB51/status/1171062616820781058
2019-09-09 13:50:13,PRB51,,1,0,3,"Why I was long: Problem with antipsychotics: Too strong for the weak patients with dementia-related psychosis, in fact they are not recommended for such patients On the other hand one would not treat a schizophrenic patient with Pimavanserin, the drug is too weak So just wright",,,,1171058227171250176,https://twitter.com/PRB51/status/1171058227171250176
2019-09-09 13:22:50,Elevate_Trader,,0,0,0,"$ACAD Announced Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis. Amazing news. ",,,,1171051338857418752,https://twitter.com/Elevate_Trader/status/1171051338857418752
2019-09-09 13:17:48,KanandaBarrons,,0,0,0,"$ACAD Rockets after late-stage trial of pimavanserin mets primary endpoint. https://www.marketwatch.com/story/acadia-pharmaceuticals-stock-rockets-after-late-stage-trial-of-pimavanserin-mets-primary-endpoint-2019-09-09?siteid=yhoof2&amp;yptr=yahoo",,,,1171050072185987072,https://twitter.com/KanandaBarrons/status/1171050072185987072
2019-09-09 13:12:07,zenbrainest,,3,7,44,"YUUGE: ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-pivotal-phase-103000599.html",,,,1171048639302529024,https://twitter.com/zenbrainest/status/1171048639302529024
2019-09-09 13:08:23,bullriders1,,0,0,0,"$ACAD +75% $41.66 PM Ph3 HARMONY (pimavanserin) for dementia-related psychosis achieves primary endpoint.",,,,1171047701988831234,https://twitter.com/bullriders1/status/1171047701988831234
2019-09-09 12:30:02,NewsQuantified,,0,0,0,"$ACAD Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis, stock rockets +70.75%, #AcadiaPharmaceuticals",,,#AcadiaPharmaceuticals,1171038047783157761,https://twitter.com/NewsQuantified/status/1171038047783157761
2019-09-09 12:29:43,BTLipschultz,,0,1,3,"In case you missed it this morning, $ACAD is up 74% after pimavanserin for treatment of dementia-related psychosis met its primary endpoint and was stopped early for efficacy. Would add about $2.5 billion in market cap if it holds",,,,1171037971535081478,https://twitter.com/BTLipschultz/status/1171037971535081478
2019-09-09 12:15:18,GantosJ,,1,4,4,"$ACAD ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis http://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial?field_nir_news_date_value[min]=",,,,1171034339708030976,https://twitter.com/GantosJ/status/1171034339708030976
2019-09-09 12:10:19,cfromhertz,,0,4,8,"$ACAD Acadia Pharma Surges as Phase 3 Pimavanserin Study Hits Goal (story via Bloomberg) ",,,,1171033086215315463,https://twitter.com/cfromhertz/status/1171033086215315463
2019-09-09 12:05:45,MarketGlance,,0,0,0,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint $ACAD - MarketWatch -",,,,1171031940339834881,https://twitter.com/MarketGlance/status/1171031940339834881
2019-09-09 12:00:58,READY_2_PROFIT,,0,0,0,"Acadia Pharmaceuticals (ACAD) stock rockets after late-stage trial of pimavanserin mets primary endpoint http $ACAD",,,,1171030736071213056,https://twitter.com/READY_2_PROFIT/status/1171030736071213056
2019-09-09 11:59:23,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis - https://sdbn.org/san-diego-biotech-news/2019/09/09/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/ #biotech #news",,,#biotech #news,1171030335007657984,https://twitter.com/sdbn/status/1171030335007657984
2019-09-09 11:57:56,CensoredToday,,0,0,0,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint Shares of Acadia Pharmaceuticals Inc. ACAD, -2.94% ... https://censored.today/2019/09/09/acadia-pharmaceuticals-stock-rockets-after-late-stage-trial-of-pimavanserin-mets-primary-endpoint/",,,,1171029971994849283,https://twitter.com/CensoredToday/status/1171029971994849283
2019-09-09 11:54:27,psk2329,,1,1,2,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis $ACAD",,,,1171029095263735808,https://twitter.com/psk2329/status/1171029095263735808
2019-09-09 11:40:18,InsiderBiotech,,0,1,2,"$ACAD ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis",,,,1171025532529586177,https://twitter.com/InsiderBiotech/status/1171025532529586177
2019-09-09 11:38:35,FaisamTrader,,0,0,0,"$spy $gspc $aapl $nflx $goog $tsla Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint https://faisamtrader.com/acadia-pharmaceuticals-stock-rockets-after-late-stage-trial-of-pimavanserin-mets-primary-endpoint/",,,,1171025099979448320,https://twitter.com/FaisamTrader/status/1171025099979448320
2019-09-09 11:28:14,MarketsTicker,,0,1,1,"Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint https://on.mktw.net/2UFNwj9",,,,1171022496952455168,https://twitter.com/MarketsTicker/status/1171022496952455168
2019-09-09 11:12:39,adamfeuerstein,,18,8,34,"Did everyone (including me) underestimate pimavanserin efficacy? Or, did we underestimate $ACAD ability to design a clinical trial to get them the result they wanted? I lean the latter but won’t matter today!",,,,1171018574997196800,https://twitter.com/adamfeuerstein/status/1171018574997196800
2019-09-09 11:09:38,Sports_bios,,1,0,3,"The most important piece of data I want to know from the $ACAD trial - the % of these - ""patients who met pre-specified criteria for treatment response were then randomized into the double-blind period of the study to continue their pimavanserin dose...""",,,,1171017815064797189,https://twitter.com/Sports_bios/status/1171017815064797189
2019-09-09 10:54:18,fwpharma,,0,0,2,"Acadia's shares jump after late-stage study of pimavanserin for dementia-related psychosis hits main goal https://www.firstwordpharma.com/node/1664736 $ACAD",,,,1171013957760557056,https://twitter.com/fwpharma/status/1171013957760557056
2019-09-09 10:41:18,Picante_Media,,0,0,0,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis https://picante.today/business-wire/2019/09/09/85080/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis/",,,,1171010686111178752,https://twitter.com/Picante_Media/status/1171010686111178752
2019-09-09 10:40:33,NewsFromBW,,0,1,1,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis http://dlvr.it/RCl7Vb",,,,1171010498512314369,https://twitter.com/NewsFromBW/status/1171010498512314369
2019-09-09 10:40:13,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin M http://crweworld.com/article/news-provided-by-business-wire/1230465/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for-positive-efficacy-as-pimavanserin-meets-the-primary-endpoint-in-patients-with-dementia-related-psychosis",,,,1171010413854519303,https://twitter.com/CrweWorld/status/1171010413854519303
2019-09-09 10:31:54,ToothFrank,,0,0,1,"$ACAD Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis",,,,1171008320125263872,https://twitter.com/ToothFrank/status/1171008320125263872
2019-09-09 10:31:16,BioStocks,,2,19,34,"$ACAD Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis",,,,1171008162104860672,https://twitter.com/BioStocks/status/1171008162104860672
2019-09-09 06:47:16,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1170951789920825345,https://twitter.com/BrainSightsApp/status/1170951789920825345
2019-09-05 21:47:17,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1169728734498304001,https://twitter.com/BrainSightsApp/status/1169728734498304001
2019-09-04 16:58:22,DerekHSuiteMD,,0,0,1,"To avoid worsening #ParkisonsDisease(PD) #motorsymptoms, only 3 #antipsychotics are recommended for #PD #psychosis: #clozapine, #pimavanserin, and #quetiapine. #mentalhealth #psychiatricmedications",,,#ParkisonsDisease #motorsymptoms #antipsychotics #PD #psychosis #clozapine #pimavanserin #quetiapine #mentalhealth #psychiatricmedications,1169293640373604362,https://twitter.com/DerekHSuiteMD/status/1169293640373604362
2019-09-02 14:56:47,nlefevre,Razuman3,0,0,1,"Three medications for your delusions are: quetiapine (Seroquel®), clozapine (Clozaril®) and the newest agent, pimavanserin (Nuplazid®). See your doctor.",,,,1168538266548756482,https://twitter.com/nlefevre/status/1168538266548756482
2019-08-31 15:50:40,jpreventionalz1,,0,2,1,"Pimavanserin: Potential Treatment For Dementia-Related Psychosis. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30298184",,,,1167827048615706625,https://twitter.com/jpreventionalz1/status/1167827048615706625
2019-08-29 14:17:16,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1167078769045254146,https://twitter.com/BrainSightsApp/status/1167078769045254146
2019-08-27 01:31:14,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights for iOS https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1166161215120445440,https://twitter.com/BrainSightsApp/status/1166161215120445440
2019-08-21 18:43:46,zenbrainest,sxbegle,1,1,4,"In the paper they highlight 5HT receptors though many approved neuro drugs target them—antidepressants, antimigraine, bispirone, atypical antipsychotics , pimavanserin and drugs showing efficacy mdma psilocybin!",,,,1164246733901242368,https://twitter.com/zenbrainest/status/1164246733901242368
2019-08-11 13:38:36,india_logic,ARanganathan72,0,0,1,"These might help Please take doctor's permission before taking them Atypical antipsychotics used to treat hallucinations, and other psychotic symptoms include: risperidone aripiprazole olanzapine ziprasidone quetiapine pimavanserin clozapine",,,,1160546058574766080,https://twitter.com/india_logic/status/1160546058574766080
2019-08-08 19:20:25,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1159544913740124162,https://twitter.com/BrainSightsApp/status/1159544913740124162
2019-08-08 18:40:38,IfSoFactSow,,0,0,0,"QuarterWatch™ (includes data from Quarter 3, 2018) Focus on Three Psychoactive Drugs: Gabapentin, Pregabalin, and Pimavanserin ",,,,1159534902884175874,https://twitter.com/IfSoFactSow/status/1159534902884175874
2019-08-08 07:20:22,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1159363708998623232,https://twitter.com/BrainSightsApp/status/1159363708998623232
2019-08-07 19:24:05,DrSandyThomson,A_MacLullich,0,0,1,"While we’re on the subject of novel pharma treatments for delirium, any work being done on pimavanserin? Evolving evidence base for delusions and hallucinations in Parkinson’s disease. Role in PD and non-PD delirium?",,,,1159183450345283586,https://twitter.com/DrSandyThomson/status/1159183450345283586
2019-08-06 09:16:31,Biotech2050,ForTheRecord01,1,0,3,"$ACAD pimavanserin can target c-Myc! For those not familiar with c-Myc https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505847/ cc @pfizer @Celgene @sanofi @GileadSciences @bmsnews @NovartisScience",,@pfizer @Celgene @sanofi @GileadSciences @bmsnews @NovartisScience,,1158668161941737472,https://twitter.com/Biotech2050/status/1158668161941737472
2019-08-06 07:15:08,ForTheRecord01,,1,2,5,"$ACAD Two doctors find that pimavanserin is effective in combating pancreatic cancer: https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1_supplement.647.35",,,,1158637614762622976,https://twitter.com/ForTheRecord01/status/1158637614762622976
2019-08-03 15:55:54,JWhelanRN,,0,0,0,"Added Pimavanserin Shows Positive Trends in Schizophrenia but Misses Primary Endpoint in Trial https://www.psychcongress.com/article/added-pimavanserin-shows-positive-trends-schizophrenia-misses-primary-endpoint-trial Another CNS drug not meeting endpoint; something needs to change in research stat!!!",,,,1157681508548849674,https://twitter.com/JWhelanRN/status/1157681508548849674
2019-08-02 15:52:04,psychopharmacol,,0,1,1,"meta-analysis: Pimavanserin was associated with improvement in psychotic symptoms vs. placebo without worsening motor function in Parkinson disease. Clozapine was also efficacious and safe. Quetiapine and Olanzapine were not efficacious and were unsafe ",,,,1157318155326414851,https://twitter.com/psychopharmacol/status/1157318155326414851
2019-08-01 14:20:00,PsychCongress,,0,0,0,"Added Pimavanserin Shows Positive Trends in #Schizophrenia but Misses Primary Endpoint in Trial: http://bit.ly/2KgZjiW",,,#Schizophrenia,1156932596179382273,https://twitter.com/PsychCongress/status/1156932596179382273
2019-07-28 13:23:06,jack_turban,,6,8,58,"#Psychiatry fact of the day: Most anti-psychotics worsen Parkinson’s disease because they are anti-dopaminergic. Quetiapine, pimavanserin, and clozapine have minimal anti-dopaminergic activity and can be used for patient’s with Parkinson’s disease and psychosis. #medtwitter",,,#Psychiatry #medtwitter,1155468725539282945,https://twitter.com/jack_turban/status/1155468725539282945
2019-07-28 12:58:15,jpreventionalz1,,0,0,0,"Pimavanserin: Potential Treatment For Dementia-Related Psychosis. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30298184",,,,1155462471278387200,https://twitter.com/jpreventionalz1/status/1155462471278387200
2019-07-28 12:10:51,FibroFlutters,,0,0,0,"Pimavanserin Misses Primary End Point in Schizophrenia Study ",,,,1155450544649117696,https://twitter.com/FibroFlutters/status/1155450544649117696
2019-07-26 23:45:24,TrialsiteN,,0,0,0,"#AcadiaPharmaceuticals Reports Phase 3 #ENHANCE #Trial of #Pimavanserin as #Adjunctive #Treatment for #Patients With #Schizophrenia #Fails to Meet Main #Endpoint https://www.trialsitenews.com/acadia-pharmaceuticals-reports-phase-3-enhance-trial-of-pimavanserin-as-adjunctive-treatment-for-patients-with-schizophrenia-fails-to-meet-main-endpoint/ via @Trial Site News #healthcare #challengedtrial",,@Trial,#AcadiaPharmaceuticals #ENHANCE #Trial #Pimavanserin #Adjunctive #Treatment #Patients #Schizophrenia #Fails #Endpoint #healthcare #challengedtrial,1154900556252471296,https://twitter.com/TrialsiteN/status/1154900556252471296
2019-07-26 20:10:04,PsychiatryAdv,,0,0,0,"Adjunctive treatment with #pimavanserin did not result in a statistically significant change from baseline in Positive and Negative Syndrome Scale total score in patients with #schizophrenia. http://ow.ly/f0Wp50vcCqP",,,#pimavanserin #schizophrenia,1154846366667104256,https://twitter.com/PsychiatryAdv/status/1154846366667104256
2019-07-25 03:13:43,ForTheRecord01,mikiass0,1,0,0,"Patients in Europe responded well to pimavanserin, and those with negative symptoms responded even better. If the negative symptoms trial succeeds, the FDA will likely allow ACAD to pool data from previous trials &amp; submit as one sNDA package.",,,,1154228205504483330,https://twitter.com/ForTheRecord01/status/1154228205504483330
2019-07-25 02:52:50,ForTheRecord01,ag76_biotech,0,0,0,"What you're saying isn't true. The FDA agreed to limit the SAPs scale to 9 items. In ACAD's phase 3 trial in PDP, pimavanserin was successful in all 20 SAPs items relevant to Parkinson's. p value for SAPs and CGI was 0.001.",,,,1154222950561677317,https://twitter.com/ForTheRecord01/status/1154222950561677317
2019-07-24 08:28:23,ThePharmaLetter,,0,0,0,"Acadia’s pimavanserin fails to meet Ph III goals in schizophrenia https://www.thepharmaletter.com/article/acadia-s-pimavanserin-fails-to-meet-ph-iii-goals-in-schizophrenia #biotech #CNSdiseases #drugtrial #neurology #research #USA",,,#biotech #CNSdiseases #drugtrial #neurology #research #USA,1153945007147143168,https://twitter.com/ThePharmaLetter/status/1153945007147143168
2019-07-23 22:23:54,RodBoydILM,,0,0,1,"$ACAD @adamfeuerstein w/ analysis of Acadia's failed trial in which Pimavanserin efficacy w/ patients is &lt; placebo in U.S. patients. (Natch drug did well in Ukraine, Russia) ",,@adamfeuerstein,,1153792884748853251,https://twitter.com/RodBoydILM/status/1153792884748853251
2019-07-23 20:45:07,eMPR,,0,0,0,"Pimavanserin fails to meet primary endpoint in phase 3 trial ",,,,1153768025172185088,https://twitter.com/eMPR/status/1153768025172185088
2019-07-23 20:02:28,Briefingcom,,0,0,0,"$SCANX: Mid cap notable movers of interest -- ACADIA Pharmaceuticals (ACAD) falls after pimavanserin trial misses... http://bit.ly/2GDe1jx",,,,1153757292308811776,https://twitter.com/Briefingcom/status/1153757292308811776
2019-07-23 19:28:00,BioPharmaDive,,0,0,1,"Adding pimavanserin to drugs like Abilify yielded no greater improvement than using antipsychotic treatment alone, results from a Phase 3 study showed $ACAD",,,,1153748615543660544,https://twitter.com/BioPharmaDive/status/1153748615543660544
2019-07-23 18:02:25,PharmaScrip,,0,0,0,"Pimavanserin Fails In ENHANCE But Other CNS Uses Targeted http://bit.ly/2SCbg6z #PharmaScrip",,,#PharmaScrip,1153727080464637952,https://twitter.com/PharmaScrip/status/1153727080464637952
2019-07-23 16:46:19,ForTheRecord01,ByMadeleineA,0,0,0,"Dr. Maurizio Fava, Associate Dean for Clinical Research at Harvard Medical School, said the study ""provides evidence that adjunctive therapy with pimavanserin may benefit patients suffering from inadequate response in major depressive disorder.” Is Dr. Fava in denial, too?",,,,1153707926843883520,https://twitter.com/ForTheRecord01/status/1153707926843883520
2019-07-23 15:47:36,sjtwitts,,0,0,0,"ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia | Business Wire ",,,,1153693149748842498,https://twitter.com/sjtwitts/status/1153693149748842498
2019-07-23 14:13:58,HottestStockNow,,0,0,0,"$ACAD 's pimavanserin fails to meet late-stage study goals in schizophrenia http://crweworld.com/symbol/ACAD",,,,1153669587101110272,https://twitter.com/HottestStockNow/status/1153669587101110272
2019-07-23 12:17:53,semodough,,1,1,3,"HCW $ACAD How should think through Phase 2 ADVANCE trial for negative symptoms point to Phase 2b study of MIN-101 developed $NERV may provide some context for pimavanserin’s Phase 2 ADVANCE trial. MIN-101 is a 5-HT2A &amp;sigma2 antagonist. A total of 224 patients are randomized to",,,,1153640375950725123,https://twitter.com/semodough/status/1153640375950725123
2019-07-23 12:11:18,IcemanStocks,,0,0,0,"TD Ameritrade (AMTD) down 0.6%. ALSO LOWER: Acadia Pharma (ACAD) down 15.3% after its phase 3 Pimavanserin trial in schizophrenia did",,,,1153638716016955399,https://twitter.com/IcemanStocks/status/1153638716016955399
2019-07-23 11:58:12,psk2329,,0,2,1,"ACADIA Pharmaceuticals shares are trading lower after the company reported its Phase 3 ENHANCE trial of Pimavanserin did not achieve statistical significance on its primary endpoint. $ACAD",,,,1153635421450121225,https://twitter.com/psk2329/status/1153635421450121225
2019-07-23 11:42:54,CareerBiotech,,0,0,0,"#jobs ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin https://goo.gl/fb/349zTn",,,#jobs,1153631568893796354,https://twitter.com/CareerBiotech/status/1153631568893796354
2019-07-23 11:14:38,algoally,,0,0,0,"$ACAD - ACADIA Pharmaceuticals shares are trading lower after the company reported its Phase 3 ENHANCE trial of Pimavanserin did not achieve statistical significance on its primary endpoint. @algoally",,@algoally,,1153624458462035969,https://twitter.com/algoally/status/1153624458462035969
2019-07-23 10:11:18,semodough,,0,2,7,"Baml $ACAD In our model, Pimavanserin in dementia-related psychosis (DRP) remains largest contributor ($23/sh) in PO expect interim readout from the pivotal HARMONY study in DRP in 2H. We maintain our Buy rating with PO $28 await data from ADVANCE and HARMONY later this year.",,,,1153608516885782529,https://twitter.com/semodough/status/1153608516885782529
2019-07-23 03:52:16,cmencke,,0,1,0,"AwesomeCapital: Acadia Pharma’s pimavanserin flunks late-stage sch... https://awesomecapital.blogspot.com/2019/07/acadia-pharmas-pimavanserin-flunks-late.html?spref=tw",,,,1153513133266391040,https://twitter.com/cmencke/status/1153513133266391040
2019-07-23 03:51:08,feed_stocks,,0,0,0,"ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia http://dlvr.it/R8vYZ5",,,,1153512847042703360,https://twitter.com/feed_stocks/status/1153512847042703360
2019-07-23 01:52:16,ToothFrank,,0,0,1,"$ACAD Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms ",,,,1153482934726385666,https://twitter.com/ToothFrank/status/1153482934726385666
2019-07-22 22:53:58,fwpharma,,0,2,0,"ACADIA's pimavanserin misses main goal of Phase III study as adjunctive treatment in schizophrenia; shares fall http://bit.ly/2GofhqC #pharma",,,#pharma,1153438062170578951,https://twitter.com/fwpharma/status/1153438062170578951
2019-07-22 22:12:17,Briefingcom,,0,0,0,"$ACAD: ACADIA Pharmaceuticals announces top-line results from Phase 3 ENHANCE trial of pimavanserin as adjunctive... http://bit.ly/2Z8cEjY",,,,1153427573143040000,https://twitter.com/Briefingcom/status/1153427573143040000
2019-07-22 22:06:04,Sanctuary_Bio,MaxJacobsEdison,2,0,4,"Typical $ACAD embellishing whatever data they come up with You can't fool everyone all the time, they should have diversified their pipeline outside of pimavanserin a long time ago ",,,,1153426005891198977,https://twitter.com/Sanctuary_Bio/status/1153426005891198977
2019-07-22 21:49:44,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment http://crweworld.com/article/news-provided-by-business-wire/1174446/acadia-pharmaceuticals-announces-top-line-results-from-phase-3-enhance-trial-of-pimavanserin-as-adjunctive-treatment-for-patients-with-schizophrenia",,,,1153421899113721861,https://twitter.com/CrweWorld/status/1153421899113721861
2019-07-22 20:42:04,BTLipschultz,,0,2,0,"$ACAD currently down 16% in after-hours trading as its Phase 3 study of pimavanserin in patients with schizophrenia failed; P-value of .0940",,,,1153404866762616834,https://twitter.com/BTLipschultz/status/1153404866762616834
2019-07-22 20:35:24,stevedoc22,MaxJacobsEdison,0,0,7,"More and more, $ACAD's pimavanserin seems like it might just be a crappy sedative with some minor antidepressant action that eeked (sp?) out one positive study in a cherry-picked population, using cherry-picked endpoints. ",,,,1153403192593539074,https://twitter.com/stevedoc22/status/1153403192593539074
2019-07-22 20:18:02,NedPagliarulo,,0,1,0,"$ACAD Phase 3 study of pimavanserin as adjunctive therapy in schizophrenia missed primary endpoint",,,,1153398818773377026,https://twitter.com/NedPagliarulo/status/1153398818773377026
2019-07-22 20:12:42,syinvesting,,0,1,3,"$ACAD announced top-line Phase 3 ENHANCE trial results. Pimavanserin as adjunct trx for schizophrenia did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms (p=0.0940). ",,,,1153397477099184128,https://twitter.com/syinvesting/status/1153397477099184128
2019-07-22 20:09:50,Allstocknews,,0,0,0,"$ACAD ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunct From our Stock News Alerts App",,,,1153396756266323968,https://twitter.com/Allstocknews/status/1153396756266323968
2019-07-22 20:08:51,BlueSkyBreaker,,0,0,1,"$ACAD Phase 3 Trial: Pimavanserin did not achieve statistical significance/failed on the primary endpoint",,,,1153396507988697088,https://twitter.com/BlueSkyBreaker/status/1153396507988697088
2019-07-22 20:06:26,MaisaCorp,,0,0,0,"$ACAD Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia Pimavanserin did not achieve statistical significance on the primary endpoint",,,,1153395898866720769,https://twitter.com/MaisaCorp/status/1153395898866720769
2019-07-22 20:05:43,zbiotech,,2,7,13,"- Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms (p=0.0940) $ACAD",,,,1153395718868090882,https://twitter.com/zbiotech/status/1153395718868090882
2019-07-22 20:05:20,TraderTexMex,,1,2,6,"$ACAD ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia #fail",,,#fail,1153395622357164032,https://twitter.com/TraderTexMex/status/1153395622357164032
2019-07-22 09:04:50,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1153229404123926528,https://twitter.com/BrainSightsApp/status/1153229404123926528
2019-07-15 07:04:49,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1150662486670172164,https://twitter.com/BrainSightsApp/status/1150662486670172164
2019-07-11 06:04:47,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1149197828180365312,https://twitter.com/BrainSightsApp/status/1149197828180365312
2019-07-09 11:30:37,LWWneurology,,0,0,0,"Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson’s Disease Psychosis http://dlvr.it/R84Thg",,,,1148555050165235714,https://twitter.com/LWWneurology/status/1148555050165235714
2019-07-05 12:35:02,PCC_CNSDisord,,0,0,1,"#Parkinson disease #psychosis causes functional decline and adversely impacts quality of life. Here, read about the pros and cons of #pimavanserin in the treatment of patients with this disabling condition. http://bit.ly/2J9gdAL",,,#Parkinson #psychosis #pimavanserin,1147121709906108416,https://twitter.com/PCC_CNSDisord/status/1147121709906108416
2019-07-01 20:31:50,DataTrials,,0,0,0,"$ACAD Phase 3 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)…NCT02970292. Estimated Primary Completion Date - 08/2019",,,,1145792148157140993,https://twitter.com/DataTrials/status/1145792148157140993
2019-07-01 13:03:01,semodough,,0,1,7,"$SAGE – Sage R&amp;D “FutureCast” on July 24 (8-9:30am ET- $ACAD – Phase 3 Nuplazid / pimavanserin data for inadequate responders in schizophrenia in mid 2019.",,,,1145679198196867072,https://twitter.com/semodough/status/1145679198196867072
2019-06-27 06:05:50,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1144124658750390272,https://twitter.com/BrainSightsApp/status/1144124658750390272
2019-06-27 06:04:49,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1144124405850759168,https://twitter.com/BrainSightsApp/status/1144124405850759168
2019-06-21 22:53:01,Rx_Ed,,0,2,7,"Do NOT confuse flibanserin with pimavanserin. Both drugs belong to the same class (5HT2 antagonists). But flibanserin is for hyposexual disorder among postmenopausal women. Pimavanserin is for psychotic symptoms among Parkinson’s patients. Learn more: http://MedQuestReviews.com",,,,1142203800012374017,https://twitter.com/Rx_Ed/status/1142203800012374017
2019-06-19 23:04:44,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1141481973942145024,https://twitter.com/BrainSightsApp/status/1141481973942145024
2019-06-18 16:40:59,ChelaWallin,,0,0,2,"Sholler: Serotonin receptor #pimavanserin decreased #oxycodone impulsive action in male rats #CPDD19",,,#pimavanserin #oxycodone #CPDD19,1141023008414474241,https://twitter.com/ChelaWallin/status/1141023008414474241
2019-06-18 16:39:41,ea_wold,,0,1,3,"#CPDD19 Cunningham lab members discussing roles for serotonin receptors in opioid use: D. Sholler shows pimavanserin (5HT2AR antago./inverse ago.) decreases opioid-induced impulsive action; C. Merritt shows the ever-popular lorcaserin (2C ago.) reduced oxycodone self-admin (rats)",,,#CPDD19,1141022681644576768,https://twitter.com/ea_wold/status/1141022681644576768
2019-06-16 15:27:00,DataTrials,,0,2,1,"$ACAD Phase 2 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression… Estimated Primary Completion Date - 07/2019",,,,1140279616751448064,https://twitter.com/DataTrials/status/1140279616751448064
2019-06-10 07:54:52,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1137991503928844289,https://twitter.com/BrainSightsApp/status/1137991503928844289
2019-06-07 00:00:23,DepressionData,,0,0,0,"New clinical trial for #depression: Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression https://medtally.com/post/safety-and-efficacy-of-pimavanserin-in-adults-with-parkinsons-disease-and-depression-306510",,,#depression,1136784932972294145,https://twitter.com/DepressionData/status/1136784932972294145
2019-06-06 23:54:51,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1136783540253843456,https://twitter.com/BrainSightsApp/status/1136783540253843456
2019-06-06 03:12:05,Ingentium_PD,,0,1,0,"Changing the treatment paradigm for #ParkinsonsDisease #parkinsons #PD psychosis with pimavanserin. http://dlvr.it/R665N7",,,#ParkinsonsDisease #parkinsons #PD,1136470790889545728,https://twitter.com/Ingentium_PD/status/1136470790889545728
2019-06-04 15:04:07,C2CLiberal,RightWingWatch,0,0,2,"He needs to consult his Dr. The drug pimavanserin my help stop the hallucinations",,,,1135925204884975616,https://twitter.com/C2CLiberal/status/1135925204884975616
2019-05-29 23:51:50,SolarMelt,,0,0,0,"$ACAD Without that Put Spread we're looking at a Put Call Ratio of only ~3.66. Still, somebody is awfully bearish about ENHANCE, a P3 trial of Pimavanserin (Inadequate Response Schizophrenia) due to readout around mid-year.",,,,1133883680299126789,https://twitter.com/SolarMelt/status/1133883680299126789
2019-05-29 20:46:42,Biotech2050,,0,0,1,"Charles Bonnet Syndrome Treated With Pimavanserin $ACAD #nuplazid https://journals.lww.com/jneuro-ophthalmology/pages/articleviewer.aspx?year=9000&amp;issue=00000&amp;article=99150&amp;type=Citation",,,#nuplazid,1133837091287261185,https://twitter.com/Biotech2050/status/1133837091287261185
2019-05-29 17:06:38,NeverForget2007,reidrobison,5,0,0,"No “breakthroughs” here and no cures- Valbenazine treats a side effect of other psychiatric drugs, brexanolone costs $34,000, eskatimine is a form of a club drug that never cured anything, and pimavanserin killed a bunch of PD patients already https://www.mdmag.com/medical-news/pimavanserin-under-scrutiny-for-reported-deaths-in-parkinsons-patients",,,,1133781706778005512,https://twitter.com/NeverForget2007/status/1133781706778005512
2019-05-29 16:00:05,reidrobison,,0,0,2,"The 4 drugs approved in psychiatry through the @US_FDA's breakthrough designation: Pimavanserin (Nuplazid) in Apr 2016 for psychosis in PD Valbenazine (ingrezza) in Apr 2017 for TD Brexanolone (zulresso) in Mar 2019 for PPD Esketamine (spravato) in Mar 2019 for TR MDD #ASCP19",,@US_FDA,#ASCP19,1133764959324663809,https://twitter.com/reidrobison/status/1133764959324663809
2019-05-29 06:35:43,Biotech2050,,1,0,0,"FYI ⁦@UofE_Research⁩ ⁦@ExeterMed⁩ Pimavanserin: A potentially safer alternative to clozapine for refractory hallucinations and delusions | MDedge Psychiatry ",,@UofE_Research @ExeterMed,,1133622931739815937,https://twitter.com/Biotech2050/status/1133622931739815937
2019-05-29 06:33:19,Biotech2050,,0,0,0,"Pimavanserin: A potentially safer alternative to clozapine for refractory #hallucinations and #delusions | MDedge Psychiatry $ACAD https://www.mdedge.com/psychiatry/article/197693/schizophrenia-other-psychotic-disorders/pimavanserin-potentially-safer/page/0/1",,,#hallucinations #delusions,1133622330503118848,https://twitter.com/Biotech2050/status/1133622330503118848
2019-05-27 12:35:02,PCC_CNSDisord,,0,0,2,"Parkinson disease psychosis causes functional decline and adversely impacts quality of life. Here, read about the pros and cons of pimavanserin in the treatment of patients with this disabling condition. http://bit.ly/2VKyFTw @UofLMedicine",,@UofLMedicine,,1132988581503541248,https://twitter.com/PCC_CNSDisord/status/1132988581503541248
2019-05-24 17:01:16,MassGeneralMDs,,0,0,0,"Add-on pimavanserin shows efficacy in major depression. @GoHealio covers study led by @MassGeneral MD Maurizio Fava",,@GoHealio @MassGeneral,,1131968417974640640,https://twitter.com/MassGeneralMDs/status/1131968417974640640
2019-05-22 16:10:10,HealioIM,,0,0,0,"Adjunctive #pimavanserin appeared safe, effective and well-tolerated in patients with #majordepressiondisorder who had inadequately responded to SSRI/SNRI therapy, according to study results presented at the @APAPsychiatric Annual Meeting. #APAAM19 https://www.healio.com/internal-medicine/psychiatry/news/online/%7B2bfe19cf-365e-4132-b074-e64f4484e2b0%7D/add-on-pimavanserin-appears-safe-effective-in-patients-with-major-depression?utm_medium=social&amp;utm_source=twitter&amp;utm_campaign=sociallinks",,@APAPsychiatric,#pimavanserin #majordepressiondisorder #APAAM19,1131230782775844864,https://twitter.com/HealioIM/status/1131230782775844864
2019-05-21 18:19:59,Dr_KetamineCat,,0,0,0,"Add-on pimavanserin shows efficacy in major depression ",,,,1130901066034417666,https://twitter.com/Dr_KetamineCat/status/1130901066034417666
2019-05-21 11:31:03,LWWneurology,,0,0,0,"Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review http://dlvr.it/R56tRl",,,,1130798153190465537,https://twitter.com/LWWneurology/status/1130798153190465537
2019-05-20 20:04:30,somsirsa,,0,0,0,"Add-on pimavanserin shows efficacy in major depression – Healio https://somsirsa.wordpress.com/2019/05/21/add-on-pimavanserin-shows-efficacy-in-major-depression-healio-2/",,,,1130564980133249025,https://twitter.com/somsirsa/status/1130564980133249025
2019-05-20 14:09:59,PsychAnnals,,0,1,2,"Adjunctive pimavanserin appeared safe, effective and tolerable among patients with major #depression who responded inadequately to #SSRI or #SNRI therapy, according to results from a phase 2 study presented at #APAAM19: https://www.healio.com/psychiatry/depression/news/online/%7Bff87b07f-4692-4630-a2a1-a04d240b5ae3%7D/add-on-pimavanserin-shows-efficacy-in-major-depression?utm_medium=social&amp;utm_source=twitter&amp;utm_campaign=sociallinks @MGH_RI",,@MGH_RI,#depression #SSRI #SNRI #APAAM19,1130475763218538497,https://twitter.com/PsychAnnals/status/1130475763218538497
2019-05-20 13:19:32,somsirsa,,0,0,0,"Add-on pimavanserin shows efficacy in major depression – Healio https://somsirsa.wordpress.com/2019/05/20/add-on-pimavanserin-shows-efficacy-in-major-depression-healio/",,,,1130463067429646337,https://twitter.com/somsirsa/status/1130463067429646337
2019-05-19 16:51:33,flylemurs,,0,0,0,"Acadia presents Phase 2 CLARITY results for Pimavanserin http://bit.ly/2Qbca8P See the rest of the story here. http://Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps in…",,,,1130154032297848839,https://twitter.com/flylemurs/status/1130154032297848839
2019-05-18 18:34:52,HottestStockNow,,0,0,0,"$ACAD to Reveal Findings from Mid-Stage Study Evaluating Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder http://crweworld.com/symbol/ACAD",,,,1129817644759040000,https://twitter.com/HottestStockNow/status/1129817644759040000
2019-05-18 18:05:05,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depre http://crweworld.com/article/news-provided-by-business-wire/1100896/acadia-pharmaceuticals-to-present-phase-2-clarity-results-for-pimavanserin-as-an-adjunctive-treatment-in-major-depressive-disorder-at-the-2019-american-psychiatric-association-annual-meeting",,,,1129810151232364544,https://twitter.com/CrweWorld/status/1129810151232364544
2019-05-18 17:18:32,Stock_Market_Pr,,0,0,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting http://dlvr.it/R4yft0",,,,1129798435844923392,https://twitter.com/Stock_Market_Pr/status/1129798435844923392
2019-05-18 17:12:02,MedFirstLtd,,0,0,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting - Associated Press http://dlvr.it/R4ydys • http://medfirst.co.uk",,,,1129796801735798784,https://twitter.com/MedFirstLtd/status/1129796801735798784
2019-05-18 17:04:20,Biotech2050,,0,0,1,"$ACAD to Present Phase 2 CLARITY Results for #Pimavanserin as an Adjunctive Treatment in Major #Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting #APAAM19 #MDD https://finance.yahoo.com/news/acadia-pharmaceuticals-present-phase-2-150000890.html",,,#Pimavanserin #Depressive #APAAM19 #MDD,1129794862449123334,https://twitter.com/Biotech2050/status/1129794862449123334
2019-05-18 16:52:50,MazenSalama,,0,0,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting - http://tinyurl.com/y4e7ejgv",,,,1129791968064630784,https://twitter.com/MazenSalama/status/1129791968064630784
2019-05-18 15:46:50,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting - https://sdbn.org/san-diego-biotech-news/2019/05/18/acadia-pharmaceuticals-to-present-phase-2-clarity-results-for-pimavanserin-as-an-adjunctive-treatment-in-major-depressive-disorder-at-the-2019-american-psychiatric-association-annual-meeting/ #biotech #news",,,#biotech #news,1129775357123530753,https://twitter.com/sdbn/status/1129775357123530753
2019-05-18 15:04:33,Picante_Media,,0,0,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting https://picante.today/business-wire/2019/05/18/33757/acadia-pharmaceuticals-to-present-phase-2-clarity-results-for-pimavanserin-as-an-adjunctive-treatment-in-major-depressive-disorder-at-the-2019-american-psychiatric-association-annual-meeting/",,,,1129764719236198401,https://twitter.com/Picante_Media/status/1129764719236198401
2019-05-18 15:04:05,NewsFromBW,,0,1,0,"ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting http://dlvr.it/R4yMWg",,,,1129764601078452224,https://twitter.com/NewsFromBW/status/1129764601078452224
2019-05-18 15:02:35,Allstocknews,,0,0,0,"$ACAD ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment i From our Stock News Alerts App",,,,1129764224421552128,https://twitter.com/Allstocknews/status/1129764224421552128
2019-05-17 14:54:55,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1129399905703911424,https://twitter.com/BrainSightsApp/status/1129399905703911424
2019-05-15 03:07:08,Ingentium_PD,,0,1,1,"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in #ParkinsonsDisease #parkinsons #PD. http://dlvr.it/R4jr5M",,,#ParkinsonsDisease #parkinsons #PD,1128497012926599169,https://twitter.com/Ingentium_PD/status/1128497012926599169
2019-05-13 19:35:33,Sleep_Bio,,0,1,0,"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin a Selective Serotonin 5HT2A Inverse Agonist to Treat Impulse Control Disorders in Parkinson's Disease. http://bioportfol.io/R4d7BC #sleep",,,#sleep,1128020976623443968,https://twitter.com/Sleep_Bio/status/1128020976623443968
2019-05-10 11:54:55,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1126817892971032576,https://twitter.com/BrainSightsApp/status/1126817892971032576
2019-05-09 15:18:13,DataTrials,,0,0,0,"$ACAD Phase 2 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)… Estimate Primary Completion Date - 05/2019",,,,1126506665379942400,https://twitter.com/DataTrials/status/1126506665379942400
2019-05-09 15:17:15,DataTrials,,0,0,0,"$ACAD Phase 2 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression… Estimate Primary Completion Date - 05/2019",,,,1126506422194192384,https://twitter.com/DataTrials/status/1126506422194192384
2019-05-06 21:08:36,nitroglycER1N,,2,0,6,"Ok getting a little pharma-nerdy Thought of 2 more drugs that contain my name (still not as good as my twitter handle tho): 1 - pimavansERIN 2 - DiffERIN Have any of y’all ever noticed your name within a drug name, or is it just me? #TwitteRx #medtwitter",,,#TwitteRx #medtwitter,1125507680955764736,https://twitter.com/nitroglycER1N/status/1125507680955764736
2019-05-06 12:35:03,PCC_CNSDisord,,0,0,2,"#Parkinson disease #psychosis causes functional decline and adversely impacts quality of life. Here, read about the pros and cons of #pimavanserin in the treatment of patients with this disabling condition. http://bit.ly/2vBvLWc",,,#Parkinson #psychosis #pimavanserin,1125378441258389505,https://twitter.com/PCC_CNSDisord/status/1125378441258389505
2019-05-04 16:41:17,geri4life,,0,3,9,"Message to @CMSGov for same price of 2 months of #agsdrugoftheyear pimavanserin could cover hearing aids for older adults!! #AGS19",,@CMSGov,#agsdrugoftheyear #AGS19,1124715632946114560,https://twitter.com/geri4life/status/1124715632946114560
2019-05-04 16:32:28,debhuang_md,,0,0,1,"Another drug with indication creep: pimavanserin for Alzheimer's behavioral symptoms #AGS19 @AmerGeriatrics @geri_doc @EWidera",,@AmerGeriatrics @geri_doc @EWidera,#AGS19,1124713413685309441,https://twitter.com/debhuang_md/status/1124713413685309441
2019-05-04 16:28:33,swchow,,0,0,0,"#AGS19 @AmerGeriatrics @EWidera @geri_doc Sarcastic Drum Roll: ""Honored"" winner of Drug of the year Pimavanserin (Nuplazid) $3000/month - 5HT2A inverse agonist and antagonist w/o dopamine D2 affinity. 2016 - Parkinson psychosis. Does it work for Alz Dz psychosis? Data says NOPE.",,@AmerGeriatrics @EWidera @geri_doc,#AGS19,1124712428632064000,https://twitter.com/swchow/status/1124712428632064000
2019-05-04 16:26:32,peichenMD,,0,0,0,"Why would we use pimavanserin to treat Alzheimer’s dementia with psychosis when the adverse events seem to have more symptoms of psychosis? #AGS19",,,#AGS19,1124711920844529664,https://twitter.com/peichenMD/status/1124711920844529664
2019-05-04 16:21:27,anniesyed3,,0,2,1,"#Pimavanserin=drug of year at #AGS19; for poor efficacy, increased harm in patients with #Alzheimerdementia psychosis. But still costs $3000/month.",,,#Pimavanserin #AGS19 #Alzheimerdementia,1124710640239513605,https://twitter.com/anniesyed3/status/1124710640239513605
2019-05-04 16:20:03,sarabwanderer,,0,0,1,"And the winner of the overpriced ($3k/mo.) questionably (in)effective and overhyped drug of the year award goes to...Nuplazid (pimavanserin). No sig. difference btwn. drug and placebo for AD psychosis. #AGS19",,,#AGS19,1124710288480133125,https://twitter.com/sarabwanderer/status/1124710288480133125
2019-05-03 15:01:46,GuidantRx,,0,0,0,"Acadia studies pimavanserin in Phase III programme for depression https://bit.ly/2V9H9bq via @PharmaTechFocus",,@PharmaTechFocus,,1124328200736268291,https://twitter.com/GuidantRx/status/1124328200736268291
2019-05-03 03:37:48,SolarMelt,,1,1,2,"$ACAD Upcoming Pimavanserin Readouts MID19 - P3 - ENHANCE - Inadequate Response Schizophrenia YE19 - P2 - ADVANCE - Negative Symptom Schizophrenia 2H19 - P3 IA - HARMONY - Dementia-Related Psychosis",,,,1124156074695827456,https://twitter.com/SolarMelt/status/1124156074695827456
2019-04-27 17:32:00,MDMagazine,,0,0,0,"Selective serotonin inverse agonist pimavanserin, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy. ",,,,1122191679690346499,https://twitter.com/MDMagazine/status/1122191679690346499
2019-04-26 19:16:00,MDMagazine,,0,0,0,"Could pimavanserin become another option for difficult-to-treat depression? https://www.mdmag.com/medical-news/phase-3-major-depression-trials-launched-for-pimavanserin",,,,1121855464038379526,https://twitter.com/MDMagazine/status/1121855464038379526
2019-04-26 18:45:03,Neurology_Bio,,0,1,0,"Charles Bonnet Syndrome Treated With Pimavanserin. http://bioportfol.io/R3Zfj4",,,,1121847676834762752,https://twitter.com/Neurology_Bio/status/1121847676834762752
2019-04-26 18:00:32,PharmaScrip,,0,0,0,"Pipeline Watch: Phase III Starts With Furaprevir/Yimitasvir, Pimavanserin http://bit.ly/2IKXD32 #PharmaScrip",,,#PharmaScrip,1121836472661835779,https://twitter.com/PharmaScrip/status/1121836472661835779
2019-04-26 15:42:00,MDMagazine,,0,0,0,"Pimavanserin, which came under fire for claims of unknown harm in Parkinson patients last year, is gearing up for a major depressive disorder indication. https://www.mdmag.com/medical-news/phase-3-major-depression-trials-launched-for-pimavanserin",,,,1121801609351135232,https://twitter.com/MDMagazine/status/1121801609351135232
2019-04-26 10:42:41,PharmaMKTnet,,0,0,0,"ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder https://magazine.pharmamkt.net/2019/04/26/acadia-pharmaceuticals-initiates-phase-3-clarity-program-with-pimavanserin-as-adjunctive-treatment-for-major-depressive-disorder/",,,,1121726286047719424,https://twitter.com/PharmaMKTnet/status/1121726286047719424
2019-04-26 09:01:58,MedRecall217,,2,0,0,"Mechanism of action of pimavanserin",,,,1121700938866135040,https://twitter.com/MedRecall217/status/1121700938866135040
2019-04-26 03:54:52,BrainSightsApp,,0,0,0,"Charles Bonnet Syndrome Treated With Pimavanserin - Jneuro - Opthalmology via BrainSights https://journals.lww.com/jneuro-ophthalmology/Fulltext/publishahead/Charles_Bonnet_Syndrome_Treated_With_Pimavanserin.99150.aspx",,,,1121623655140610048,https://twitter.com/BrainSightsApp/status/1121623655140610048
2019-04-25 19:54:38,MaisaCorp,,0,0,0,"$ACAD has started the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in upcoming months to evaluate the efficacy and safety of pimavanserin in patients with major depressive disorder who have an inadequate response to standard antidepressant therapy",,,,1121502798120652801,https://twitter.com/MaisaCorp/status/1121502798120652801
2019-04-25 14:07:39,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder - https://sdbn.org/san-diego-biotech-news/2019/04/25/acadia-pharmaceuticals-initiates-phase-3-clarity-program-with-pimavanserin-as-adjunctive-treatment-for-major-depressive-disorder-3/ #biotech #news",,,#biotech #news,1121415476909834241,https://twitter.com/sdbn/status/1121415476909834241
2019-04-25 14:07:39,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder - https://sdbn.org/san-diego-biotech-news/2019/04/25/acadia-pharmaceuticals-initiates-phase-3-clarity-program-with-pimavanserin-as-adjunctive-treatment-for-major-depressive-disorder-4/ #biotech #news",,,#biotech #news,1121415476859613184,https://twitter.com/sdbn/status/1121415476859613184
2019-04-25 14:07:39,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder - https://sdbn.org/san-diego-biotech-news/2019/04/25/acadia-pharmaceuticals-initiates-phase-3-clarity-program-with-pimavanserin-as-adjunctive-treatment-for-major-depressive-disorder-2/ #biotech #news",,,#biotech #news,1121415476851171329,https://twitter.com/sdbn/status/1121415476851171329
2019-04-25 14:07:39,sdbn,,0,0,0,"SDBN Feed: ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder - https://sdbn.org/san-diego-biotech-news/2019/04/25/acadia-pharmaceuticals-initiates-phase-3-clarity-program-with-pimavanserin-as-adjunctive-treatment-for-major-depressive-disorder/ #biotech #news",,,#biotech #news,1121415476666671104,https://twitter.com/sdbn/status/1121415476666671104
2019-04-25 13:08:23,portefeuillefun,,0,0,0,"$ACAD. #ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with #Pimavanserin as Adjunctive Treatment for Major Depressive Disorder https://www.businesswire.com/news/home/20190425005313/en/ACADIA-Pharmaceuticals-Initiates-Phase-3-CLARITY-Program.",,,#ACADIA #Pimavanserin,1121400561591554051,https://twitter.com/portefeuillefun/status/1121400561591554051
2019-04-25 13:06:10,NewsFromBW,,0,0,0,"ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder http://dlvr.it/R3Tz8D",,,,1121400003258273793,https://twitter.com/NewsFromBW/status/1121400003258273793
2019-04-25 13:02:03,Allstocknews,,0,0,0,"$ACAD ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for From our Stock News Alerts App",,,,1121398968423002112,https://twitter.com/Allstocknews/status/1121398968423002112
2019-04-23 10:21:17,MarcGozlan,ericsnoopy,0,0,0,"Treatment may be helpful in reducing progression of symptoms. After reducing dopaminergic medication to the lowest dose without compromising motor function, additional treatment with clozapine, quetiapine or pimavanserin may be helpful if necessary. ",,,,1120633735458766849,https://twitter.com/MarcGozlan/status/1120633735458766849
2019-04-22 21:18:10,uncommoncom,eravacycline,1,0,0,"It doesn’t seem anything you tweet has anything to do with the drug Nuplazid. What am I missing?",,,,1120436655775784961,https://twitter.com/uncommoncom/status/1120436655775784961
2019-04-21 12:27:17,Biotech2050,,0,1,2,"#Pimavanserin tartrate: A potential drug for #pancreatic #cancer therapy in future $ACAD https://www.jacksonimmuno.com/secondary-antibody-resource/company-news/travel-grant-2019-winner/",,,#Pimavanserin #pancreatic #cancer,1119940668179218432,https://twitter.com/Biotech2050/status/1119940668179218432
2019-04-21 04:43:59,AlertJantaINDIA,Retributions,0,0,0,"Typical antipsychotics used to treat hallucinations, and other psychotic symptoms include: risperidone aripiprazole olanzapine ziprasidone quetiapine pimavanserin clozapine See your GP straight away you're experiencing hallucinations Sir.",,,,1119824075772194816,https://twitter.com/AlertJantaINDIA/status/1119824075772194816
2019-04-20 23:23:56,SeeFisch,Rx_Ed,0,4,17,"Damn right! Parkinson treatment psychosis: Quetiapine USED the most, clozapine the most effective, and pimavanserin works through 5HT so less adverse effects ",,,,1119743533462773761,https://twitter.com/SeeFisch/status/1119743533462773761
2019-04-20 07:07:53,iamvkrm,dawso007,1,0,1,"Agree, the attendings I rotated with tried the same. Thinking If drugs like pimavanserin could be a potential solution to the TD issue due to the serotonergic activity and lack of a dopaminergic influence. The few patients I saw with TD just suffer a lot..",,,,1119497901959340032,https://twitter.com/iamvkrm/status/1119497901959340032
2019-04-19 14:53:34,iamvkrm,,0,1,1,"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day https://www.ncbi.nlm.nih.gov/pubmed/22954754",,,,1119252705698926595,https://twitter.com/iamvkrm/status/1119252705698926595
2019-04-19 01:52:53,dawso007,,0,1,2,"Full text article on pimavanserin augmentation of risperidone or haloperidol from 2012: https://www.ncbi.nlm.nih.gov/pubmed/22954754",,,,1119056240926240769,https://twitter.com/dawso007/status/1119056240926240769
2019-04-19 01:42:30,ErikMessamoreMD,ErikMessamoreMD,1,0,0,"It's certainly possible that pimavanserin will work as well as Nasrallah claims. I just wish the message came from a messenger without that kind of connection to the manufacturer.",,,,1119053627195305984,https://twitter.com/ErikMessamoreMD/status/1119053627195305984
2019-04-18 19:41:35,kday9,dawso007,1,0,2,"My family member has been on clozaril for 10 months. Not much improvement. Granted, he used meth for a portion of that time but has two weeks clean. At what point might we consider Pimavanserin?",,,,1118962801655943169,https://twitter.com/kday9/status/1118962801655943169
2019-04-18 05:44:15,dawso007,,1,0,3,"My review of pimavanserin from a couple of years ago. Current package insert is probably more informative: https://real-psychiatry.blogspot.com/2016/05/pimavanserin.html",,,,1118752077075894272,https://twitter.com/dawso007/status/1118752077075894272
2019-04-18 05:42:27,dawso007,,4,5,25,"Very interesting article on initial use of pimavanserin in patients non-responsive to clozapine. (full text): ",,,,1118751625605206016,https://twitter.com/dawso007/status/1118751625605206016
2019-04-17 12:34:12,Biotech_Beast,,0,0,2,"Competitors in the pipeline include drugs like $ACAD's pimavanserin and $TAK's TAK-831. The good news for $NERV longs is that data from roluperidone should come first. I'm predicting success for roluperidone.",,,,1118492855788429312,https://twitter.com/Biotech_Beast/status/1118492855788429312
2019-04-16 03:47:51,SolarMelt,,1,1,7,"$ACAD Dug up the P2 data supporting ENHANCE, the ongoing P3 trial of Pimavanserin in patients with inadequate response to standard antipsychotic therapy. Results expected around mid-year. Looks pretty good. No FDA approved treatment for this indication. ",,,,1117998011110633472,https://twitter.com/SolarMelt/status/1117998011110633472
2019-04-15 04:15:24,Biotech2050,,0,0,0,"#PIMAVANSERIN IN #ALZHEIMER’S #DISEASE #PSYCHOSIS: EFFICACY IN #PATIENTS WITH MORE PRONOUNCED #PSYCHOTIC #SYMPTOMS $ACAD @Clive_Ballard @UofE_Research #nuplazid http://www.jpreventionalzheimer.com/3268-pimavanserin-in-alzheimers-disease-psychosis-efficacy-in-patients-with-more-pronounced-psychotic-symptoms.html",,@Clive_Ballard @UofE_Research,#PIMAVANSERIN #ALZHEIMER #DISEASE #PSYCHOSIS #PATIENTS #PSYCHOTIC #SYMPTOMS #nuplazid,1117642553615093760,https://twitter.com/Biotech2050/status/1117642553615093760
2019-04-15 02:54:10,helsekh,EvilBobJ,0,0,7,"& lacking -Lithium -Clozapine -Sertraline -Paroxetine -Fluoxetine -Venlafaxine -Risperidone -Aripiprazole -Olanzapine -Ziprasidone -Quetiapine -Pimavanserin with an overdose of brainwashing from steeple building leaders talking about a book he hasnt read!",,,,1117622112087265280,https://twitter.com/helsekh/status/1117622112087265280
2019-04-12 16:17:50,SolarMelt,,1,2,5,"$ACAD Nice Pipeline. Huge potential from Nuplazid (aka Pimavanserin), which is already approved in PDP. Well established safety and tolerability profile. ",,,,1116737198630604801,https://twitter.com/SolarMelt/status/1116737198630604801
2019-04-12 13:25:56,SolarMelt,,1,3,3,"$ACAD Upcoming Events H1 - P3 Init - Pimavanserin (Major Depressive Disorder) MID - P3 - Pimavanserin (Inadequate Response Schizophrenia) - ENHANCE H2 - P3 IA - Pimavanserin (Dementia-Delated Sychosis) - HARMONY H2 - P3 Init - Trofinetide (Rett syndrome)",,,,1116693938642067463,https://twitter.com/SolarMelt/status/1116693938642067463
2019-04-10 17:10:04,NeurologyToday,,0,1,1,"NT Correction: We incorrectly stated that pimavanserin required specialized monitoring; the Movement Disorders Society Evidence-Based Committee guideline update said it did not. Read more about the review findings here. https://bit.ly/2WXjqHz #ParkinsonsAwarenessMonth",,,#ParkinsonsAwarenessMonth,1116025565046300672,https://twitter.com/NeurologyToday/status/1116025565046300672
2019-04-08 13:16:39,OnceDailyPharma,,0,0,0,"New post: Nuplazid Email: “What to expect from NUPLAZID® (pimavanserin)” http://oncedailypharma.com/2019/nuplazid-email-what-to-expect-from-nuplazid-pimavanserin?utm_campaign=wp-to-tweet&amp;utm_medium=twitter&amp;utm_source=twitter #digitalpharma",,,#digitalpharma,1115242051359133697,https://twitter.com/OnceDailyPharma/status/1115242051359133697
2019-04-03 17:42:13,Fedup4Brain,,0,0,0,"Pimavanserin: A potentially safer alternative to clozapine for refractory hallucinations and delusions ",,,,1113496943051689984,https://twitter.com/Fedup4Brain/status/1113496943051689984
2019-04-02 20:51:03,ForTheRecord01,,0,0,1,"$acad Vanderbilt Medical Center study (2016-2018): -- 76% of patients receiving Nuplazid (pimavanserin) showed clinical improvement. -- Patients with dementia, delusions &amp; prior antipsychotic failure improved with pimavanserin. See https://www.ncbi.nlm.nih.gov/pubmed/30924099",,,,1113182076008669184,https://twitter.com/ForTheRecord01/status/1113182076008669184
2019-03-31 03:06:03,Ingentium_PD,,0,1,0,"Pimavanserin for Psychosis in #parkinsonsdisease-Related Disorders: A Retrospective Chart Review. http://dlvr.it/R1tBpT",,,#parkinsonsdisease,1112189285640228864,https://twitter.com/Ingentium_PD/status/1112189285640228864
2019-03-28 15:47:43,hhask,,0,0,1,".@ismp1 QuarterWatch: Focus on 3 Psychoactive Drugs: (Neurontin), pregabalin (Lyrica) and pimavanserin (Nuplazid), new antipsychotic for Parkinson’s patients https://www.ismp.org/resources/focus-three-psychoacrtive-drugs/",,@ismp1,,1111293799664361474,https://twitter.com/hhask/status/1111293799664361474
2019-03-26 21:06:50,equijada,,1,0,2,"1. Pain management - acetaminophen 2. bright light therapy + melatonin 3. Dextromethorphan-quinidine 4. pimavanserin - psychosis in PD 5. anticonvulsants - data not that good 6. avoid benzos #dementiasummit19",,,#dementiasummit19,1110649334809255936,https://twitter.com/equijada/status/1110649334809255936
2019-03-23 20:11:30,DavidDa25346593,FrankZhen,0,0,0,"Well, well, well, now someone thinks proving the fact actually matters here",,,,1109548246341304320,https://twitter.com/DavidDa25346593/status/1109548246341304320
2019-03-23 14:57:09,DavidDa25346593,DavidDa25346593,0,0,0,"Oh yeah, the same BS (I don’t mean you, I mean endless negative coverage plus cooking up all kind of conspiracy to slander the man) has been going on with another of Jackson’s body, want to make a guess who that is?",,,,1109469133756784642,https://twitter.com/DavidDa25346593/status/1109469133756784642
2019-03-23 14:52:19,DavidDa25346593,DavidDa25346593,2,0,0,"Well, since you don’t give a damn about the “irrelevant info”(quote on quote fact), you might have to either ask the lord or dig up his grave and ask the man himself",,,,1109467917739917312,https://twitter.com/DavidDa25346593/status/1109467917739917312
2019-03-23 14:50:14,DavidDa25346593,DavidDa25346593,2,0,0,"Did he molest the child? No. Did he have sex with the child? No. Are the “child”s claim on his possession of child pornography and the time, the location, of the sexual abuse and the “characteristics” of Jackson’s dick real? No. Is Jackson a pedophile because he sleep with kids?",,,,1109467395746205701,https://twitter.com/DavidDa25346593/status/1109467395746205701
2019-03-23 14:45:14,DavidDa25346593,DavidDa25346593,1,0,0,"Dub, this ain’t some fathomless philosophical discussion of man’s potential sexual desire expressed through little details like saying “I like to spending time with the kid’s family” or sleep with kiddos, (especially consider the man as a father of two sons and one daughter)",,,,1109466137757016067,https://twitter.com/DavidDa25346593/status/1109466137757016067
2019-03-23 14:36:09,DavidDa25346593,DavidDa25346593,1,0,0,"Unless you are a faithful believer of psycho analysis then I might give your claim some damn credit, still, this controversy ain’t for you to exploit",,,,1109463848958853125,https://twitter.com/DavidDa25346593/status/1109463848958853125
2019-03-23 14:32:54,DavidDa25346593,FrankZhen,1,0,0,"Boy, they accused him of withholding kiddy pornography, accused him of molesting the child, accused him of giving the child a wedding ring and so on, sleeping with the kid ain’t one the slender, since you know, that’s not an indicator of damn sexual desire",,,,1109463032780881920,https://twitter.com/DavidDa25346593/status/1109463032780881920
2019-03-23 14:16:21,DavidDa25346593,FrankZhen,1,0,0,"Maybe the solar system if you’d like to take this conversation to that direction, your call captain",,,,1109458868910751744,https://twitter.com/DavidDa25346593/status/1109458868910751744
2019-03-23 14:06:22,DavidDa25346593,DavidDa25346593,0,0,0,"I don’t care what you have on your mind about the “ill”, modern and cringe stand of Jackson and the kind of culture he represents, for only one thing, and I hate to say this, facts don’t care about your feeling, and what you are trying to do here, is a dangerous habit to indulge",,,,1109456354014457856,https://twitter.com/DavidDa25346593/status/1109456354014457856
2019-03-23 13:59:25,DavidDa25346593,FrankZhen,2,0,0,"Then you don’t belong here, you’re trying to redefine pedophilia, I am proving the fact that Jackson’s case from Chandler to Robson is a fraudulent slander; you are trying to installing the idea Jackson is a pedophile no matter what, I am saying Jackson didn’t have sex with kids",,,,1109454606545743874,https://twitter.com/DavidDa25346593/status/1109454606545743874
2019-03-23 13:37:16,DavidDa25346593,DavidDa25346593,1,0,0,"Never mind the numerous times Jackson’s case was exonerated in court review, when you heard a grown man stated in court that he told his family his was abused in 2005, and later stated he didn’t realize the abuse till 2013, it’s not fishy, it’s bs",,,,1109449032374448134,https://twitter.com/DavidDa25346593/status/1109449032374448134
2019-03-23 13:16:36,DavidDa25346593,FrankZhen,2,0,0,"Base facts based on the self-conflicting words from Wade Robson and the British numbnut Dan Reed’s masterpiece featuring anecdote after anecdote after anecdote. Sure, you are right, there are enough defenders as there are more than enough slander on this man for 20 damn year",,,,1109443829327814656,https://twitter.com/DavidDa25346593/status/1109443829327814656
2019-03-23 09:41:30,DavidDa25346593,FrankZhen,1,0,0,"Falling for the same slanderous media propaganda ain’t typical of you sir",,,,1109389700391829505,https://twitter.com/DavidDa25346593/status/1109389700391829505
2019-03-20 07:19:43,Psychia_Updates,,0,0,0,"CNS Spectrums - Current Issue Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors Editorial Stephen M. Stahl, CNS... ",,,,1108266856916443136,https://twitter.com/Psychia_Updates/status/1108266856916443136
2019-03-20 07:07:35,SaariTT,vaughanbell,0,0,1,"I don't know about the others, but pimavanserin has raised a lot of criticism in AJGP, for example: https://www.ajgponline.org/article/S1064-7481(18)30357-9/fulltext https://www.ajgponline.org/article/S1064-7481(18)30376-2/fulltext https://www.ajgponline.org/article/S1064-7481(18)30375-0/fulltext",,,,1108263800535437312,https://twitter.com/SaariTT/status/1108263800535437312
2019-03-20 05:27:45,vaughanbell,,3,8,32,"Esketamine for depression, pimavanserin for psychosis in Parkinson's, now Brexanolone for postpartum depression. All new mechanisms. We'll see if they hold out in post-approval trials.",,,,1108238679787622400,https://twitter.com/vaughanbell/status/1108238679787622400
2019-03-20 00:13:19,Starr_Rx,evolutionarypsy,1,0,1,"What are your thoughts about the clinical significance of the trial? I treat mostly older males (VA), so I am curious to hear about what others see the utility of this drug. I was pumped about pimavanserin mechanism wise when it first came out (now wary)",,,,1108159548194463747,https://twitter.com/Starr_Rx/status/1108159548194463747
2019-03-16 12:45:25,AGerontologique,,0,0,1,"Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30569083",,,,1106899269183770624,https://twitter.com/AGerontologique/status/1106899269183770624
2019-03-15 07:00:56,amplia2mente,,0,0,0,"Nuplazid (Pimavanserin Tablets) - updated on RxList ",,,,1106450186895835137,https://twitter.com/amplia2mente/status/1106450186895835137
2019-03-09 02:53:10,SexDrugsPD,BrundinPatrik,0,0,1,"Thanks for putting this on my radar! It’s unfortunate there are so few options (pimavanserin, quetiapine, clozapine, etc.) available to treat such a major symptom, and the drug profiles are...not great... Regardless of the outcome with Nuplazid, we need better/safer treatments.",,,,1104213507199979520,https://twitter.com/SexDrugsPD/status/1104213507199979520
2019-03-08 16:29:19,AgentPjr,,0,0,0,"The commercial says #Nuplazid (@Pimavanserin) helps with delusional thoughts and hallucinations related to Parkinson's This may be a treatment to help with #TDS Time for a double-blind study.",,@Pimavanserin,#Nuplazid #TDS,1104056511511310338,https://twitter.com/AgentPjr/status/1104056511511310338
2019-03-08 14:57:31,HuynhCassie,,0,1,6,"Pimavanserin has no sustained benefit for psychosis in Alzheimer’s disease in a UK study presented at #PALTC19 keynote. #BlackBoxWarning #Geriatrics #LTCMedicine",,,#PALTC19 #BlackBoxWarning #Geriatrics #LTCMedicine,1104033409658245120,https://twitter.com/HuynhCassie/status/1104033409658245120
2019-03-08 03:55:03,leafs_s,,0,0,1,"Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist https://www.sciencedirect.com/science/article/pii/S0920996419300787?via%3Dihub",,,,1103866692856295424,https://twitter.com/leafs_s/status/1103866692856295424
2019-03-07 17:49:43,Biotech2050,,0,0,3,"Successful treatment of clozapine-nonresponsive refractory #hallucinations and #delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist $ACAD #nuplazid https://www.ncbi.nlm.nih.gov/pubmed/30837203#",,,#hallucinations #delusions #nuplazid,1103714357228326913,https://twitter.com/Biotech2050/status/1103714357228326913
2019-03-07 15:27:25,zenbrainest,,0,2,7,"""This series of 10 cases of patients with refractory psychosis who responded to pimavanserin is an important new finding that has never been reported before."" https://www.ncbi.nlm.nih.gov/pubmed/30837203",,,,1103678548152332288,https://twitter.com/zenbrainest/status/1103678548152332288
2019-02-27 21:13:43,MaisaCorp,,0,0,2,"$ACAD expect to report top-line results of the ENHANCE study mid-2019. ADVANCE is a Phase 2 study evaluating pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia.",,,,1100866593708478486,https://twitter.com/MaisaCorp/status/1100866593708478486
2019-02-27 21:13:28,MaisaCorp,,0,0,1,"$ACAD plan to initiate a Phase 3 program for pimavanserin as an adjunctive treatment for MDD in the first half of 2019.",,,,1100866529585967105,https://twitter.com/MaisaCorp/status/1100866529585967105
2019-02-27 00:38:22,Sanctuary_Bio,humour_humourrr,0,0,0,"I remember when ACAD peaked in 2017, it was off their 2nd BTD for pimavanserin http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&amp;p=irol-newsArticle&amp;ID=2304720 … To be blunt, there is a good chance the pumpers there never see that price again.",,,,1100555705742876672,https://twitter.com/Sanctuary_Bio/status/1100555705742876672
2019-02-20 11:13:10,CarollynnPorte8,,0,0,0,"FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis ",,,,1098178743326179329,https://twitter.com/CarollynnPorte8/status/1098178743326179329
2019-02-14 17:38:22,MEMilitant1,ProfRobHoward,1,1,3,"1) That sounds like a straw-manning of patients. Maybe some are foolish, many are not. 2) There are reasons for concern about pharma research, but Pimavanserin trials seem to be double-blind, not telling participants mid-trial they were receiving effective treatment like in PACE. ",,,,1096101355855507456,https://twitter.com/MEMilitant1/status/1096101355855507456
2019-02-14 11:01:06,RobertHMcMullen,ProfRobHoward,0,5,12,"2) PACE was an unblinded trial that relied on subjective outcome measures. Like all drugs, Pimavanserin was tested in a placebo-controlled, double-blind trial. Unblinded trials require objective outcome measures (see:https://journals.sagepub.com/doi/full/10.1177/1359105317700886) Disagree?",,,,1096001378584088578,https://twitter.com/RobertHMcMullen/status/1096001378584088578
2019-02-14 07:43:33,ProfRobHoward,RobertHMcMullen,7,0,0,"1. Some think (wrongly) that psychological explanation dismisses validity/gravity of their symptoms. 2. Yes. Drugs have gained licence on less/poorer evidence. Look at Pimavanserin. 3. This is one way to look at the trial data. PACE, like every trial, imperfect of course.",,,,1095951664576692224,https://twitter.com/ProfRobHoward/status/1095951664576692224
2019-02-02 09:08:46,Jetlax,,1,0,0,"""...the 2019 AGS Beers Criteria recognize quetiapine, clozapine, and pimavanserin as exceptions to the general recommendation to avoid all antipsychotics in older adults with Parkinson disease...none of these three excepted drugs is close to ideal in either efficacy or safety...""",,,,1091624456856862720,https://twitter.com/Jetlax/status/1091624456856862720
2019-01-20 21:47:53,semodough,,0,0,6,"$ACAD recovery of the Nuplazid launch.1) interim Phase 3 data for pimavanserin in dementia-related psychosis (DRP) in 2H19; (2) Phase 3 data pimavanserin in schizophrenia with inadequate response to antipsychotics in ~mid-2019;initiation of Phase 3 for pimavanserin MMD in 2H19;",,,,1087104452291641344,https://twitter.com/semodough/status/1087104452291641344
2019-01-19 00:43:01,ls691208,eravacycline,0,0,0,"You won’t be regret, I am pretty sure ...",,,,1086423748352237568,https://twitter.com/ls691208/status/1086423748352237568
2019-01-17 06:14:17,medivizor,,0,1,0,"Pimavanserin improves sleep symptoms in patients with Parkinson’s disease https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ via @medivizor #Parkinson",,@medivizor,#Parkinson,1085782341136596993,https://twitter.com/medivizor/status/1085782341136596993
2019-01-11 23:28:36,FrontPharmacol,,0,0,0,"Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats ",,,,1083868305704677377,https://twitter.com/FrontPharmacol/status/1083868305704677377
2019-01-10 17:00:53,semodough,semodough,1,1,2,"$ACAD catalysts interim Phase 3 data for pimavanserin in dementia-related psychosis (DRP) in 2H19; (2) Phase 3 data for pimavanserin in schizophrenia with inadequate response to antipsychotics in ~mid-2019; (3) initiation of Phase 3 program for pimavanserin in MMD in 2H19 ",,,,1083408348765143040,https://twitter.com/semodough/status/1083408348765143040
2019-01-09 22:40:00,byMattHoffman,,0,0,0,"This guide includes everything you need to know about pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of delusions and hallucinations associated with Parkinson disease psychosis. ",,,,1083131300771495937,https://twitter.com/byMattHoffman/status/1083131300771495937
2019-01-09 20:49:42,JAAPAonline,,0,0,0,"#WednesdayWisdom – Can pimavanserin help treat patients with Parkinson disease psychosis? http://bit.ly/2H06NIT",,,#WednesdayWisdom,1083103541798096903,https://twitter.com/JAAPAonline/status/1083103541798096903
2019-01-05 16:01:16,Ingentium_PD,,0,0,0,"Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. https://magazine.ingentium.com/2019/01/04/guidance-for-switching-from-off-label-antipsychotics-to-pimavanserin-for-parkinsons-disease-psychosis-an-expert-consensus/ #ingentium #parkinsons_disease",,,#ingentium #parkinsons_disease,1081581403396100096,https://twitter.com/Ingentium_PD/status/1081581403396100096
2018-12-26 08:27:03,jpreventionalz1,,0,0,0,"Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30569083",,,,1077843219948453889,https://twitter.com/jpreventionalz1/status/1077843219948453889
2018-12-21 14:25:48,zenbrainest,,0,1,2,"Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. https://www.ncbi.nlm.nih.gov/pubmed/30569083",,,,1076121561688608768,https://twitter.com/zenbrainest/status/1076121561688608768
2018-12-20 14:49:01,cpa61,,0,0,0,"Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats https://buff.ly/2Utl8jx",,,,1075765015184097280,https://twitter.com/cpa61/status/1075765015184097280
2018-12-15 03:10:49,medivizor,,0,0,0,"Pimavanserin improves sleep symptoms in patients with Parkinson’s disease from @medivizor: https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ #Parkinson",,@medivizor,#Parkinson,1073777371952615424,https://twitter.com/medivizor/status/1073777371952615424
2018-12-11 13:10:51,medivizor,,0,4,1,"New by @Medivizor: Pimavanserin improves sleep symptoms in patients with Parkinson’s disease https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ #Parkinson",,@medivizor,#Parkinson,1072478823646724096,https://twitter.com/medivizor/status/1072478823646724096
2018-12-09 22:34:27,MeyersCohen,,0,0,0,"RT "" A Deal Is In The Works_Bristol-Myers Squibb $BMY To Open Discussions With ACADIA Pharmaceuticals $ACAD As It Pursues Pimavanserin For Schizophrenia Market https://rumormurmursbuzz.blogspot.com/2018/11/a-deal-is-in-worksbristol-myers-squibb.html … $BORK $BOOT $BONTQ $BOLD $BOKF $BOJA $BOH $BOE $BNPQY $BNFT $BNED $BNCL $TYG $TXCCQ $TX $…",,,,1071895882411458561,https://twitter.com/MeyersCohen/status/1071895882411458561
2018-12-09 21:48:27,StockWatchHQ,,0,3,1,"A Deal Is In The Works_Bristol-Myers Squibb $BMY To Open Discussions With ACADIA Pharmaceuticals $ACAD As It Pursues Pimavanserin For Schizophrenia Market https://rumormurmursbuzz.blogspot.com/2018/11/a-deal-is-in-worksbristol-myers-squibb.html $BORK $BOOT $BONTQ $BOLD $BOKF $BOJA $BOH $BOE $BNPQY $BNFT $BNED $BNCL $TYG $TXCCQ $TX $TVOG $TTOO",,,,1071884303762513921,https://twitter.com/StockWatchHQ/status/1071884303762513921
2018-12-09 14:11:56,jpreventionalz1,,0,0,1,"Pimavanserin: Potential Treatment For Dementia-Related Psychosis. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30298184",,,,1071769418714267648,https://twitter.com/jpreventionalz1/status/1071769418714267648
2018-12-08 22:15:43,medivizor,,0,0,1,"Pimavanserin improves sleep symptoms in patients with Parkinson’s disease (via @medivizor) https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ #Parkinson",,@medivizor,#Parkinson,1071528778864779264,https://twitter.com/medivizor/status/1071528778864779264
2018-12-08 21:10:34,medivizor,,0,0,0,"New: Pimavanserin improves sleep symptoms in patients with Parkinson’s disease https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ via @medivizor #Parkinson",,@medivizor,#Parkinson,1071512384815202304,https://twitter.com/medivizor/status/1071512384815202304
2018-12-04 00:10:47,medivizor,,0,0,0,"Check out: Pimavanserin improves sleep symptoms in patients with Parkinson’s disease https://medivizor.com/blog/SampleLibrary/parkinsons-disease/pimavanserin-improves-sleep-symptoms-in-patients-with-parkinsons-disease/ via @medivizor #Parkinson",,@medivizor,#Parkinson,1069745797468774406,https://twitter.com/medivizor/status/1069745797468774406
2018-12-03 11:56:38,semodough,CowenResearch,0,2,6,"$ACAD KOLs Convinced Of A Real Efficacy Signal For Pimavanserin In Adjunct Depression ACAD presented top-line data from its Ph 2 CLARITY trial of pimavanserin as adjunct therapy in MDD in late October ",,,,1069561043788226560,https://twitter.com/semodough/status/1069561043788226560
2018-11-29 10:50:35,euparkinsons,,0,0,0,"#Pimavanserin for #Parkinson's Disease #psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. https://bit.ly/2Pbdzuh #Parkinsons #research",,,#Pimavanserin #Parkinson #psychosis #Parkinsons #research,1068094866339627008,https://twitter.com/euparkinsons/status/1068094866339627008
2018-11-27 03:45:35,MedquestReviews,,0,2,11,"Pimavanserin: *Anti-psychotic *5HT inhibitor *Not a dopamine inhibitor Best in psychosis from Parkinson's disease Deep Brain stimulation is STANDARD not experimental Substantia nigra transplant is EXPERIMENTAL in Parkinson's @nsonpal",,@nsonpal,,1067263139031498752,https://twitter.com/MedquestReviews/status/1067263139031498752
2018-11-25 20:07:01,StockWatchHQ,,0,5,1,"A Deal Is In The Works_Bristol-Myers Squibb $BMY To Open Discussions With ACADIA Pharmaceuticals $ACAD As It Pursues Pimavanserin For Schizophrenia Market https://rumormurmursbuzz.blogspot.com/2018/11/a-deal-is-in-worksbristol-myers-squibb.html $BDRAF $ZKIN $TPCS $HLYK $GALXF $NGHCO $CRIUF $LYSDY $PANL $FMBH $CHDGF $ULH $DLRpC $ATHOF $TCTZF",,,,1066785349446262784,https://twitter.com/StockWatchHQ/status/1066785349446262784
2018-11-22 16:33:45,MazenSalama,,0,0,0,"Pimavanserin More Effective in PD Psychosis With Cognitive Impairment - http://tinyurl.com/ya99umoj",,,,1065644513329172481,https://twitter.com/MazenSalama/status/1065644513329172481
2018-11-21 14:33:49,drjkwan,,0,0,0,"Worth a try: #mirtazapine, #pimavanserine and pain management; although #pimavanserin increases mortality x4",,,#mirtazapine #pimavanserine #pimavanserin,1065251944137146368,https://twitter.com/drjkwan/status/1065251944137146368
2018-11-21 01:50:03,BehaviourPharma,,0,0,2,"Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease http://dlvr.it/QrkWwj",,,,1065059733915164674,https://twitter.com/BehaviourPharma/status/1065059733915164674
2018-11-20 11:32:13,nxtstop1,,1,0,0," #BGSconf /@GeriSoc DAY 3: Dr. Rimona Weil on #Dementia in #Parkinsons &amp; Lewy Body D. #DLB Visual Hallucinations Pimavanserin to treat them –––is it safe? A: Evidence says benefits outweigh risks....... but note those risks! #SharedDecisionMaking w/pt /family/carers",,@GeriSoc,#BGSconf #Dementia #Parkinsons #DLB #SharedDecisionMaking,1064843856905216002,https://twitter.com/nxtstop1/status/1064843856905216002
2018-11-16 14:53:26,GeriSoc,,0,3,3,"Pimavanserin for visual hallucinations, is it safe? Answer, evidence says benefits outweigh risk #bgsconf",,,#bgsconf,1063444943228801026,https://twitter.com/GeriSoc/status/1063444943228801026
2018-11-08 13:32:00,enfermedadpsp,,0,0,0," Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications - Espay https://onlinelibrary.wiley.com/doi/full/10.1002/mds.27488#.W-Oh62ti1rE.twitter #Parkinson #neurologia",,,#Parkinson #neurologia,1060525344526979072,https://twitter.com/enfermedadpsp/status/1060525344526979072
2018-11-06 16:53:20,Biotech2050,,0,0,3,"In preparation of $ACAD Q3 results one can listen to what @Clive_Ballard said about pimavanserin #hallucinations #psychosis",,@Clive_Ballard,#hallucinations #psychosis,1059851237049450497,https://twitter.com/Biotech2050/status/1059851237049450497
2018-11-05 19:11:06,PracticalNeuro,,0,1,2,"Practical Neurology - Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder #Neurology #Acadia #Nuplazid #Parkinsons https://hubs.ly/H0fptQC0",,,#Neurology #Acadia #Nuplazid #Parkinsons,1059523518600282115,https://twitter.com/PracticalNeuro/status/1059523518600282115
2018-11-05 16:00:46,Ingentium_PD,,0,0,0,"Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and ... https://magazine.ingentium.com/2018/11/04/pimavanserin-for-parkinsons-disease-psychosis-effects-stratified-by-baseline-cognition-and-use-of-cognitive-enhancing-medications/",,,,1059475620764233729,https://twitter.com/Ingentium_PD/status/1059475620764233729
2018-11-03 14:32:55,ScienceofPD,,0,0,1,"ACADIA Pharmaceuticals have published preliminary data for their antipsychotic pimavanserin (aka Nuplazid), a selective serotonin 2A receptor inverse agonist, in people with #Parkinsons with cognitive impairment https://onlinelibrary.wiley.com/doi/full/10.1002/mds.27488",,,#Parkinsons,1058728736768573440,https://twitter.com/ScienceofPD/status/1058728736768573440
2018-11-03 12:12:37,MyNeuroNewscom,,0,0,0,"(Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline ...) has been published on MyN ... - https://myneuronews.com/uncategorized/pimavanserin-for-parkinsons-disease-psychosis-effects-stratified-by-baseline-cognition-and-use-of-cognitive%e2%80%90enhancing-medications/",,,,1058693426881982464,https://twitter.com/MyNeuroNewscom/status/1058693426881982464
2018-11-01 19:30:36,PlexusVentures,,0,0,0,"#ACADIA #Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of #Pimavanserin for Adjunctive Treatment in Patients with #MajorDepressiveDisorder (#MDD) https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-positive-top-103000970.html @YahooFinance",,@YahooFinance,#ACADIA #Pharmaceuticals #Pimavanserin #MajorDepressiveDisorder #MDD,1058078875421458433,https://twitter.com/PlexusVentures/status/1058078875421458433
2018-10-31 16:24:27,wyldementia,,0,0,1,"Pimavanserin for psychosis in Alzheimer's disease from @Clive_Ballard - promising but may not have a long term benefit #28AEC",,@Clive_Ballard,#28AEC,1057669638476181504,https://twitter.com/wyldementia/status/1057669638476181504
2018-10-31 13:48:14,Complexificator,JacobPlieth,1,0,0,"Slide 8 makes it look like the pimavanserin arm stopped at 5 weeks... is that incorrect?",,,,1057630328913719298,https://twitter.com/Complexificator/status/1057630328913719298
2018-10-31 11:42:30,HottestStockNow,,0,0,0,"$ACAD Reveals Promising Findings from Mid-Stage Study Evaluating Pimavanserin for Adjunctive Treatment in Major Depressive Disorder Patients http://crweworld.com/symbol/ACAD",,,,1057598683762421760,https://twitter.com/HottestStockNow/status/1057598683762421760
2018-10-31 11:27:47,jonnajarian,,1,0,3,"$ACAD Top-line results from Pimavanserin Phase 2 CLARITY trial for Adjunctive treatment in patients with Major Depressive Disorder (MDD) met primary and secondary endpoints, shares up 14.5% &amp; plenty of unusual call buying my friends! ",,,,1057594981815386112,https://twitter.com/jonnajarian/status/1057594981815386112
2018-10-31 11:24:59,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive http://crweworld.com/article/news-provided-by-business-wire/858180/acadia-pharmaceuticals-announces-positive-top-line-results-from-phase-2-clarity-trial-of-pimavanserin-for-adjunctive-treatment-in-patients-with-major-depressive-disorder-mdd",,,,1057594278451396609,https://twitter.com/CrweWorld/status/1057594278451396609
2018-10-31 11:13:18,bethelightgb,,0,0,0,"ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD) https://yhoo.it/2RmcoJI",,,,1057591337795678208,https://twitter.com/bethelightgb/status/1057591337795678208
2018-10-31 11:02:30,Biotech2050,,0,0,5,"$ACAD Announces Positive Top-line Results from Phase 2 CLARITY Trial of #Pimavanserin for Adjunctive Treatment in Patients with Major #Depressive Disorder (#MDD)",,,#Pimavanserin #Depressive #MDD,1057588617076527104,https://twitter.com/Biotech2050/status/1057588617076527104
2018-10-31 10:57:32,AlmightyZeezA,,0,0,1,"$ACAD Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)",,,,1057587370634153984,https://twitter.com/AlmightyZeezA/status/1057587370634153984
2018-10-31 10:49:37,adamfeuerstein,,2,1,3,"The only positive gleaned from today’s $ACAD PR is pimavanserin didn’t kill anyone.",,,,1057585375785426944,https://twitter.com/adamfeuerstein/status/1057585375785426944
2018-10-31 10:36:11,NewsFromBW,,0,0,0,"ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD) http://dlvr.it/Qq4D3c",,,,1057581995222421505,https://twitter.com/NewsFromBW/status/1057581995222421505
2018-10-31 10:35:10,MatteoNecci,,0,0,1,"$ACAD ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-positive-top-103000970.html?soc_src=social-sh&amp;soc_trk=tw",,,,1057581740229844993,https://twitter.com/MatteoNecci/status/1057581740229844993
2018-10-31 10:33:42,Allstocknews,,0,0,0,"$ACAD ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin f From our Stock News Alerts App",,,,1057581369478524928,https://twitter.com/Allstocknews/status/1057581369478524928
2018-10-31 10:32:23,_B_I_O_T_E_C_H_,,0,2,1,"$ACAD ACADIA - PIMAVANSERIN MET PRIMARY ENDPOINT POSITIVE RESULTS ALSO OBSERVED ON SEVEN ADDITIONAL SECONDARY ENDPOINTS TO INITIATE PHASE 3 PROGRAM IN ADJUNCTIVE MDD IN 1H 2019 PIMAVANSERIN MET KEY SECONDARY ENDPOINT",,,,1057581039986581509,https://twitter.com/_B_I_O_T_E_C_H_/status/1057581039986581509
2018-10-31 10:31:41,BioStocks,,0,5,11,"$ACAD Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with MDD. CC 8.30 ET",,,,1057580864140427264,https://twitter.com/BioStocks/status/1057580864140427264
2018-10-31 10:31:38,odibro,,0,9,13,"$ACAD Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD) https://www.businesswire.com/news/home/20181031005271/en/ACADIA-Pharmaceuticals-Announces-Positive-Top-line-Results-Phase",,,,1057580849464569856,https://twitter.com/odibro/status/1057580849464569856
2018-10-30 14:16:10,MazenSalama,,0,0,0,"Mortality Rates in Parkinson Disease Psychosis With Pimavanserin, Quetiapine - http://tinyurl.com/yb7ycxl7",,,,1057274967434321920,https://twitter.com/MazenSalama/status/1057274967434321920
2018-10-25 15:00:42,Ingentium_PD,,0,0,0,"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. https://magazine.ingentium.com/2018/10/24/mortality-in-patients-with-parkinson-disease-psychosis-receiving-pimavanserin-and-quetiapine/",,,,1055474238084263937,https://twitter.com/Ingentium_PD/status/1055474238084263937
2018-10-25 03:21:16,Rx_Ed,,0,1,3,"Page 215 in “Step Up To Medicine” no mention of pimavanserin (5HT inverse agonist/antagonist) for Parkinson’s induced psychosis. This is 2018. Not 1998. Get current. Get accurate. Get MedQuest Pharm.",,,,1055298218777608192,https://twitter.com/Rx_Ed/status/1055298218777608192
2018-10-22 21:51:16,movanfleni,,0,2,3,"Mortality in patients with #Parkinson disease psychosis receiving pimavanserin and quetiapine. @GreenJournal",,@GreenJournal,#Parkinson,1054490395302940672,https://twitter.com/movanfleni/status/1054490395302940672
2018-10-15 21:35:00,Parkinsons_HU,,0,0,0,"The US FDA reaffirmed the safety of pimavanserin (Nuplazid), as being a safe and effective course of treatment for hallucinations and delusions in PD psychosis. http://parkinsonsdisease.net/?p=8950",,,,1051949586791755776,https://twitter.com/Parkinsons_HU/status/1051949586791755776
2018-10-13 00:22:08,KualiResearch,,0,0,1,"Novel drug has been linked to increased mortality, but @UCSanDiego scientists find no statistically significant evidence in study comparing #pimavanserin (Nuplazid) to another #drug and to combination therapy. #PDP https://health.ucsd.edu/news/releases/Pages/2018-09-26-Researchers-Evaluate-Controversial-Treatment-for-Parkinson%E2%80%99s-Disease-Psychosis.aspx",,@UCSanDiego,#pimavanserin #drug #PDP,1050904482622660608,https://twitter.com/KualiResearch/status/1050904482622660608
2018-10-12 17:30:25,UCSDGRR,,0,0,2,"Researchers at @UCSDMedSchool conducted a retrospective study of qualifying patients with #Parkinson's Disease, concluding that the new drug, pimavanserin (marketed as Nuplazid), did not pose a statistically significant greater risk of death. http://ow.ly/r79d30m5nnD",,@UCSDMedSchool,#Parkinson,1050800873390137344,https://twitter.com/UCSDGRR/status/1050800873390137344
2018-10-10 01:51:05,Rx_Ed,,0,1,3,"Pimavanserin is selective serotonin modulator SPECIFICALLY for Parkinson’s induced psychosis.",,,,1049839707402600449,https://twitter.com/Rx_Ed/status/1049839707402600449
2018-10-09 16:36:19,dpmlawfirm,,0,0,1,"Nuplazid (also known as pimavanserin) was approved by the FDA in the middle of this already-dicey situation. Hope for Nuprazid rested mostly on a single Phase 3 trial lasting just six weeks.",,,,1049700093597835264,https://twitter.com/dpmlawfirm/status/1049700093597835264
2018-10-05 17:31:32,Biotech2050,,0,0,1,"Study to Evaluate the Efficacy and Safety of Adjunctive #Pimavanserin in Major #Depressive Disorder (CLARITY) Trial updated today. Results could be out any day now by $ACAD",,,#Pimavanserin #Depressive,1048264436736188416,https://twitter.com/Biotech2050/status/1048264436736188416
2018-10-03 18:13:21,BGSMDS,,0,3,6,"FDA concludes that benefits of pimavanserin (not licensed in UK) likely to exceed risks for hallucinations and delusions in #Parkinson’s psychosis",,,#Parkinson,1047550186296422400,https://twitter.com/BGSMDS/status/1047550186296422400
2018-10-03 00:14:01,JoinAPPA,,0,0,1,"FDA Analysis Concludes No Unexpected Safety Risks Associated With Pimavanserin ",,,,1047278560673710082,https://twitter.com/JoinAPPA/status/1047278560673710082
2018-10-02 17:57:10,geropsych,,0,0,0,"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine http://n.neurology.org/content/early/2018/09/26/WNL.0000000000006396",,,,1047183723383246849,https://twitter.com/geropsych/status/1047183723383246849
2018-10-01 14:01:00,neurology_live,,0,0,0,"#ICYMI: The FDA approved galcanezumab, and confirmed the safety of pimavanserin for Parkinson disease. Also, treating augmentation in restless legs syndrome, and gene therapies for the treatment of Alzheimer disease. ",,,#ICYMI,1046761905140961280,https://twitter.com/neurology_live/status/1046761905140961280
2018-09-30 16:20:00,neurology_live,,0,0,0,"#ICYMI: After the #FDA announced its stance on the safety of pimavanserin for Parkinson disease psychosis, an independent study from researchers at @UCSDHealth has found no statistically significant evidence to the contrary.",,@UCSDHealth,#ICYMI #FDA,1046434496516706304,https://twitter.com/neurology_live/status/1046434496516706304
2018-09-30 12:58:00,neurology_live,,0,0,0,"#ICYMI, this week on Neurology News Network: FDA approves galcanezumab, the agency confirms the safety of pimavanserin for Parkinson disease, treating augmentation in restless legs syndrome, and gene therapies for the treatment of Alzheimer disease. https://www.neurologylive.com/videos/galcanezumab-approved-pimavanserin-safety-augmentation-rls-genetics-alzheimer",,,#ICYMI,1046383661229232129,https://twitter.com/neurology_live/status/1046383661229232129
2018-09-29 17:17:00,neurology_live,,0,0,0,"#ICYMI: An independent investigation out of @UCSDHealth has found no statistically significant evidence showing a higher risk of mortality with #pimavanserin compared to quetiapine or combination therapy. https://www.neurologylive.com/clinical-focus/pimavanserin-safety-reiterated-independent-study",,@UCSDHealth,#ICYMI #pimavanserin,1046086453107847169,https://twitter.com/neurology_live/status/1046086453107847169
2018-09-29 14:00:00,byMattHoffman,,0,1,2,"This week on Neurology News Network: FDA approves galcanezumab, the agency confirms the safety of pimavanserin for Parkinson disease, treating augmentation in restless legs syndrome, and gene therapies for the treatment of Alzheimer disease. https://www.neurologylive.com/videos/galcanezumab-approved-pimavanserin-safety-augmentation-rls-genetics-alzheimer",,,,1046036877340368896,https://twitter.com/byMattHoffman/status/1046036877340368896
2018-09-29 13:49:00,neurology_live,,0,0,0,"This week on Neurology News Network: FDA approves galcanezumab, the agency confirms the safety of pimavanserin for Parkinson disease, treating augmentation in restless legs syndrome, and gene therapies for the treatment of Alzheimer disease. https://www.neurologylive.com/videos/galcanezumab-approved-pimavanserin-safety-augmentation-rls-genetics-alzheimer",,,,1046034108307189762,https://twitter.com/neurology_live/status/1046034108307189762
2018-09-28 20:39:00,neurology_live,,0,1,1,"After the #FDA announced its stance on the safety of pimavanserin for Parkinson disease psychosis, an independent study from researchers at @UCSDHealth has found no statistically significant evidence to the contrary. https://www.neurologylive.com/clinical-focus/pimavanserin-safety-reiterated-independent-study",,@UCSDHealth,#FDA,1045774899883593728,https://twitter.com/neurology_live/status/1045774899883593728
2018-09-28 15:18:00,byMattHoffman,,0,0,0,"I asked Dr. Fatta Nahab, from @UCSDHealth, about his thoughts on the risks associated with pimavanserin. ""In my own practice, I had not had concern about the safety of pimavanserin."" https://www.neurologylive.com/clinical-focus/pimavanserin-safety-reiterated-independent-study",,@UCSDHealth,,1045694117760696320,https://twitter.com/byMattHoffman/status/1045694117760696320
2018-09-28 13:38:00,neurology_live,,0,0,0,"An independent investigation out of @UCSDHealth has found no statistically significant evidence showing a higher risk of mortality with #pimavanserin compared to quetiapine or combination therapy. https://www.neurologylive.com/clinical-focus/pimavanserin-safety-reiterated-independent-study",,@UCSDHealth,#pimavanserin,1045668951902973952,https://twitter.com/neurology_live/status/1045668951902973952
2018-09-26 22:19:42,UCSDMedSchool,,0,0,1,"In contrast to recent reports linking increased mortality and new #Parkinsons disease psychosis drug pimavanserin (Nuplazid), our researchers found the drug did not pose a statistically significant greater risk of death https://go.ucsd.edu/2R7e36O @GreenJournal",,@GreenJournal,#Parkinsons,1045075467512868864,https://twitter.com/UCSDMedSchool/status/1045075467512868864
2018-09-25 17:17:00,neurology_live,,0,0,2,"#ICYMI: The @US_FDA has released a statement reiterating its stance on the safety of #pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of hallucinations and delusions due to #Parkinson disease psychosis.",,@US_FDA,#ICYMI #pimavanserin #Parkinson,1044636901536223232,https://twitter.com/neurology_live/status/1044636901536223232
2018-09-25 15:45:34,JuneSanson,,0,0,0,"FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis ",,,,1044613890729025537,https://twitter.com/JuneSanson/status/1044613890729025537
2018-09-25 15:28:46,surgeonshall,eravacycline,0,0,1,"It is an Aspirateur de Dieulafoy which is a suction pump used to remove liquid from the pleura.",,,,1044609665995362306,https://twitter.com/surgeonshall/status/1044609665995362306
2018-09-25 10:29:37,surgeonshall,eravacycline,0,0,0,"It wasn't used for enema!",,,,1044534381489074176,https://twitter.com/surgeonshall/status/1044534381489074176
2018-09-25 07:35:26,medicalnewser,,0,0,1,"FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis...",,,,1044490547115839488,https://twitter.com/medicalnewser/status/1044490547115839488
2018-09-24 21:07:00,MDMagazine,,0,0,0,"Last week, the FDA concluded that the benefits of pimavanserin for #Parkinsons still outweighed its risks:",,,#Parkinsons,1044332395577659398,https://twitter.com/MDMagazine/status/1044332395577659398
2018-09-24 19:34:39,sp3cul8r,,4,0,5,"This $AMRN turn-around today reminds me sooo much of $ACAD back in early 2013 where I got in at $8. Pimavanserin had been overlooked &amp; the biotech world didn't expect ANYTHING from the company. Same here in $AMRN 7% short &amp; not many expected this. Which means, could run for years",,,,1044309156616957958,https://twitter.com/sp3cul8r/status/1044309156616957958
2018-09-24 19:27:27,MDedgeNeurology,,0,3,6,"Is #pimavanserin superior to #quetiapine for #Parkinson’s disease #psychosis?",,,#pimavanserin #quetiapine #Parkinson #psychosis,1044307341821313025,https://twitter.com/MDedgeNeurology/status/1044307341821313025
2018-09-24 15:25:08,Spanishcountry,,0,0,0,"FDA Reaffirms Safety of Pimavanserin in PD Psychosis https://www.medscape.com/viewarticle/902334?nlid=125097_4562&amp;src=wnl_dne_180924_mscpedit&amp;uac=236010BZ&amp;impID=1748112&amp;faf=1?src=soc_tw_share via @medscape",,@Medscape,,1044246363406573568,https://twitter.com/Spanishcountry/status/1044246363406573568
2018-09-24 14:22:00,neurology_live,,0,0,0,"The @US_FDA has released a statement reiterating its stance on the safety of #pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of hallucinations and delusions due to #Parkinson disease psychosis. https://www.neurologylive.com/clinical-focus/fda-confirms-pimavanserin-safety-for-parkinson-disease-psychosis",,@US_FDA,#pimavanserin #Parkinson,1044230473441005568,https://twitter.com/neurology_live/status/1044230473441005568
2018-09-24 14:17:00,byMattHoffman,,0,1,1,"The @US_FDA has released a statement reiterating its stance on the safety of #pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of hallucinations and delusions due to #Parkinson disease psychosis. https://www.neurologylive.com/clinical-focus/fda-confirms-pimavanserin-safety-for-parkinson-disease-psychosis",,@US_FDA,#pimavanserin #Parkinson,1044229215418122240,https://twitter.com/byMattHoffman/status/1044229215418122240
2018-09-24 09:41:25,SlingshotCtlyst,,0,0,0,"FDA Analysis Issued for Acadia's (ACAD) NUPLAZID (pimavanserin) in Patients Parkinson's Psychosis $ACAD",,,,1044159862983282688,https://twitter.com/SlingshotCtlyst/status/1044159862983282688
2018-09-24 06:49:56,fdadaily,,0,0,0,"FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis, ,http://fdadaily.com/2018/09/20/fda-issues-statement-reaffirming-the-positive-benefit-risk-profile-of-nuplazid-pimavanserin-for-patients-with-hallucinations-and-delusions-associated-with-parkinsons-disease-psychosis/",,,,1044116706359160832,https://twitter.com/fdadaily/status/1044116706359160832
2018-09-23 16:31:08,ParkinsonDoctor,,0,0,0,"#FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of #NUPLAZID® (pimavanserin) for Patients with #Hallucinations and #Delusions Associated with #Parkinson Disease #Psychosis http://news.acadia-pharm.com/phoenix.zhtml?c=125180&amp;p=irol-newsArticle_Print&amp;ID=2368361",,,#FDA #NUPLAZID #Hallucinations #Delusions #Parkinson #Psychosis,1043900583340650498,https://twitter.com/ParkinsonDoctor/status/1043900583340650498
2018-09-23 05:14:16,Biotech2050,Biotech2050,1,0,2,"Every patient who stopped taking $ACAD pimavanserin on your CNN ""medical"" advice is a patient exposed to 4 times the risk of death and stroke. All such deaths, if any, could have been avoidable had balanced reporting taken place.",,,,1043730244300091392,https://twitter.com/Biotech2050/status/1043730244300091392
2018-09-23 03:58:07,Biotech2050,ForTheRecord01,0,0,1,"4. Endorsement by University of Exeter on $ACAD pimavanserin ",,,,1043711081988980737,https://twitter.com/Biotech2050/status/1043711081988980737
2018-09-23 03:55:41,Biotech2050,ForTheRecord01,1,0,1,"And so do university of Exeter. Pity I am blocked by Adam who might not see this pic. $ACAD pimavanserin endorsement ",,,,1043710466688724992,https://twitter.com/Biotech2050/status/1043710466688724992
2018-09-23 03:52:25,Biotech2050,Biotech2050,0,0,2,"What CNN could do is interview @Clive_Ballard the Dean of @ExeterMed and get their opinion on mortality rates by using antipsychotics versus mortality rates using pimavanserin. Also ask on the further untapped potential of pimavanserin. $ACAD",,@Clive_Ballard @ExeterMed,,1043709644143771648,https://twitter.com/Biotech2050/status/1043709644143771648
2018-09-23 03:46:54,Biotech2050,ForTheRecord01,2,0,3,"This pic sums it all for $ACAD pimavanserin. Exeter University is at the forefront in the study of #Alzheimer #parkinsons #dementia #psychosis #Schizophrenia and they are looking forward for the launch of pimavanserin in UK. ",,,#Alzheimer #parkinsons #dementia #psychosis #Schizophrenia,1043708256407949312,https://twitter.com/Biotech2050/status/1043708256407949312
2018-09-23 03:43:03,Biotech2050,semodough,0,0,3,"#Parkinson #dementia #psychosis $ACAD This pic by Exeter University sums up the pros of pimavanserin and the negatives of using anti psychotics. 4 times chance of death using the latter. Even FDA issued warning not to use latter = gross endorsement for pimavanserin use ",,,#Parkinson #dementia #psychosis,1043707288714919937,https://twitter.com/Biotech2050/status/1043707288714919937
2018-09-22 21:00:39,MDEdgePsych,,0,2,3,"The @US_FDA find no new or unexpected safety findings in their review of pimavanserin, a treatment for #hallucinations and delusions associated with #Parkinson's disease. #psychiatry",,@US_FDA,#hallucinations #Parkinson #psychiatry,1043606019958628352,https://twitter.com/MDEdgePsych/status/1043606019958628352
2018-09-22 04:51:47,pharmacopsych,,0,0,0,"FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis ",,,,1043362198188384256,https://twitter.com/pharmacopsych/status/1043362198188384256
2018-09-21 21:09:21,OCPhA_CA,,0,0,0,"FDA analysis finds no new or unexpected safety risks associated with pimavanserin https://ift.tt/2NY7PHH #pharmacist #pharmacy #health #healthcare",,,#pharmacist #pharmacy #health #healthcare,1043245821951660032,https://twitter.com/OCPhA_CA/status/1043245821951660032
2018-09-21 18:50:18,fdadaily,,0,0,0,"FDA Reaffirms Safety of Pimavanserin in PD Psychosis, ,http://fdadaily.com/2018/09/21/fda-reaffirms-safety-of-pimavanserin-in-pd-psychosis/",,,,1043210830941171712,https://twitter.com/fdadaily/status/1043210830941171712
2018-09-21 18:32:14,BrainSightsApp,,0,0,0,"FDA Reaffirms Safety of Pimavanserin in PD Psychosis - Medscape - Neurology via BrainSights http://www.medscape.com/viewarticle/902334?src=rss",,,,1043206283602669568,https://twitter.com/BrainSightsApp/status/1043206283602669568
2018-09-21 18:25:00,SpecialtyPTimes,,0,0,0,"#FDA: No Unexpected Safety Risks Associated With Pimavanserin http://bit.ly/2MWY0oU",,,#FDA,1043204462523731968,https://twitter.com/SpecialtyPTimes/status/1043204462523731968
2018-09-21 15:50:58,PharmaMKTnet,,0,0,0,"FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis https://magazine.pharmamkt.net/2018/09/21/fda-issues-statement-reaffirming-the-positive-benefit-risk-profile-of-nuplazid-pimavanserin-for-patients-with-hallucinations-and-delusions-associated-with-parkinsons-disease-psychosis/",,,,1043165697780658176,https://twitter.com/PharmaMKTnet/status/1043165697780658176
2018-09-21 14:17:05,WSPARX,,0,0,0,"The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety... ",,,,1043142071467601920,https://twitter.com/WSPARX/status/1043142071467601920
2018-09-21 14:04:19,ComplyFda,,0,0,0,"FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis ",,,,1043138859763212290,https://twitter.com/ComplyFda/status/1043138859763212290
2018-09-21 08:14:42,ScienceofPD,,1,1,1,"The @US_FDA gives Nuplazid (Pimavanserin) a clean bill of health for the treatment of #Parkinsons psychosis. ""Analysis finds no new or unexpected safety risks associated with"" the treatment https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm",,@US_FDA,#Parkinsons,1043050875361677312,https://twitter.com/ScienceofPD/status/1043050875361677312
2018-09-21 06:51:03,DennisPartners,,0,0,0,"FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis ",,,,1043029824824958977,https://twitter.com/DennisPartners/status/1043029824824958977
2018-09-21 06:01:50,MatteoNecci,,0,0,0,"$ACAD the circle closes: FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) fo... https://finance.yahoo.com/news/fda-issues-statement-reaffirming-positive-211500474.html?soc_src=social-sh&amp;soc_trk=tw di",,,,1043017440483930113,https://twitter.com/MatteoNecci/status/1043017440483930113
2018-09-21 05:26:16,fourtyonethirty,,0,0,0,"$ACAD FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) https://finance.yahoo.com/news/fda-issues-statement-reaffirming-positive-211500474.html",,,,1043008489667231744,https://twitter.com/fourtyonethirty/status/1043008489667231744
2018-09-21 05:16:12,ForTheRecord01,,0,0,1,"$acad The FDA would've seen the recent study below which found that antipsychotics like pimavanserin do NOT increase mortality: ",,,,1043005956580233217,https://twitter.com/ForTheRecord01/status/1043005956580233217
2018-09-21 05:12:59,ForTheRecord01,,0,0,1,"$acad The FDA would've evaluated a recent report which shows ""pimavanserin is about 5 times more likely to result in clinical response [than] discontinuation due to an adverse event."" ",,,,1043005144365916160,https://twitter.com/ForTheRecord01/status/1043005144365916160
2018-09-21 05:09:01,ForTheRecord01,,0,0,0,"$acad In reaching its decision, the FDA examined over 25 clinical studies of pimavanserin involving over 1,200 patients &amp; 600 PDP patients. ",,,,1043004148063424514,https://twitter.com/ForTheRecord01/status/1043004148063424514
2018-09-21 04:33:09,dipi1_con,,0,1,0,"#FDA: no risks associated with #Nuplazid (#Pimavanserin), a medication to treat the hallucinations and delusions of #Parkinson’s disease psychosis https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm @FDA_Drug_Info #ECM",,@FDA_Drug_Info,#FDA #Nuplazid #Pimavanserin #Parkinson #ECM,1042995121254330368,https://twitter.com/dipi1_con/status/1042995121254330368
2018-09-21 01:45:32,psk2329,,0,0,3,"$ACAD shares closed up 27% to $19.11 following news that the FDA has completed a postmarketing review, reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. #Bullish",,,#Bullish,1042952939646713856,https://twitter.com/psk2329/status/1042952939646713856
2018-09-21 01:14:33,womens_womens,,0,1,0,"Cowen $ACAD Next Up Pimavaserin Clarity Data in Adjunct Depressioncontinue to expect Ph2 CLARITY trial data of pimavanserin for adjunct depression in 4Q18.modest expectations for datastrongly believe the market has NO expectations for the data with no:… http://bioportfol.io/Qkt01L",,,,1042945140208263169,https://twitter.com/womens_womens/status/1042945140208263169
2018-09-20 23:58:37,semodough,,0,7,9,"Cowen $ACAD Next Up: Pimavaserin Clarity Data in Adjunct Depression continue to expect Ph2 CLARITY trial data of pimavanserin for adjunct depression in 4Q18.modest expectations for data,strongly believe the market has NO expectations for the data, with no value built into shares",,,,1042926032133795840,https://twitter.com/semodough/status/1042926032133795840
2018-09-20 22:01:45,bdailystocks,,0,0,0,"FDA reaffirms positive benefit-risk profile of $ACAD 's NUPLAZID (pimavanserin) for patients with Parkinson’s disease psychosis http://crweworld.com/article/news-provided-by-business-wire/810240/fda-issues-statement-reaffirming-the-positive-benefit-risk-profile-of-nuplazid-pimavanserin-for-patients-with-hallucinations-and-delusions-associated-with-parkinsons-disease-psychosis",,,,1042896622676467712,https://twitter.com/bdailystocks/status/1042896622676467712
2018-09-20 21:58:08,CrweWorld,,0,0,0,"FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Ha http://crweworld.com/article/news-provided-by-business-wire/810240/fda-issues-statement-reaffirming-the-positive-benefit-risk-profile-of-nuplazid-pimavanserin-for-patients-with-hallucinations-and-delusions-associated-with-parkinsons-disease-psychosis",,,,1042895711623245825,https://twitter.com/CrweWorld/status/1042895711623245825
2018-09-20 21:18:19,Allstocknews,,0,0,0,"$ACAD FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Pati From our Stock News Alerts App",,,,1042885691653451781,https://twitter.com/Allstocknews/status/1042885691653451781
2018-09-20 20:57:06,FillSmith3,,0,0,0,"RT FDA_Drug_Info: #FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin): https://go.usa.gov/xPT88. Access PI @: https://go.usa.gov/xPT8s.",,,#FDA,1042880352140906496,https://twitter.com/FillSmith3/status/1042880352140906496
2018-09-20 20:06:00,MDMagazine,,0,0,1,"The @US_FDA has concluded a five-month post-marketing review, concluding that pimavanserin (Nuplazid) is not associated with additional unknown serious adverse events or patient deaths ",,@US_FDA,,1042867491150671872,https://twitter.com/MDMagazine/status/1042867491150671872
2018-09-20 19:50:06,Pharmacy_Times,,0,0,0,"Breaking: U.S. Food and Drug Administration Analysis Concludes No Unexpected Safety Risks Associated With #Pimavanserin https://bit.ly/2xmAWuH",,,#Pimavanserin,1042863490996809728,https://twitter.com/Pharmacy_Times/status/1042863490996809728
2018-09-20 19:29:50,KanandaBarrons,,0,0,0,"$ACAD Soared after FDA says that finds no new or unexpected safety risks associated with Nuplazid (pimavanserin). #Bullish trend detected, bouncing off my trendline! Consolidating 25% Profits ...",,,#Bullish,1042858389200666624,https://twitter.com/KanandaBarrons/status/1042858389200666624
2018-09-20 17:07:50,RodBoydILM,,2,1,4,"FDA puts out unusual statement re $ACAD drug Nupalzid (pimavanserin),says benefits still outweigh risks. https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm Here's @SIRF_Report story discussing $ACAD biz model",,@SIRF_Report,,1042822655429234688,https://twitter.com/RodBoydILM/status/1042822655429234688
2018-09-20 16:48:03,FDA_Drug_Info,,2,12,11,"#FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin): https://go.usa.gov/xPT88. Access PI @: https://go.usa.gov/xPT8s.",,,#FDA,1042817677897752577,https://twitter.com/FDA_Drug_Info/status/1042817677897752577
2018-09-20 16:33:34,odibro,,4,18,33,"$ACAD FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis ",,,,1042814031457857536,https://twitter.com/odibro/status/1042814031457857536
2018-09-20 16:33:04,BioRunUp,,0,2,4,"$ACAD spiking on this news from the FDA ""FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis"" ",,,,1042813906010308609,https://twitter.com/BioRunUp/status/1042813906010308609
2018-09-20 16:26:18,SWIMKILLS,,0,0,0,"$ACAD FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis",,,,1042812203626377218,https://twitter.com/SWIMKILLS/status/1042812203626377218
2018-09-20 16:25:34,sfef84,,0,2,1,"$ACAD 17.93 FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis",,,,1042812019366416387,https://twitter.com/sfef84/status/1042812019366416387
2018-09-20 16:21:54,rebelfd,eravacycline,1,0,0,"That doesn’t count other reservoirs like the eyes or sperm.",,,,1042811097613524994,https://twitter.com/rebelfd/status/1042811097613524994
2018-09-19 15:17:37,MindfulDoc_1,,0,0,1,"Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis (Harmony Study) https://www.lbda.org/harmonystudy",,,,1042432532644552704,https://twitter.com/MindfulDoc_1/status/1042432532644552704
2018-09-18 15:26:59,surgeonshall,eravacycline,1,0,0,"Spot on ",,,,1042072501860401153,https://twitter.com/surgeonshall/status/1042072501860401153
2018-09-15 13:02:28,CrweWorld,,0,0,0,"Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease P http://crweworld.com/article/news-provided-by-business-wire/803298/analyses-of-pimavanserin-studies-evaluating-treatment-in-alzheimers-disease-psychosis-and-parkinsons-disease-psychosis-published-in-the-journal-of-prevention-of-alzheimers-disease-suggestn-potential-for-treating-dementia-related-psychosis",,,,1040948968295825408,https://twitter.com/CrweWorld/status/1040948968295825408
2018-09-14 15:15:00,ExeterMed,,0,0,0,"Advancing #dementia can bring with it #psychosis, which can adversely affect quality of life for #PWD. We found that #pimavanserin significantly reduced psychosis in ppl w/ #alzheimers w/ no adverse effects on cog. func: https://bit.ly/2ul2QYJ #ExeterDementia #WorldAlzMonth",,,#dementia #psychosis #PWD #pimavanserin #alzheimers #ExeterDementia #WorldAlzMonth,1040619932352864257,https://twitter.com/ExeterMed/status/1040619932352864257
2018-09-13 09:08:39,Biotech2050,Clive_Ballard,0,0,0,"$ACAD The safety and efficacy of #Pimavanserin as a treatment for #psychosis in #dementia https://twitter.com/Clive_Ballard/status/1040140525112897537 Dear @Clive_Ballard At $2B the UK NHS or @UofE_Research could buyout ACADIA Pharm, get the pills free of charge in UK and then sell pills to US and EU. Bargain!",,@Clive_Ballard @UofE_Research,#Pimavanserin #psychosis #dementia,1040165348874567680,https://twitter.com/Biotech2050/status/1040165348874567680
2018-09-13 07:30:00,Clive_Ballard,,0,5,9,"At #AAIC18, I spoke to @neurology_live about the safety and efficacy of #Pimavanserin as a treatment for #psychosis in #dementia. Watch my interview here: https://bit.ly/2NYXCrj #ExeterDementia #WorldAlzMonth",,@neurology_live,#AAIC18 #Pimavanserin #psychosis #dementia #ExeterDementia #WorldAlzMonth,1040140525112897537,https://twitter.com/Clive_Ballard/status/1040140525112897537
2018-09-12 18:30:01,ABSOLUTvodka_US,eravacycline,1,0,0,"Alas, it does not.",,,,1039944234537820160,https://twitter.com/ABSOLUTvodka_US/status/1039944234537820160
2018-09-12 12:36:59,surgeonshall,eravacycline,0,0,1,"I should add that job title to my CV! I'm not all that exciting to meet.",,,,1039855392958959616,https://twitter.com/surgeonshall/status/1039855392958959616
2018-09-12 11:25:05,prometheusgreen,surgeonshall,0,0,1,"that's a relief. I was afraid it was something urological... Thanks!",,,,1039837298412728320,https://twitter.com/prometheusgreen/status/1039837298412728320
2018-09-12 08:02:21,surgeonshall,prometheusgreen,1,0,0,"It is a Trilite inhaler",,,,1039786275673452544,https://twitter.com/surgeonshall/status/1039786275673452544
2018-09-11 17:13:27,prometheusgreen,surgeonshall,1,0,0,"does not look like an optical instrument, but I still don't like the looks of it...",,,,1039562576911376384,https://twitter.com/prometheusgreen/status/1039562576911376384
2018-09-11 11:23:03,surgeonshall,eravacycline,1,0,0,"That's what I thought it was when I first saw it, however it's not a lens.",,,,1039474397055201281,https://twitter.com/surgeonshall/status/1039474397055201281
2018-09-10 20:32:21,DDNewsOnline,,0,0,2,"Researchers review potential of ACADIA Pharma’s pimavanserin in #dementia-related #psychoses Initial findings in #Parkinsons &amp; #Alzheimer’s promising; hopeful for other conditions https://link.springer.com/article/10.14283/jpad.2018.29 #pharma #ExeterDementia",,,#dementia #psychoses #Parkinsons #Alzheimer #pharma #ExeterDementia,1039250244301549568,https://twitter.com/DDNewsOnline/status/1039250244301549568
2018-09-10 20:30:23,DDNewsOnline,,1,0,1,"ACADIA Pharma announces add’l analysis of Ph2 #clinicaltrial of pimavanserin vs #Alzheimer’s-assoc #psychosis Patients w/ more pronounced psychotic symptoms also saw improvement vs placebo, confirming primary results https://link.springer.com/article/10.14283/jpad.2018.30 #pharma #dementia #ExeterDementia",,,#clinicaltrial #Alzheimer #psychosis #pharma #dementia #ExeterDementia,1039249752536178688,https://twitter.com/DDNewsOnline/status/1039249752536178688
2018-09-10 15:02:01,Briefingcom,,0,2,1,"$ACAD: ACADIA Pharmaceuticals announces publication of additional data from a Phase 2 study of pimavanserin for the... http://bit.ly/2O7n6T5",,,,1039167115775827968,https://twitter.com/Briefingcom/status/1039167115775827968
2018-09-10 13:57:45,ANTELLIS2015,,0,1,0,"http://www.antellis.com/ Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest ... https://www.eei-biotechfinances.com/analyses-of-pimavanserin-studies-evaluating-treatment-in-alzheimers-disease-psychosis-and-parkinsons-disease-psychosis-published-in-the-journal-of-preventio/ #pharmaceutical #laboratoire #pharma",,,#pharmaceutical #laboratoire #pharma,1039150942527127552,https://twitter.com/ANTELLIS2015/status/1039150942527127552
2018-09-10 13:18:04,Neurology_Bio,,0,1,0,"Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimers Disease Psychosis and Parkinsons Disease Psychosis Published in The Journal of Prevention of Alzheimers Disease Suggest Potential for Treating DementiaRelated Psychosis: ACADIA… http://bioportfol.io/QjjvFP",,,,1039140953657765889,https://twitter.com/Neurology_Bio/status/1039140953657765889
2018-09-10 13:15:37,odibro,,0,6,7,"$ACAD publishes additional data from Phase 2 study of pimavanserin for the treatment of psychosis in Alzheimer Disease https://www.businesswire.com/news/home/20180910005166/en/Analyses-Pimavanserin-Studies-Evaluating-Treatment-Alzheimer%E2%80%99s-Disease",,,,1039140338282192896,https://twitter.com/odibro/status/1039140338282192896
2018-09-10 13:05:38,MatteoNecci,,0,2,2,"$ACAD Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s and Parkinson’s Disease Psychosis https://finance.yahoo.com/news/analyses-pimavanserin-studies-evaluating-treatment-130000856.html?soc_src=social-sh&amp;soc_trk=tw These results further demonstrate that pimavanserin may have the potential to treat dementia-related psychosis",,,,1039137826988802048,https://twitter.com/MatteoNecci/status/1039137826988802048
2018-09-10 13:05:20,Allstocknews,,0,0,0,"$ACAD Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer's Disease Psychosis and Parkinson's From our Stock News Alerts App",,,,1039137749419388931,https://twitter.com/Allstocknews/status/1039137749419388931
2018-09-10 13:04:09,NewsFromBW,,0,0,0,"Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis http://dlvr.it/QjjplR",,,,1039137451866906624,https://twitter.com/NewsFromBW/status/1039137451866906624
2018-09-10 13:03:44,stocknewsdotcom,,0,0,0,"$ACAD Announces publication of additional data from a Phase 2 study of pimavanserin for the treatment of psychosis… https://stocknews.com/news/acad-announces-publication-of-additional-data-from-a-phase-2-study/",,,,1039137345633693696,https://twitter.com/stocknewsdotcom/status/1039137345633693696
2018-08-30 11:32:16,LWWneurology,,0,0,0,"Most Popular: A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic http://dlvr.it/QhY78P",,,,1035128063757975552,https://twitter.com/LWWneurology/status/1035128063757975552
2018-08-20 20:37:00,harryalba,,0,0,0,"The Emerging Role of Pimavanserin in the Management of Parkinson’s Disease Psychosis: Journal of Managed Care &amp; Specialty Pharmacy: Vol 23, No 6-b Suppl https://www.jmcp.org/doi/full/10.18553/jmcp.2017.23.6-b.s2#.W3smRy-EnSM.twitter #Parkinsons #Neurology #MentalHealth",,,#Parkinsons #Neurology #MentalHealth,1031641269964103680,https://twitter.com/harryalba/status/1031641269964103680
2018-08-17 07:04:47,jared_tyndall,,0,0,0,"@strohsymtae @kingscats was invested in this before pimavanserin was improved I know exactly the journey. You’re new to me though",,@KingsCats,,1030349705442680833,https://twitter.com/jared_tyndall/status/1030349705442680833
2018-08-14 21:05:43,jenna_pay,,0,5,7,"The professor of age-related diseases and Dean of the University of Exeter Medical School, @Clive_Ballard, provided insight into the safety and efficacy of #pimavanserin studied in treatment for #Alzheimer #psychosis.",,@Clive_Ballard,#pimavanserin #Alzheimer #psychosis,1029474170638422021,https://twitter.com/jenna_pay/status/1029474170638422021
2018-08-14 15:39:04,surgeonshall,eravacycline,0,0,1,"You're absolutely spot on!",,,,1029391966407192576,https://twitter.com/surgeonshall/status/1029391966407192576
2018-08-14 09:33:11,surgeonshall,eravacycline,0,0,0,"There's no cup the other half is just empty. You're very close though.",,,,1029299887723171840,https://twitter.com/surgeonshall/status/1029299887723171840
2018-08-14 08:38:41,surgeonshall,eravacycline,1,0,0,"It's coming your way in 20 minutes!",,,,1029286172735025152,https://twitter.com/surgeonshall/status/1029286172735025152
2018-08-13 06:34:03,ForTheRecord01,,0,0,1,"$acad Study: ""Pimavanserin is about five times more likely to result in clinical response [than] discontinuation due to an adverse event."" ",,,,1028892421294239745,https://twitter.com/ForTheRecord01/status/1028892421294239745
2018-08-12 21:35:10,DrLindseyFitz,eravacycline,0,0,2,"I’m a big fan of that book!",,,,1028756807450279936,https://twitter.com/DrLindseyFitz/status/1028756807450279936
2018-08-12 21:32:10,DrLindseyFitz,eravacycline,1,0,0,"That’s interesting! Thanks for sharing!",,,,1028756052483997701,https://twitter.com/DrLindseyFitz/status/1028756052483997701
2018-08-11 07:26:15,KateMadeAce,eravacycline,0,0,0,"I’m in the neighborhood near where he did his loop, recovered, caught fire, and crashed. I’m feeling that same sadness for him.",,,,1028180782664151040,https://twitter.com/KateMadeAce/status/1028180782664151040
2018-08-09 16:32:44,ForTheRecord01,,0,0,1,"$acad Dr. Conrad Tenenbaum: ""The data suggest that use of pimavanserin is associated with significantly improved treatment outcomes, both within and beyond six months of treatment."" ",,,,1027593532758880257,https://twitter.com/ForTheRecord01/status/1027593532758880257
2018-08-09 12:10:20,semodough,,0,1,4,"Stifel $ACAD seriously question validity of the conclusions of the CNN report (and we think FDA may too, which could lead to a small rebound in shares), but we'd wait for clear signals that the pimavanserin perception issue has been transcended before going overweight the stock.",,,,1027527497418727427,https://twitter.com/semodough/status/1027527497418727427
2018-08-08 12:53:00,neurology_live,,0,0,0,"Phase II pimavanserin trial results demonstrated efficacy in #Alzheimer disease #psychosis at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS. https://www.neurologylive.com/clinical-focus/clive-ballard-pimavanserin-treatment-hallucinations-delusions-dementia-related-psychosis",,,#Alzheimer #psychosis,1027175845750747136,https://twitter.com/neurology_live/status/1027175845750747136
2018-08-07 21:47:00,byMattHoffman,,0,0,1,"The professor of age-related diseases and Dean of the University of @UniofExeter Medical School provided insight into the safety and efficacy of #pimavanserin studied in treatment for #Alzheimer psychosis. #AAIC18 https://www.neurologylive.com/clinical-focus/clive-ballard-pimavanserin-treatment-hallucinations-delusions-dementia-related-psychosis",,@UniofExeter,#pimavanserin #Alzheimer #AAIC18,1026947843452325888,https://twitter.com/byMattHoffman/status/1026947843452325888
2018-08-07 20:56:00,neurology_live,,0,1,1,"#ICYMI: ""If pimavanserin does turn out to be a more effective and safer alternative, that would be a great step forward in treating these distressing symptoms.""— @Clive_Ballard, MD, on pimavanserin for treatment #dementia-related #psychosis #AAIC18 https://www.neurologylive.com/clinical-focus/clive-ballard-pimavanserin-treatment-hallucinations-delusions-dementia-related-psychosis",,@Clive_Ballard,#ICYMI #dementia #psychosis #AAIC18,1026935009268121602,https://twitter.com/neurology_live/status/1026935009268121602
2018-08-07 18:27:22,neurology_live,,0,2,5,"Dean of @UniofExeter med school, @Clive_Ballard spoke about the findings of the phase II trial of pimavanserin for treatment of #Alzheimer #psychosis https://www.neurologylive.com/clinical-focus/clive-ballard-pimavanserin-treatment-hallucinations-delusions-dementia-related-psychosis",,@UniofExeter @Clive_Ballard,#Alzheimer #psychosis,1026897606121807874,https://twitter.com/neurology_live/status/1026897606121807874
2018-08-04 20:34:29,Biotech2050,,0,0,2,"$ACAD #Pimavanserin use in a movement disorders clinic: a single-center experience #Parkinsons #psychosis #hallucinations",,,#Pimavanserin #Parkinsons #psychosis #hallucinations,1025842430850019329,https://twitter.com/Biotech2050/status/1025842430850019329
2018-08-03 21:45:05,UofE_Research,Biotech2050,0,2,5,"RT @Clive_Ballard: We presented on #pimavanserin on ppl with #Alzheimer psychosis at #AAIC18 - watch the vid from @neurology_live #ExeterDementia",,@Clive_Ballard @neurology_live,#pimavanserin #Alzheimer #AAIC18 #ExeterDementia,1025497811767492608,https://twitter.com/UofE_Research/status/1025497811767492608
2018-08-03 15:38:26,Biotech2050,,0,0,1,"Abstract for #Alzheimer's with results stating: ""Regarding future treatments for #psychosis, the greatest priority was placed on pimavanserin"" (= #nuplazid $ACAD )",,,#Alzheimer #psychosis #nuplazid,1025405541940645890,https://twitter.com/Biotech2050/status/1025405541940645890
2018-08-03 04:15:59,Biotech2050,,0,1,5,""".......we find that patients treated with 34 mg of pimavanserin achieve significantly better physician-reported control of … symptoms, especially compared with those who receive low-dose quetiapine,” said Dr. Tenenbaum and colleagues Good news for $ACAD https://www.mdedge.com/neurologyreviews/article/171747/parkinsons-disease/pimavanserin-may-be-superior-quetiapine",,,,1025233796386435073,https://twitter.com/Biotech2050/status/1025233796386435073
2018-08-02 14:56:53,Biotech2050,Clive_Ballard,0,0,0,"Read @Clive_Ballard 's tweet slowly........ next step for $ACAD #pimavanserin is #Alzheimers #psychosis #ADP! Watch the video &amp; check out his comments on mortality rates. Market opportunity for ADP is huge.",,@Clive_Ballard,#pimavanserin #Alzheimers #psychosis #ADP,1025032696890834949,https://twitter.com/Biotech2050/status/1025032696890834949
2018-08-02 14:11:06,Clive_Ballard,Biotech2050,0,8,11,"We presented on #pimavanserin on ppl with #Alzheimer psychosis at #AAIC18 - watch the vid from @neurology_live #ExeterDementia",,@neurology_live,#pimavanserin #Alzheimer #AAIC18 #ExeterDementia,1025021173669801984,https://twitter.com/Clive_Ballard/status/1025021173669801984
2018-08-02 13:19:29,Biotech2050,,0,0,4,"@Clive_Ballard MD: #Pimavanserin In Patients With #Dementia-Related #Psychosis video https://www.youtube.com/watch?v=UX-ZtAoNBxo&amp;app=desktop $ACAD",,@Clive_Ballard,#Pimavanserin #Dementia #Psychosis,1025008184413618181,https://twitter.com/Biotech2050/status/1025008184413618181
2018-08-01 18:12:51,stephanamayer,,0,3,8,"Pimavanserin use in a movement disorders clinic: a single-center experience. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/30032332",,,,1024719623386750977,https://twitter.com/stephanamayer/status/1024719623386750977
2018-08-01 07:10:41,BehaviourPharma,,0,0,2,"Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease http://dlvr.it/QdRBPS",,,,1024552986297622529,https://twitter.com/BehaviourPharma/status/1024552986297622529
2018-07-31 15:31:59,surgeonshall,eravacycline,0,0,0,"You were not far off! It is an ostetome which acts like a chisel and is used to cut bone.",,,,1024316754565189634,https://twitter.com/surgeonshall/status/1024316754565189634
2018-07-31 09:44:47,MatteoNecci,sly_clank,0,0,1,"I'm not a neurologist, I just try to line up some considerations to see if there is a security problem. For this reason I try to understand from the studies done on Pimavanserin with attention to safety, listening to everyone's opinions.",,,,1024229377440186369,https://twitter.com/MatteoNecci/status/1024229377440186369
2018-07-31 06:48:41,MatteoNecci,,1,0,1,"$ACAD Pimavanserin use in a movement disorders clinic: a single-center experience. https://www.ncbi.nlm.nih.gov/pubmed/30032332 CONCLUSION: In our series based on a small sample size, pimavanserin is well-tolerated and effective as both monotherapy and adjuvant treatment for moderate to severe ...",,,,1024185062378692608,https://twitter.com/MatteoNecci/status/1024185062378692608
2018-07-30 13:59:40,MatteoNecci,,0,0,0,"$ACAD Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo https://www.neurologyadvisor.com/alzheimers-psychosis-pimavanserin-treatment-more-effective-than-placebo/article/783447/ via @neuroadvisor",,@NeuroAdvisor,,1023931133166276609,https://twitter.com/MatteoNecci/status/1023931133166276609
2018-07-28 15:03:09,Ingentium_PD,,0,0,0,"Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the ... https://magazine.ingentium.com/2018/07/27/pimavanserin-nuplazid-for-the-treatment-of-parkinson-disease-psychosis-a-review-of-the-literature/",,,,1023222334952488961,https://twitter.com/Ingentium_PD/status/1023222334952488961
2018-07-26 04:29:13,MazenSalama,,0,0,0,"Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo - http://tinyurl.com/ycrqxs2k",,,,1022338023340425217,https://twitter.com/MazenSalama/status/1022338023340425217
2018-07-24 15:18:43,surgeonshall,eravacycline,0,0,1,"It was used to remove bullets during the early 19th century.",,,,1021776700005339138,https://twitter.com/surgeonshall/status/1021776700005339138
2018-07-24 15:17:11,Clive_Ballard,,0,5,19,"Three posters in a row at #AAIC18 today! Come &amp; chat to me at 1pm on research on pimavanserin, adverse events in buprenorphine &amp; enrichment factors that predict AD progression. Stands 1-3 #ExeterDementia",,,#AAIC18 #ExeterDementia,1021776313517002754,https://twitter.com/Clive_Ballard/status/1021776313517002754
2018-07-24 15:00:18,Ingentium_PD,,0,0,0,"Pimavanserin use in a movement disorders clinic: a single-center experience. https://magazine.ingentium.com/2018/07/23/pimavanserin-use-in-a-movement-disorders-clinic-a-single-center-experience/",,,,1021772066519957504,https://twitter.com/Ingentium_PD/status/1021772066519957504
2018-07-24 10:23:34,surgeonshall,eravacycline,1,0,0,"Good answer but it's not what this was used for.",,,,1021702422970941441,https://twitter.com/surgeonshall/status/1021702422970941441
2018-07-24 09:32:46,surgeonshall,eravacycline,1,0,1,"Thank you! It's not detachable but it can be angled using a small lever near the top of the handle.",,,,1021689637021130752,https://twitter.com/surgeonshall/status/1021689637021130752
2018-07-21 23:47:36,AMahajanMD,,0,0,1,"Our experience with Pimavanserin use @HenryFordNeuro Movement disorders clinic. @stephanamayer",,@HenryFordNeuro @stephanamayer,,1020817601436569600,https://twitter.com/AMahajanMD/status/1020817601436569600
2018-07-19 12:13:42,Clive_Ballard,,1,3,18,"Head down in preparation for @alzassociation’s 2018 International Conference in #Chicago! We’ve got plenty of exciting stuff coming up on #pain, #pimavanserin, as well as our PROTECT &amp; WHELD programmes – stay tuned! #ExeterDementia #AAIC18",,@alzassociation,#Chicago #pain #pimavanserin #ExeterDementia #AAIC18,1019918199377334272,https://twitter.com/Clive_Ballard/status/1019918199377334272
2018-07-15 15:01:44,Ingentium_PD,,0,0,1,"Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review. https://magazine.ingentium.com/2018/07/14/pimavanserin-for-psychotic-symptoms-in-people-with-parkinsonism-a-second-chart-review/",,,,1018510936137785348,https://twitter.com/Ingentium_PD/status/1018510936137785348
2018-07-12 08:14:48,surgeonshall,eravacycline,0,0,0,"We're taking a break from our #TriviaTuesday this week and next but it will return!",,,#TriviaTuesday,1017321362040545280,https://twitter.com/surgeonshall/status/1017321362040545280
2018-07-10 20:44:07,UNGLambert,eravacycline,0,0,2,"I have the reaction too! But I'm a historian of science and medicine so I've made myself look at smallpox over and over again. I don't spring it on my students, tho",,,,1016785158962368512,https://twitter.com/UNGLambert/status/1016785158962368512
2018-07-09 16:30:01,TheSkeptic21,,0,1,3,"In which @RodBoydILM of @SIRF_Report anchors an excellent piece on pimavanserin's serious safety issues with an excellent illustration by @edelstudio $ACAD",,@RodBoydILM @SIRF_Report @edelstudio,,1016358826172444673,https://twitter.com/TheSkeptic21/status/1016358826172444673
2018-07-06 21:33:30,Psychia_Updates,,0,0,0,"The American Journal of Geriatric Psychiatry Absence of evidence v. evidence of absence – Pimavanserin... https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?rc=3&amp;redirect=https%3A%2F%2Fwww.ajgponline.org%2Farticle%2FS1064-7481%2818%2930376-2%2Ffulltext%3Frss%3Dyes",,,,1015348033616338944,https://twitter.com/Psychia_Updates/status/1015348033616338944
2018-07-03 15:24:54,surgeonshall,eravacycline,1,0,1,"They are cortical retractors.",,,,1014168110079926272,https://twitter.com/surgeonshall/status/1014168110079926272
2018-07-03 11:15:19,surgeonshall,eravacycline,1,0,0,"Again, good guesses but not the right answer!",,,,1014105300864045058,https://twitter.com/surgeonshall/status/1014105300864045058
2018-07-03 10:52:21,surgeonshall,eravacycline,1,0,0,"Good guesses but not the right answers I'm afraid.",,,,1014099519640948737,https://twitter.com/surgeonshall/status/1014099519640948737
2018-07-02 12:26:19,PharmaNewsUSA,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) ",,,,1013760778938339328,https://twitter.com/PharmaNewsUSA/status/1013760778938339328
2018-06-30 18:50:05,medicalnewser,,0,0,0,"Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin)...",,,,1013132582031110144,https://twitter.com/medicalnewser/status/1013132582031110144
2018-06-30 09:53:09,feed_stocks,,0,0,0,"Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin), https://stocksnewsfeed.com/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin/",,,,1012997457276493824,https://twitter.com/feed_stocks/status/1012997457276493824
2018-06-30 08:49:34,fdadaily,,0,0,0,"Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin), ,http://fdadaily.com/2018/06/29/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin-2/",,,,1012981459039203328,https://twitter.com/fdadaily/status/1012981459039203328
2018-06-29 14:46:38,EpiscopalianTra,EpiscopalianTra,0,0,0,"NUPLAZID® (pimavanserin) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.. **Pimavanserin in phase 3 for 2 other usages, which is encouraging ",,,,1012708927895564288,https://twitter.com/EpiscopalianTra/status/1012708927895564288
2018-06-29 14:43:21,trader1x,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-fda-approval-113000320.html",,,,1012708100652974083,https://twitter.com/trader1x/status/1012708100652974083
2018-06-29 13:54:19,stocksharks_,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) New Dosing Formulation and Strength Address Needs in Treating Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis ",,,,1012695763598696448,https://twitter.com/stocksharks_/status/1012695763598696448
2018-06-29 13:47:16,PharmaMKTnet,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) http://magazine.pharmamkt.net/newswire_new/fda-newswire_new/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin/",,,,1012693988023984128,https://twitter.com/PharmaMKTnet/status/1012693988023984128
2018-06-29 12:11:43,financialbuzz,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) http://financialbuzz.com/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin-1131630",,,,1012669942510960641,https://twitter.com/financialbuzz/status/1012669942510960641
2018-06-29 12:00:04,CrweWorld,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) http://crweworld.com/article/news-provided-by-business-wire/720993/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin",,,,1012667009601974272,https://twitter.com/CrweWorld/status/1012667009601974272
2018-06-29 11:49:24,fdadaily,,0,0,0,"ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin), ,http://fdadaily.com/2018/06/29/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin/",,,,1012664326027661312,https://twitter.com/fdadaily/status/1012664326027661312
2018-06-29 11:32:04,stocknewsdotcom,,0,0,1,"$ACAD Announces FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin… https://stocknews.com/news/acad-announces-fda-approval-of-a-new-capsule-dose-formulation-and/",,,,1012659962827431938,https://twitter.com/stocknewsdotcom/status/1012659962827431938
2018-06-29 11:30:55,ZoZoStockwatch,,0,0,0,"$ACAD Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) http://businesswire.com/news/home/2018",,,,1012659674473205760,https://twitter.com/ZoZoStockwatch/status/1012659674473205760
2018-06-29 11:30:42,odibro,,0,10,11,"$ACAD Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) ",,,,1012659618462470144,https://twitter.com/odibro/status/1012659618462470144
2018-06-28 22:39:55,viajaVolaris,eravacycline,0,0,0,"Hi, Nuplazid! Sorry for the inconveniences, if you want to verify a situation with us, feel free to contact us through DM. *MV",,,,1012465646683283457,https://twitter.com/viajaVolaris/status/1012465646683283457
2018-06-25 11:33:08,elenabakerglenn,,0,0,0,"Pimavanserin promising for Parkinson’s psychosis. Difficult to interpret adverse effects @RCPsych #rcpsychic",,@rcpsych,#rcpsychic,1011210683193667585,https://twitter.com/elenabakerglenn/status/1011210683193667585
2018-06-20 04:42:08,vikas6th,nehasinghjazz,0,0,0,"NUPLAZID® (pimavanserin) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and ...",,,,1009295310919782401,https://twitter.com/vikas6th/status/1009295310919782401
2018-06-14 19:16:02,AboutMedtech,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://bit.ly/2ybpXqC",,,,1007340906519941122,https://twitter.com/AboutMedtech/status/1007340906519941122
2018-06-14 19:16:02,LakeviewJulie,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://bit.ly/2ybpXqC",,,,1007340905530044416,https://twitter.com/LakeviewJulie/status/1007340905530044416
2018-06-13 21:34:35,Psychia_Updates,,0,0,0,"The American Journal of Geriatric Psychiatry Perspective on Pimavanserin and the SAPS-PD: Novel scale... https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?rc=3&amp;redirect=https%3A%2F%2Fwww.ajgponline.org%2Farticle%2FS1064-7481%2818%2930357-9%2Ffulltext%3Frss%3Dyes",,,,1007013385551085568,https://twitter.com/Psychia_Updates/status/1007013385551085568
2018-06-12 10:36:44,surgeonshall,eravacycline,0,0,0,"It's just two metal prongs with the woven cloth over the top.",,,,1006485447701393408,https://twitter.com/surgeonshall/status/1006485447701393408
2018-06-12 10:28:38,surgeonshall,eravacycline,1,0,0,"Close but not quite!",,,,1006483406220419072,https://twitter.com/surgeonshall/status/1006483406220419072
2018-06-10 16:00:43,BrainHealthMD,,0,1,8,"Pimavanserin can be effective for #Parkinsons disease psychosis but there are possible safety concerns, although it clearly helps some patients. My big question is why this drug costs almost $3000 for a monthly supply? Seems exorbitant. https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2018&amp;issue=06070&amp;article=00004&amp;type=Fulltext",,,#Parkinsons,1005842200943525889,https://twitter.com/BrainHealthMD/status/1005842200943525889
2018-06-10 04:39:03,portefeuillefun,,0,0,0,"For Your Patients-Parkinson's Disease: FDA Revisits #Pimavanserin Amid Reports of Serious Adverse Events, Deaths in Parkinson's Patients https://journals.lww.com/neurotodayonline/Fulltext/2018/06070/For_Your_Patients_Parkinson_s_Disease__FDA.4.aspx. $ACAD",,,#Pimavanserin,1005670655533121537,https://twitter.com/portefeuillefun/status/1005670655533121537
2018-06-08 20:40:27,TrrPress,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects ",,,,1005187825401192448,https://twitter.com/TrrPress/status/1005187825401192448
2018-06-08 16:40:05,TheRxConsultant,,0,0,0,"Pimavanserin – Reexamined After Reports of Death Pimavanserin (Nuplazid™), the first atypical antipsychotic for Parkinson’s disease (PD) - related psychosis... Read more in the Rx News Advisory Feed: https://rxconsultant.com/#rxnews #pharmacists #nursepractitioners",,,#pharmacists #nursepractitioners,1005127334108672000,https://twitter.com/TheRxConsultant/status/1005127334108672000
2018-06-07 15:38:51,mb_Neurology,,0,0,0,"For Your Patients-Parkinson's Disease: FDA Revisits Pimavanserin Amid Reports of Serious Adverse Events, Deaths in ... - LWW Journals: For Your Patients-Parkinson's Disease: FDA Revisits Pimavanserin Amid Reports of Serious Adverse Events, Deaths in ...… http://dlvr.it/QWWSQN",,,,1004749536105881600,https://twitter.com/mb_Neurology/status/1004749536105881600
2018-06-06 20:39:12,ProfRobHoward,vivek_pattan,1,0,5,"Small, old, open trial of ondansetron showed good efficacy. We now need an adequately powered RCT. Cholinesterase inhibitors probably no better than placebo for psychosis. Pimavanserin efficacy far from convincing and apparently no safer than atypicals.",,,,1004462732979113984,https://twitter.com/ProfRobHoward/status/1004462732979113984
2018-06-06 16:44:13,ProfRobHoward,raj_psyc,1,5,16,"A head-to-head comparison of clozapine and pimavanserin would really move things forward. Additionally, some of us are interested in conducting independent trials of repurposed agents, including ondansetron, in this indication. ",,,,1004403598703448065,https://twitter.com/ProfRobHoward/status/1004403598703448065
2018-06-06 16:27:23,raj_psyc,,0,5,5,"The #pimavanserin dilemma; Treating #psychosis in #Parkinson's disease @TheLancetNeuro",,@TheLancetNeuro,#pimavanserin #psychosis #Parkinson,1004399363639128067,https://twitter.com/raj_psyc/status/1004399363639128067
2018-06-04 05:45:00,LaFaverMD,ValKaasinen,0,2,5,"""Randomised controlled trials should examine the relative risk of pimavanserin compared with those of current (although off-label) treatments, and research must continue into novel drugs for psychosis in frail populations."" #Parkinson's disease #psychosis",,,#Parkinson #psychosis,1003512925649293313,https://twitter.com/LaFaverMD/status/1003512925649293313
2018-06-01 12:00:01,GeriMedJC,,0,6,3,"Did you miss the last #GeriMedJC on the pimavanserin for Alzheimer’s disease psychosis @NEJM RCT? It's on our @youtube archives https://www.youtube.com/watch?v=Vqlc9B7wJP8! @Clive_Ballard @GeriInterestGp @AlzToronto @dementiarehab",,@NEJM @YouTube @Clive_Ballard @GeriInterestGp @AlzToronto @dementiarehab,#GeriMedJC,1002520136228560897,https://twitter.com/GeriMedJC/status/1002520136228560897
2018-05-25 12:11:16,GeriMedJC,,0,0,1,"Results. Table 2. Summary of adverse events. Serious adverse events in 17% with pimavanserin vs 11% with placebo. http://www.ncbi.nlm.nih.gov/pubmed/29452684. #GeriMedJC",,,#GeriMedJC,999986255617081344,https://twitter.com/GeriMedJC/status/999986255617081344
2018-05-25 12:09:31,GeriMedJC,,0,0,0,"Results. Figure 3. 55% vs 37% response (defined at > 30% improvement in NPI-NH psychosis score) to pimavanserin p=0·016 http://www.ncbi.nlm.nih.gov/pubmed/29452684. #GeriMedJC",,,#GeriMedJC,999985815387164672,https://twitter.com/GeriMedJC/status/999985815387164672
2018-05-25 12:02:26,GeriMedJC,,0,1,0,".@medstudent1000 now starting off #GeriMedJC with short article from @NEJM on pimavanserin vs placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Join in via @zoom_us web conferencing https://zoom.us/j/102282147.",,@medstudent1000 @NEJM @zoom_us,#GeriMedJC,999984031222587392,https://twitter.com/GeriMedJC/status/999984031222587392
2018-05-25 00:00:00,GeriMedJC,,0,0,0,"12 hours until #GeriMedJC. Short article from @NEJM on pimavanserin ves placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Join us via @zoom_us web conferencing https://zoom.us/j/102282147",,@NEJM @zoom_us,#GeriMedJC,999802225848455168,https://twitter.com/GeriMedJC/status/999802225848455168
2018-05-24 12:00:01,GeriMedJC,,0,0,0,"24 hours until #GeriMedJC. Short article from @NEJM on pimavanserin ves placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Join us via @zoom_us web conferencing https://zoom.us/j/102282147",,@NEJM @zoom_us,#GeriMedJC,999621034142658560,https://twitter.com/GeriMedJC/status/999621034142658560
2018-05-23 15:00:00,GeriMedJC,,1,1,3,".@dementiarehab Join #GeriMedJC May 25 08:00ET as we discuss pimavanserin versus placebo in Alzheimer's disease psychosis. Would love a geriatric psychiatry perspective! https://www.ncbi.nlm.nih.gov/pubmed/29452684 Tune in via web conferencing via @zoom_us",,@dementiarehab @zoom_us,#GeriMedJC,999303942524682240,https://twitter.com/GeriMedJC/status/999303942524682240
2018-05-22 16:00:02,GeriMedJC,,0,0,0,".@AlzCanada Tune into #GeriMedJC May 25 08:00ET as we discuss pimavanserin versus placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Join us via web conferencing via @zoom_us https://zoom.us/j/102282147",,@AlzCanada @zoom_us,#GeriMedJC,998956662634364928,https://twitter.com/GeriMedJC/status/998956662634364928
2018-05-22 15:14:56,surgeonshall,eravacycline,0,0,0,"You're right, it's a dental pelican. They're used to extract teeth, although this one isn't very versatile and can only remove one size of tooth.",,,,998945313405702144,https://twitter.com/surgeonshall/status/998945313405702144
2018-05-22 12:00:00,GeriMedJC,,0,0,0,"Mark it down. Next #GeriMedJC May 25 08:00ET tackles pimavanserin vs placebo in Alzheimer's disease psychosis http://gerimedjc.utorontoeit.com/index.php/2018/05/19/789/ Join us via @zoom_us web conferencing https://zoom.us/j/102282147",,@zoom_us,#GeriMedJC,998896255668387846,https://twitter.com/GeriMedJC/status/998896255668387846
2018-05-21 23:00:00,GeriMedJC,,0,2,2,".@CAGPsych Join #GeriMedJC May 25 08:00ET as we discuss pimavanserin versus placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Tune in via web conferencing via @zoom_us https://zoom.us/j/102282147",,@CAGPsych @zoom_us,#GeriMedJC,998699962572537856,https://twitter.com/GeriMedJC/status/998699962572537856
2018-05-21 16:00:01,GeriMedJC,,0,1,3,".@AlzToronto Tune into #GeriMedJC May 25 08:00ET as we discuss pimavanserin versus placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684 Join us via web conferencing via @zoom_us https://zoom.us/j/102282147",,@AlzToronto @zoom_us,#GeriMedJC,998594267604905984,https://twitter.com/GeriMedJC/status/998594267604905984
2018-05-21 13:00:00,GeriMedJC,,0,1,1,"As the lead author @Clive_Ballard, hope you’ll tune into #GeriMedJC May 25 08:00ET as we discuss pimavanserin vs placebo in Alzheimer's disease psychosis https://www.ncbi.nlm.nih.gov/pubmed/29452684. Join us via @zoom_us web conferencing https://zoom.us/j/102282147",,@Clive_Ballard @zoom_us,#GeriMedJC,998548966831685632,https://twitter.com/GeriMedJC/status/998548966831685632
2018-05-17 22:45:44,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,997246818390966278,https://twitter.com/TripPrimaryCare/status/997246818390966278
2018-05-17 03:46:46,tripdatabase,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,996960190116360194,https://twitter.com/tripdatabase/status/996960190116360194
2018-05-16 14:01:03,PsychiatryAdv,,0,0,0,"Acadia Pharmaceuticals has issued a statement regarding the safety and efficacy of Nuplazid (pimavanserin) in patients with #Parkinson disease. https://bit.ly/2HCyGGG",,,#Parkinson,996752390282973184,https://twitter.com/PsychiatryAdv/status/996752390282973184
2018-05-14 10:57:12,nikhilprasad11,,0,0,0,"RT docplexus ""Pimavanserin Catastrophe: Is FDA Getting Rash Over Drug Approvals? docplexus #EmpoweringDoctors #startup https://www.docplexus.org/share/XUSZL9""",,,#EmpoweringDoctors #startup,995981349881286656,https://twitter.com/nikhilprasad11/status/995981349881286656
2018-05-14 10:56:17,DrAvinashSakhar,,0,0,0,"docplexus ""Pimavanserin Catastrophe: Is FDA Getting Rash Over Drug Approvals? docplexus #EmpoweringDoctors #startup https://www.docplexus.org/share/XUSZL9""",,,#EmpoweringDoctors #startup,995981116833181696,https://twitter.com/DrAvinashSakhar/status/995981116833181696
2018-05-14 10:55:11,parikhatil,,0,0,0,"RT docplexus ""Pimavanserin Catastrophe: Is FDA Getting Rash Over Drug Approvals? docplexus #EmpoweringDoctors #startup https://www.docplexus.org/share/XUSZL9""",,,#EmpoweringDoctors #startup,995980840067915778,https://twitter.com/parikhatil/status/995980840067915778
2018-05-14 10:54:12,RakeshM61018486,,0,0,0,"docplexus ""Pimavanserin Catastrophe: Is FDA Getting Rash Over Drug Approvals? docplexus #EmpoweringDoctors #startup https://www.docplexus.org/share/XUSZL9""",,,#EmpoweringDoctors #startup,995980593631498240,https://twitter.com/RakeshM61018486/status/995980593631498240
2018-05-14 10:53:01,docplexus,,0,1,0,"Pimavanserin Catastrophe: Is FDA Getting Rash Over Drug Approvals? @docplexus #EmpoweringDoctors #startup https://www.docplexus.org/share/XUSZL9",,@docplexus,#EmpoweringDoctors #startup,995980296209117184,https://twitter.com/docplexus/status/995980296209117184
2018-05-12 10:45:56,TripPrimaryCare,,0,0,1,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,995253737122947073,https://twitter.com/TripPrimaryCare/status/995253737122947073
2018-05-10 22:00:38,SperlingMD,,0,0,0,"A new type of antipsychotic drug, pimavanserin, is FDA-approved to treat psychosis associated with Parkinson’s disease. It does not cause the adverse health effects of conventional antipsychotic medications. http://ow.ly/ct7430jT71A",,,,994698754031747072,https://twitter.com/SperlingMD/status/994698754031747072
2018-05-10 21:24:21,DrAdamSagot,dr_mago,0,0,0,"As a resident of dr. Lex Denysenko I am proud to share commentary on his piece on pimavanserin. It was far too enjoyable discussing it with the reps at #APAAM18 this week and hearing their attempts to respond. #psychsomatic #consultpsych #mentors",,,#APAAM18 #psychsomatic #consultpsych #mentors,994689625657667584,https://twitter.com/DrAdamSagot/status/994689625657667584
2018-05-10 12:05:30,TheLancet,,0,3,1,"Pimavanserin: @US_FDA conducting an evaluation of available evidence - new World Report",,@US_FDA,,994548985665871874,https://twitter.com/TheLancet/status/994548985665871874
2018-05-10 03:13:05,RspPharma,,0,0,0,"USES; Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. #Pharmaceuticalmedicine #RSP",,,#Pharmaceuticalmedicine #RSP,994414998674817024,https://twitter.com/RspPharma/status/994414998674817024
2018-05-09 04:26:43,tripdatabase,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,994071138669072384,https://twitter.com/tripdatabase/status/994071138669072384
2018-05-08 22:45:47,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,993985339848118272,https://twitter.com/TripPrimaryCare/status/993985339848118272
2018-05-08 18:58:04,geri_doc,,2,20,24,"Industry funded RCT of Pimavanserin for Alzheimers psychosis: Reduced psychosis symptoms at 6 weeks, but no benefit at 12 weeks However, Pimavanserin increased agitation, aggression, weight loss, edema Conclusion: This drug has no role in RX of Alzheimers ",,,,993928036499124224,https://twitter.com/geri_doc/status/993928036499124224
2018-05-05 03:03:48,rubenroa,,0,0,0,"[World Report] Pimavanserin evaluated by the FDA via The Lancet - The US Food and Drug Administration is conducting an evaluation of available evidence about pimavanserin. Paul Webster reports. ",,,,992600724000460800,https://twitter.com/rubenroa/status/992600724000460800
2018-05-03 16:45:47,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,992082807064285184,https://twitter.com/TripPrimaryCare/status/992082807064285184
2018-05-01 18:00:16,PsychiatryAdv,,0,0,0,"Acadia Pharmaceuticals has issued a statement regarding the safety and efficacy of Nuplazid (pimavanserin) in patients with #Parkinson disease. https://bit.ly/2HCyGGG",,,#Parkinson,991376775996420096,https://twitter.com/PsychiatryAdv/status/991376775996420096
2018-05-01 16:40:05,medicalnewser,,0,0,0,"Safety of Parkinson's Drug Nuplazid (pimavanserin) Being Reviewed by FDA - http://www.medicalnewser.com/2018/05/01/safety-of-parkinsons-drug-nuplazid-pimavanserin-being-reviewed-by-fda.html\",,,,991356596310695937,https://twitter.com/medicalnewser/status/991356596310695937
2018-05-01 13:08:30,4rxcard,,0,0,0,"Safety of Parkinson's Drug Nuplazid (pimavanserin) Being Reviewed by FDA http://dlvr.it/QRNXW9",,,,991303347075334145,https://twitter.com/4rxcard/status/991303347075334145
2018-05-01 06:45:35,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,991206985365368834,https://twitter.com/TripPrimaryCare/status/991206985365368834
2018-04-30 22:03:34,Debra_Myers,,0,0,0,"Nuplazid (pimavanserin) is a new-generation Parkinson’s disease drug, introduced in April 2016. The U.S. Food and Drug Administration (FDA) has already received at least 5,735 adverse event reports including 712 deaths linked to... ",,,,991075616303796225,https://twitter.com/Debra_Myers/status/991075616303796225
2018-04-28 15:45:57,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,990255808570183681,https://twitter.com/TripPrimaryCare/status/990255808570183681
2018-04-28 14:57:00,tripdatabase,,0,0,2,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,990243489005883392,https://twitter.com/tripdatabase/status/990243489005883392
2018-04-27 13:54:53,ANTELLIS2015,,0,0,0,"http://www.antellis.com/ ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting https://www.eei-biotechfinances.com/acadia-pharmaceuticals-announces-presentation-of-clinical-experience-data-for-nuplazid-pimavanserin-at-2018-american-academy-of-neurology-aan-annual-meeting/ #pharma #medicinal #laboratory",,,#pharma #medicinal #laboratory,989865470701592576,https://twitter.com/ANTELLIS2015/status/989865470701592576
2018-04-27 12:37:01,sdbn,,0,0,1,"SDBN Feed: ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting via SDBN Blog, News: SAN DIEGO--(BUSINESS WIRE)--ACADIA ... http://tinyurl.com/ya67x246",,,,989845876154781696,https://twitter.com/sdbn/status/989845876154781696
2018-04-27 12:11:09,PharmaMKTnet,,0,0,0,"ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting https://ift.tt/2FmUsbt via BusinessWire",,,,989839362580992000,https://twitter.com/PharmaMKTnet/status/989839362580992000
2018-04-27 12:09:55,financialbuzz,,0,0,0,"ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 Am.. http://financialbuzz.com/acadia-pharmaceuticals-announces-presentation-of-clinical-experience-data-for-nuplazid-pimavanserin-at-2018-american-academy-of-neurology-aan-annual-meeting-1072523",,,,989839055515893761,https://twitter.com/financialbuzz/status/989839055515893761
2018-04-27 12:04:13,Allstocknews,,0,0,0,"$ACAD ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) a From our Stock News Alerts App",,,,989837620183224320,https://twitter.com/Allstocknews/status/989837620183224320
2018-04-27 12:04:04,Market_Screener,,0,0,0,"ACADIA Pharmaceuticals : Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting http://www.4-traders.com/ACADIA-PHARMACEUTICALS-IN-8222/news/ACADIA-Pharmaceuticals-Announces-Presentation-of-Clinical-Experience-Data-for-NUPLAZID-Pimavanser-26446431/",,,,989837580752519168,https://twitter.com/Market_Screener/status/989837580752519168
2018-04-27 12:01:16,odibro,,0,4,2,"$ACAD Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at #AAN18 https://www.businesswire.com/news/home/20180427005270/en/ACADIA-Pharmaceuticals-Announces-Presentation-Clinical-Experience-Data",,,#AAN18,989836876533125121,https://twitter.com/odibro/status/989836876533125121
2018-04-27 08:00:13,easybodyfit,,0,0,0,"Safety of Parkinson&#039;s Drug Nuplazid (Pimavanserin) Being Reviewed by FDA #heartattack",,,#heartattack,989776215727792128,https://twitter.com/easybodyfit/status/989776215727792128
2018-04-26 22:40:42,MedkitInfo,,0,0,0,"Safety of Parkinson’s Drug Nuplazid (Pimavanserin) Being Reviewed by FDA https://medkit.info/2018/04/26/safety-of-parkinsons-drug-nuplazid-pimavanserin-being-reviewed-by-fda/",,,,989635407590645760,https://twitter.com/MedkitInfo/status/989635407590645760
2018-04-26 22:13:47,dr_mago,,0,0,2,"Does pimavanserin (Nuplazid) increase risk of dying? Recently, concern regarding its safety has been raised in an article by CNN. Dr. Lex Denysenko summarizes the relevant facts and gives us his conclusions to help us make sense of them. https://bit.ly/2FiE0t1 #psych #mhsm",,,#psych #mhsm,989628635874197504,https://twitter.com/dr_mago/status/989628635874197504
2018-04-26 21:01:32,Drugscom,,0,2,0,"Safety of Parkinson's Drug #Nuplazid (#Pimavanserin) Being Reviewed by FDA - ",,,#Nuplazid #Pimavanserin,989610453616734208,https://twitter.com/Drugscom/status/989610453616734208
2018-04-26 16:23:30,Daniel_Kudro,,0,1,0,"FDA re-examines safety of controversial new drug pimavanserin, the only drug approved for Parkinson disease psychosis. https://www.cnn.com/2018/04/25/health/fda-nuplazid-safety-evaluation-invs/index.html",,,,989540484107288576,https://twitter.com/Daniel_Kudro/status/989540484107288576
2018-04-26 14:20:46,TomLamb,,0,0,0,"FDA re-examining Parkinson's drug [Nuplazid (pimavanserin)] after reports of deaths ",,,,989509597047197698,https://twitter.com/TomLamb/status/989509597047197698
2018-04-26 13:11:02,AMahajanMD,,0,1,5,"Day 6 of #AANAM I will be presenting two posters: cervical dystonia and substance abuse using the dystonia coalition data (P.061) and our experience with Pimavanserin use (P.065). Hope to see you there!",,,#AANAM,989492048230137857,https://twitter.com/AMahajanMD/status/989492048230137857
2018-04-26 12:55:48,SpRnch,,0,0,1,"FDA To Take Another Look At Nuplazid Approval After Reported Deaths, Drug Used To ... - http://blkcosmo.com/fda-to-take-another-look-at-nuplazid-approval-after-reported-deaths-drug-used-to-treat-parkinsons-psychosis/ #AdverseEventReportingSystem #CHEMISTRY #FoodAndDrugAdministration #FoodAndDrugAdministrationAmendmentsAct #Health #PharmaceuticalIndustry #Pimavanserin #ScottGottlieb",,,#AdverseEventReportingSystem #CHEMISTRY #FoodAndDrugAdministration #FoodAndDrugAdministrationAmendmentsAct #Health #PharmaceuticalIndustry #Pimavanserin #ScottGottlieb,989488215009779712,https://twitter.com/SpRnch/status/989488215009779712
2018-04-26 12:55:47,blkcosmo,,0,0,0,"Black #Cosmopolitan FDA To Take Another Look At Nuplazid Approval After Reported ... - http://blkcosmo.com/fda-to-take-another-look-at-nuplazid-approval-after-reported-deaths-drug-used-to-treat-parkinsons-psychosis/ #AdverseEventReportingSystem #CHEMISTRY #FoodAndDrugAdministration #FoodAndDrugAdministrationAmendmentsAct #Health #PharmaceuticalIndustry #Pimavanserin #ScottGottlieb",,,#Cosmopolitan #AdverseEventReportingSystem #CHEMISTRY #FoodAndDrugAdministration #FoodAndDrugAdministrationAmendmentsAct #Health #PharmaceuticalIndustry #Pimavanserin #ScottGottlieb,989488210182107136,https://twitter.com/blkcosmo/status/989488210182107136
2018-04-26 11:34:02,NewFdaApprovals,,0,0,0,"134 - Pimavanserin safety in Parkinsons; Trelegy in COPD; Medtronic's drug-coated balloon to treat long superficial femoral artery lesion; Lumendi's endoscopic surgery accessory http://newfda.libsyn.com/134-pimavanserin-safety-in-parkinsons-trelegy-in-copd-medtronics-drug-coated-balloon-to-treat-long-superficial-femoral-artery-lesion-lumendis-endoscopic-surgery-accessory?tdest_id=657084",,,,989467634411466754,https://twitter.com/NewFdaApprovals/status/989467634411466754
2018-04-26 07:33:30,MatteoNecci,,0,0,1,"$ACAD Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352252/ Like all other antipsychotic drugs, pimavanserin has a black box warning on its package labeling in the USA for increasing mortality in elderly patients with PDP.",,,,989407102950170624,https://twitter.com/MatteoNecci/status/989407102950170624
2018-04-26 03:37:45,Biotech2050,Clive_Ballard,0,0,0,"What is your UK experience on Pimavanserin trials in treating #Alzheimers &amp; #Parkinson’s disease psychosis and dementia? Would it be beneficial for patients &amp; caregivers? Any timeline from $ACAD to get it approved in UK &amp; EU?",,,#Alzheimers #Parkinson,989347776692654082,https://twitter.com/Biotech2050/status/989347776692654082
2018-04-25 21:37:34,TripPrimaryCare,,0,0,0,"New2Trip: Evaluation of safety, tolerability, & efficacy of pimavanserin versus placebo in patients w/ Alzheimer`s … http://bit.ly/2r0UzUY",,,,989257132251013120,https://twitter.com/TripPrimaryCare/status/989257132251013120
2018-04-25 21:01:13,bio_pharmer,,1,1,2,"$ACAD Pimavanserin was approved for treating pts with psychosis related to Parkinson's disease. Pts who exhibit psychosis typically have late stage disease. The 1yr mortality rate for late stage disease is high. Is there any evidence that these are drug related deaths?",,,,989247983857225729,https://twitter.com/bio_pharmer/status/989247983857225729
2018-04-25 18:21:05,Sanctuary_Bio,zbiotech,0,0,0,"This hit 52 week highs when they got a 2nd BTD in pimavanserin for DRP But I thought BTD = success and with 2 BTD you can't lose!!!!!! ",,,,989207686536314880,https://twitter.com/Sanctuary_Bio/status/989207686536314880
2018-04-25 09:49:21,LeilaMemorialGH,,0,0,1,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects: A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer's disease worldwide https://www.sciencedaily.com/releases/2018/02/180213183620.htm",,,,989078902051147776,https://twitter.com/LeilaMemorialGH/status/989078902051147776
2018-04-24 16:52:00,MDEdgeTweets,,0,0,0,"Real-world data so far support pimavanserin trial results. #AANAM #AAN2018 https://bit.ly/2HVe6OD",,,#AANAM #AAN2018,988822880447336449,https://twitter.com/MDEdgeTweets/status/988822880447336449
2018-04-24 16:51:47,ClinNeuroNews,,1,2,3,"Real-world data so far support pimavanserin trial results. #AANAM #AAN2018 https://bit.ly/2HVe6OD",,,#AANAM #AAN2018,988822823161430019,https://twitter.com/ClinNeuroNews/status/988822823161430019
2018-04-16 16:05:49,JeffreyBeckham,,0,0,0,"Anti Parkinsons Antipsychotic Nuplazid (pimavanserin) preclinical studies interesting for pancreatic cancer. @aacr18 @andybiotech @bradloncar http://www.abstractsonline.com/pp8/#!/4562/presentation/10717",,@aacr18 @AndyBiotech @bradloncar,,985912151855382528,https://twitter.com/JeffreyBeckham/status/985912151855382528
2018-04-16 12:19:49,MatteoNecci,,0,0,1,"$ACAD in vivo tumor models: Pimavanserin treatment induced 2-5 fold apoptosis in pancreatic cancer cells ... http://www.abstractsonline.com/pp8/#!/4562/presentation/10717 ... Pimavanserin did not show any general signs of toxicity and no apparent changes were observed in the behavioral activity of mice",,,,985855279177912320,https://twitter.com/MatteoNecci/status/985855279177912320
2018-04-13 23:30:16,Rx_Ed,,0,2,4,"Anti-psychosis drug SPECIFICALLY for Parkinson’s disease patients? Pimavanserin Anti-seizure drug SPECIFICALLY for Tuberous Sclerosis patients? Everolimus Tomorrow #USMLE step 3 class starts! Book your ticket to GREATNESS! http://medquestreviews.com",,,#USMLE,984936839340584961,https://twitter.com/Rx_Ed/status/984936839340584961
2018-04-12 09:01:00,SIETES7,,0,0,2,"""Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis"" http://www.sietes.org/buscar/cita/102509 vía @SIETES7",,@SIETES7,,984355694181801984,https://twitter.com/SIETES7/status/984355694181801984
2018-04-11 19:42:07,MaisaCorp,,0,0,0,"$ACAD cited an email from the FDA saying ""While the risks of pimavanserin cannot be mitigated, they can be labeled along with the efficacy data to allow for rational decision-making by clinicians, patients, and family members struggling to manage the symptoms of PDP.""",,,,984154646917808129,https://twitter.com/MaisaCorp/status/984154646917808129
2018-04-11 16:49:00,MDMagazine,,0,0,0,"#ICYMI: Acadia Pharmaceutical’s #antipsychotic therapy pimavanserin (Nuplazid) is facing public scrutiny and fiscal uncertainty after a report from @CNN detailed the deaths of 700+ patients prescribed the therapy for #ParkinsonsDisease since June 2016.",,@CNN,#ICYMI #antipsychotic #ParkinsonsDisease,984111083005734912,https://twitter.com/MDMagazine/status/984111083005734912
2018-04-11 11:20:31,TheACLM,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links ",,,,984028416138719233,https://twitter.com/TheACLM/status/984028416138719233
2018-04-11 00:52:00,mb_Neurology,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links - MedPage Today: MedPage Today New Coma Score; Pimavanserin Concerns; ALS-FTD Links MedPage Today (Neurobiology of Aging). Genome-wide analyses and mouse model data identified common genetic pathways… http://dlvr.it/QP6dxm",,,,983870243683516416,https://twitter.com/mb_Neurology/status/983870243683516416
2018-04-10 21:56:00,MDMagazine,,0,1,0,"#ICYMI: Acadia Pharmaceutical’s #antipsychotic therapy pimavanserin (Nuplazid) is facing public scrutiny and fiscal uncertainty after a report from @CNN detailed the deaths of 700+ patients prescribed the therapy for #ParkinsonsDisease since June 2016. http://www.mdmag.com/medical-news/pimavanserin-under-scrutiny-for-reported-deaths-in-parkinsons-patients",,@CNN,#ICYMI #antipsychotic #ParkinsonsDisease,983825953443868672,https://twitter.com/MDMagazine/status/983825953443868672
2018-04-10 19:36:54,induspedia,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links #Pediatrics http://dld.bz/gJFMr",,,#Pediatrics,983790949158604800,https://twitter.com/induspedia/status/983790949158604800
2018-04-10 19:36:52,induscard,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links #Cardiology http://dld.bz/gJFMr",,,#Cardiology,983790938098225152,https://twitter.com/induscard/status/983790938098225152
2018-04-10 19:32:19,indusneuro,,0,2,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links #Neurology http://dld.bz/gJFMr",,,#Neurology,983789794055553024,https://twitter.com/indusneuro/status/983789794055553024
2018-04-10 19:32:18,indusgeri,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links #Geriatrics http://dld.bz/gJFMr",,,#Geriatrics,983789788192034818,https://twitter.com/indusgeri/status/983789788192034818
2018-04-10 18:06:14,ProfRobHoward,,1,8,16,"Via @LonSchneiderMD, chastening story of probable dangers of rushed and emotion-based FDA approval of pimavanserin for PD psychosis. Sadly, perceived safety was practically all the drug had going for it. ",,@LonSchneiderMD,,983768128558698496,https://twitter.com/ProfRobHoward/status/983768128558698496
2018-04-10 17:32:04,CarloRajMD,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links #medicalnews http://dld.bz/gJFMr",,,#medicalnews,983759533670567938,https://twitter.com/CarloRajMD/status/983759533670567938
2018-04-10 17:06:00,MDMagazine,,0,0,0,"Acadia Pharmaceutical’s #antipsychotic therapy pimavanserin (Nuplazid) is facing public scrutiny and fiscal uncertainty after a report from @CNN detailed the deaths of more than 700 patients prescribed the therapy for #ParkinsonsDisease since June 2016. http://www.mdmag.com/medical-news/pimavanserin-under-scrutiny-for-reported-deaths-in-parkinsons-patients",,@CNN,#antipsychotic #ParkinsonsDisease,983752972239687680,https://twitter.com/MDMagazine/status/983752972239687680
2018-04-10 16:59:58,_HOSPITNAL_,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links http://www.medpagetoday.com/neurology/generalneurology/72238?utm_source=dlvr.it&amp;utm_medium=twitter | http://trapier.org",,,,983751451938668545,https://twitter.com/_HOSPITNAL_/status/983751451938668545
2018-04-10 16:54:00,byMattHoffman,,1,1,1,"Not good news: Acadia Pharmaceutical's antipsychotic pimavanserin has come under fire recently, as it's been linked to the deaths of 700+ #Parkinson patients since June '16. http://www.mdmag.com/medical-news/pimavanserin-under-scrutiny-for-reported-deaths-in-parkinsons-patients",,,#Parkinson,983749951854383104,https://twitter.com/byMattHoffman/status/983749951854383104
2018-04-10 16:25:08,luciekaisin571,,0,0,0,"New Coma Score; Pimavanserin Concerns; ALS-FTD Links http://bit.ly/2GN2U9z",,,,983742686329962498,https://twitter.com/luciekaisin571/status/983742686329962498
2018-04-10 15:34:33,NotADoctorKevin,,0,0,0,"Pimavanserin (Nuplazid) has been under fire since the 700-plus deaths of PD patients was reported by CNN: http://www.mdmag.com/medical-news/pimavanserin-under-scrutiny-for-reported-deaths-in-parkinsons-patients",,,,983729958857199617,https://twitter.com/NotADoctorKevin/status/983729958857199617
2018-04-10 12:12:33,ThorntonFirm,,0,0,0,"Reports of 244 deaths spark concern over new drug https://hubs.ly/H0bCK6X0 by @cnn #Parkinsons #drug #Nuplazid #pimavanserin",,@CNN,#Parkinsons #drug #Nuplazid #pimavanserin,983679121816420352,https://twitter.com/ThorntonFirm/status/983679121816420352
2018-04-10 03:35:26,PVasan2013,amarsahni59,0,0,0,"Clinical trials for Nuplazid, also known as Pimavanserin, the drug behind this controversy, were also done in India; but I'm willing to bet, without adequate knowledge and information to patients and family on its possible side-effects . ",,,,983548986597392390,https://twitter.com/PVasan2013/status/983548986597392390
2018-04-09 23:00:24,medpagetoday,,0,0,0,"Parkinson drug pimavanserin (Nuplazid) under scrutiny in wake of patients' deaths. https://cnn.it/2qiY60t",,,,983479773774204928,https://twitter.com/medpagetoday/status/983479773774204928
2018-04-09 19:42:07,LonSchneiderMD,,1,7,7,"Atypical antipsychotic #Nuplazid #pimavanserin was FDA-approved based on 1 RCT of 199 PD pts &amp; 3 negative RCTs. Showed modest efficacy for pts. w/ mild vis. hallucinations but not severe. It took 5000 pts to discern deaths w/ atypicals in #Alzheimers @CNN",,@CNN,#Nuplazid #pimavanserin #Alzheimers,983429871014526977,https://twitter.com/LonSchneiderMD/status/983429871014526977
2018-04-09 16:49:03,AlpBugraBasat,,0,0,0,"Not sure worth mentioning but $AXON also got a me too version of pimavanserin, called nelotanserin. $127.19M mcap though, can't go below 0.",,,,983386320264482818,https://twitter.com/AlpBugraBasat/status/983386320264482818
2018-04-09 14:14:20,wjdeardorff,,1,0,1,"New CNN article on #Nuplazid and risk of death. FDA summary reviewer already felt that the causes of death would not be ""monitorable or specifically preventable"" and are ""hard to attribute to pimavanserin"" $ACAD https://www.cnn.com/2018/04/09/health/parkinsons-drug-nuplazid-invs/index.html",,,#Nuplazid,983347384225640448,https://twitter.com/wjdeardorff/status/983347384225640448
2018-04-09 13:41:30,walidgellad,,2,4,8,"Story from CNN about Nuplazid (pimavanserin), for Parkinson's associated psychosis, and concerns about whether its benefits outweigh its risks. P.s. Its list price has gone up 30% since approval. https://cnn.it/2HjXXlC",,,,983339118687072256,https://twitter.com/walidgellad/status/983339118687072256
2018-04-09 13:40:41,7LadyQ,,0,0,0,"$ACAD Acadia Pharmaceuticals (NASDAQ:ACAD) slumps 17% on increased volume in apparent response to a CNN article on the incidence of reported adverse events related to NUPLAZID (pimavanserin), approved in the U.S. two years ago for Parkinson's disease psychosis.",,,,983338916538232838,https://twitter.com/7LadyQ/status/983338916538232838
2018-04-09 13:27:31,Vegastrader66,,0,0,0,"Acadia Pharma down 17% premarket on Nuplazid safety concerns Apr. 9, 2018 9:26 AM ET|By: Douglas W. House, SA News Editor slumps 17% on increased volume in apparent response to a CNN article on the incidence of reported adverse events related to NUPLAZID (pimavanserin).",,,,983335603080019974,https://twitter.com/Vegastrader66/status/983335603080019974
2018-04-09 11:19:57,nashvillesam29,CNN,0,0,3,"Pimavanserin, saved you a click",,,,983303496475856896,https://twitter.com/nashvillesam29/status/983303496475856896
2018-04-09 10:40:03,UofE_Research,,0,0,1,"MT @Clive_Ballard: Advancing #dementia can bring #psychosis which can adversely affect quality of life for #PWD Study found that #pimavanserin significantly reduced psychosis in ppl w/ #alzheimers w/ no adverse effects on #cognitivefunction: https://bit.ly/2ul2QYJ #ExeerDementia",,@Clive_Ballard,#dementia #psychosis #PWD #pimavanserin #alzheimers #cognitivefunction #ExeerDementia,983293458847817728,https://twitter.com/UofE_Research/status/983293458847817728
2018-04-09 08:20:32,Clive_Ballard,,0,7,17,"Advancing #dementia can bring with it #psychosis, which can adversely affect the quality of life for #PWD. Our study found that #pimavanserin significantly reduced psychosis in ppl w/ #alzheimers w/ no adverse effects on #cognitivefunction: https://bit.ly/2ul2QYJ #ExeerDementia",,,#dementia #psychosis #PWD #pimavanserin #alzheimers #cognitivefunction #ExeerDementia,983258348152934400,https://twitter.com/Clive_Ballard/status/983258348152934400
2018-04-07 14:30:11,MedNewsBulletin,,0,0,0,"A recent study investigated whether pimavanserin, a treatment for Parkinson’s disease psychosis, could also treat Alzheimer’s disease psychosis. #Alzheimers #psychosis #clinicaltrials",,,#Alzheimers #psychosis #clinicaltrials,982626596975767554,https://twitter.com/MedNewsBulletin/status/982626596975767554
2018-04-06 18:02:00,Innov_Clin_Neur,,0,0,0,"Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis http://bit.ly/2nOzQSS",,,,982317513873780737,https://twitter.com/Innov_Clin_Neur/status/982317513873780737
2018-04-01 23:06:29,SeeFisch,usamabasit,0,1,16,"these were never best. Quetiapine was best because it had least EPS symptoms. Pimavanserine does not work through inhibiting dopamine. Pimavanserin inhibits 5HT",,,,980582198326808577,https://twitter.com/SeeFisch/status/980582198326808577
2018-04-01 23:04:22,SeeFisch,MDPatron,0,1,4,"yes! Pimavanserin because it does not interfere with dopamine ",,,,980581665360744449,https://twitter.com/SeeFisch/status/980581665360744449
2018-04-01 22:39:42,MDPatron,SeeFisch,0,0,0,"Pimavanserin, but if you can not afford it Quetiapine or Clozapine can be used.",,,,980575459753840643,https://twitter.com/MDPatron/status/980575459753840643
2018-04-01 12:58:24,Ingentium_PD,,0,0,1,"Safety and Efficacy of Adjunctive Pimavanserin in Adults With Parkinson's Disease and Inadequ... https://magazine.ingentium.com/2018/03/30/safety-and-efficacy-of-adjunctive-pimavanserin-in-adults-with-parkinsons-disease-and-inadequately-controlled-depression/",,,,980429172081397761,https://twitter.com/Ingentium_PD/status/980429172081397761
2018-03-31 11:37:50,Ingentium_PD,,0,0,0,"Safety and Efficacy of Adjunctive Pimavanserin in Adults With Parkinson's Disease and Inadequ... https://magazine.ingentium.com/2018/03/30/safety-and-efficacy-of-adjunctive-pimavanserin-in-adults-with-parkinsons-disease-and-inadequately-controlled-depression/",,,,980046509218631680,https://twitter.com/Ingentium_PD/status/980046509218631680
2018-03-30 03:49:21,CureHuntr,,0,0,0,"#clinicaltrial Safety and Efficacy of Adjunctive Pimavanserin in Adults With Parkinson's Disease and Inadequately Controlled Depression https://ift.tt/2J1xrxP",,,#clinicaltrial,979566224051974145,https://twitter.com/CureHuntr/status/979566224051974145
2018-03-30 03:35:17,TrialBulletin,,0,0,0,"Safety and Efficacy of Adjunctive Pimavanserin in Adults With Parkinson's Disease and Inadequately Controlled Depression: Status: Recruiting, Condition Summary: Adjunctive Treatment of Depression Associated With Parkinson's Disease (PD) http://bit.ly/2GjmZnD",,,,979562682226561024,https://twitter.com/TrialBulletin/status/979562682226561024
2018-03-29 14:17:37,GGBB90,,1,1,1,"$ACAD forget technicals. Raised Nuplazid sales. Nov announced Pimavanserin Alzheimer’s disease psychosis met P2 primary endpoint. Statistically significant reduction vs Placebo! Takeout target. Baker Bros buying more shares &amp; control Board position!",,,,979361942505738240,https://twitter.com/GGBB90/status/979361942505738240
2018-03-22 11:32:05,LWWneurology,,0,0,0,"Most Popular: A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic http://dlvr.it/QLzh43",,,,976783570197819392,https://twitter.com/LWWneurology/status/976783570197819392
2018-03-22 04:13:50,frotheggwhite,,0,0,0,"“Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's …” http://htn.to/nGziMpDLhz",,,,976673279912984577,https://twitter.com/frotheggwhite/status/976673279912984577
2018-03-18 16:28:11,SolarMelt,,1,1,1,"$ACAD Several late-stage trials for Pimavanserin are set to readout in fairly rapid succession: 4Q18 - P2 CLARITY - MDD 1Q19 - P3 ENHANCE - Inadequate Response Schizophrenia 2Q19 - P2 ADVANCE - Negative Symptoms of Schizophrenia 2020 - P3 HARMONY - Dementia-Related Psychosis",,,,975408532739772416,https://twitter.com/SolarMelt/status/975408532739772416
2018-03-18 16:27:59,SolarMelt,,1,1,0,"$ACAD Acadia generated sales of $124.9M in 2017, all from NUPLAZID, aka Pimavanserin, in Parkinson's Disease Psychosis. Mgnt now expects sales to more than double in 2018 to $255-$270M. While ACAD has primarily been a earnings play, late-stage trial results will soon gain focus.",,,,975408483234471937,https://twitter.com/SolarMelt/status/975408483234471937
2018-03-17 13:42:20,Clive_Ballard,lushfleury,1,0,0,"Indeed - see last tweet! I do present on that regularly, including in relation to #pimavanserin as potential alternative... but it is a different symposium!",,,#pimavanserin,975004409863208961,https://twitter.com/Clive_Ballard/status/975004409863208961
2018-03-16 16:11:00,LampeandCompany,,0,0,0,"Data from Pimavanserin phase 2 trial in #AlzheimersDisease published: http://bit.ly/2FpWz2g",,,#AlzheimersDisease,974679434023223297,https://twitter.com/LampeandCompany/status/974679434023223297
2018-03-16 08:30:18,Clive_Ballard,,0,3,3,"[2/2] Our study highlights the potential of #pimavanserin for #psychosis in #Alzheimers – particularly for those with the most severe #psychoticsymptoms: http://bit.ly/2ocpjRp #ExeterDementia",,,#pimavanserin #psychosis #Alzheimers #psychoticsymptoms #ExeterDementia,974563496124968960,https://twitter.com/Clive_Ballard/status/974563496124968960
2018-03-15 15:04:21,NeuroAdvisor,,0,0,0,"In patients with #Alzheimersdisease with no apparent negative effects on #cognitive or motor function, pimavanserin is effective for short-term improvement of #psychotic symptoms at up to 6 weeks of treatment. http://ow.ly/Ujpx30iXRgQ",,,#Alzheimersdisease #cognitive #psychotic,974300272615985152,https://twitter.com/NeuroAdvisor/status/974300272615985152
2018-03-15 12:44:17,Newmind63,Clive_Ballard,0,0,0,"Pimavanserin on the cards anytime soon?",,,,974265024217862145,https://twitter.com/Newmind63/status/974265024217862145
2018-03-15 11:23:32,jcbriscoe1,ndyG83,0,0,2,"Pimavanserin also an (expensive) option for PD psychosis #hpm18",,,#hpm18,974244705193136128,https://twitter.com/jcbriscoe1/status/974244705193136128
2018-03-13 11:30:56,LWWneurology,,0,0,0,"Current Issue: A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic http://dlvr.it/QKqmzQ",,,,973521789337743360,https://twitter.com/LWWneurology/status/973521789337743360
2018-03-12 11:30:49,Meddocslu,,0,1,1,"Pimavanserin an atypical antipsychotic is used for the treatment of Parkinson's disease psychosis and possibly Lewy-Body dementia. Unlike other antipsychotics, it is not a dopamine receptor antagonist, but acts as a highly selective antagonist of the serotonin 5-HT2A receptor",,,,973159371927687169,https://twitter.com/Meddocslu/status/973159371927687169
2018-03-11 17:17:11,neethishell,SeeFisch,0,0,0,"Pimavanserin no d2 action highly selective on 5HT2a",,,,972884150674890752,https://twitter.com/neethishell/status/972884150674890752
2018-03-11 03:32:47,SeeFisch,SassyPharmD,0,6,23,"Correct Boobies! Pimavanserin is an anti-psychotic that inhibits 5HT and not dopamine. Pimavanserin is specifically made for Parkinson's disease ",,,,972676681642233856,https://twitter.com/SeeFisch/status/972676681642233856
2018-03-10 19:00:36,eMarketerSocial,,0,0,0,"Pimavanserin may Treat Psychosis in Patients With Alzheimer's Disease #diseñoweb http://cmun.it/kklhg4iw - Grow your followers by posting better content https://commun.it/growth/?tc=n&amp;aid=content_13",,,#dise,972547788553801728,https://twitter.com/eMarketerSocial/status/972547788553801728
2018-03-09 17:37:00,Innov_Clin_Neur,,0,0,0,"Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis http://bit.ly/2nOzQSS",,,,972164362080104449,https://twitter.com/Innov_Clin_Neur/status/972164362080104449
2018-03-09 15:05:18,lifecourseUofT,,0,1,3,"New research finds that pimavanserin improves psychosis symptoms in people with #alzheimers without devastating side effects of current antipsychotics http://ow.ly/OG0Z30iJRo8 #AgingUofT",,,#alzheimers #AgingUofT,972126186926157824,https://twitter.com/lifecourseUofT/status/972126186926157824
2018-03-08 10:30:37,AlzheimerEurope,,1,5,6,"#Pimavanserin Phase 2 trial results for #Alzheimer’s disease #psychosis have been published in @TheLancetNeuro http://bit.ly/2HhgI8h",,@TheLancetNeuro,#Pimavanserin #Alzheimer #psychosis,971694670655959041,https://twitter.com/AlzheimerEurope/status/971694670655959041
2018-03-07 15:17:50,BrownUResearch,,0,2,3,"The antipsychotics Nuplazid (pimavanserin) &amp; Clozaril (clozapine) are therapies shown to improve Parkinson’s disease psychosis symptoms without impairing motor function, according to a study by Joseph Friedman, @BrownUniversity @BrownMedicine professor",,@BrownUniversity @BrownMedicine,,971404562493001729,https://twitter.com/BrownUResearch/status/971404562493001729
2018-03-06 17:14:55,sassafras4ucom,,0,0,0,"46 (3-6): #Pimavanserin: Relief from #psychosis in #dementia, without devastating side-effects. #antipsychotic #THT2A #nerve_receptor",,,#Pimavanserin #psychosis #dementia #antipsychotic #THT2A #nerve_receptor,971071641135472640,https://twitter.com/sassafras4ucom/status/971071641135472640
2018-03-03 17:58:59,BrainBoxNic,,0,0,0,"Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/29497575",,,,969995566892683270,https://twitter.com/BrainBoxNic/status/969995566892683270
2018-03-01 16:00:50,YGOUCHA,,0,0,0,"@craniu_md any opinion on pimavanserin as an expert in neuroscience?",,,,969241058826752001,https://twitter.com/YGOUCHA/status/969241058826752001
2018-02-28 00:48:59,rogersvillerx,,0,0,1,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/YUQUs0kP",,,,968649193484115968,https://twitter.com/rogersvillerx/status/968649193484115968
2018-02-28 00:48:50,RuweRx,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/7nFzncNom",,,,968649155815108608,https://twitter.com/RuweRx/status/968649155815108608
2018-02-28 00:48:23,davecrevar,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/2aOiIs6Sk",,,,968649045668433920,https://twitter.com/davecrevar/status/968649045668433920
2018-02-28 00:47:49,NewClintonPharm,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/4IhICGLus",,,,968648902328180736,https://twitter.com/NewClintonPharm/status/968648902328180736
2018-02-28 00:47:00,ApthorpRX,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/T6REI7JN",,,,968648694869512193,https://twitter.com/ApthorpRX/status/968648694869512193
2018-02-28 00:34:45,OakwoodRx,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/4U1cO0BNX",,,,968645612420894720,https://twitter.com/OakwoodRx/status/968645612420894720
2018-02-28 00:33:51,WannamakerDrug,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/1AwWlvttz",,,,968645387794993152,https://twitter.com/WannamakerDrug/status/968645387794993152
2018-02-28 00:33:01,coastalpharmOS,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/4utEqlWTh",,,,968645175990988800,https://twitter.com/coastalpharmOS/status/968645175990988800
2018-02-28 00:32:16,WShorePharmacy,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/1ADngKgmq",,,,968644987679330304,https://twitter.com/WShorePharmacy/status/968644987679330304
2018-02-28 00:25:40,DignityPGH,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/1J4GN2P4Q",,,,968643326470627328,https://twitter.com/DignityPGH/status/968643326470627328
2018-02-28 00:19:42,HometownPharmRx,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/8p06mMjcm",,,,968641824393920514,https://twitter.com/HometownPharmRx/status/968641824393920514
2018-02-28 00:18:13,CustomCCRx,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/7FxY09yuY",,,,968641451797155840,https://twitter.com/CustomCCRx/status/968641451797155840
2018-02-28 00:17:08,TaylorsDrugS,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/8e1VT8Tiv",,,,968641180027174912,https://twitter.com/TaylorsDrugS/status/968641180027174912
2018-02-28 00:11:59,PRB51,,2,1,6,"$ACAD Sales growth is 22% Q/Q: quite good at this stage Early to give honest view on compliance / persistence Also pimavanserin received Breakthrough Therapy Designation from the FDA last October for Parkinson’s Disease Psychosis, is currently in P3 (second BTD in fact)",,,,968639886180970496,https://twitter.com/PRB51/status/968639886180970496
2018-02-28 00:04:31,FCRXMarion,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/1U7YiqJn5",,,,968638003584389120,https://twitter.com/FCRXMarion/status/968638003584389120
2018-02-28 00:04:04,schwietermanrx,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/WZpboLE7",,,,968637893190340608,https://twitter.com/schwietermanrx/status/968637893190340608
2018-02-28 00:03:33,bvpharmacy24416,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/4v4iDQjyQ",,,,968637762164416512,https://twitter.com/bvpharmacy24416/status/968637762164416512
2018-02-27 18:16:25,marcroms,,0,0,0,"Nuplazid (pimavanserin) may relieve symptoms of Alzheimer’s disease psychosis | RxWiki https://fb.me/9SAAwG9Kx",,,,968550402600984576,https://twitter.com/marcroms/status/968550402600984576
2018-02-27 11:40:09,AcademiaGoFIR,,0,0,0,"Pimavanserin Phase 2 Trial Data Published http://alzforum.org/news/research-…",,,,968450677696495616,https://twitter.com/AcademiaGoFIR/status/968450677696495616
2018-02-27 09:16:02,JordiSM_,,0,0,0,"Pimavanserin Phase 2 Trial Data Published https://www.alzforum.org/news/research-news/pimavanserin-phase-2-trial-data-published",,,,968414409004666880,https://twitter.com/JordiSM_/status/968414409004666880
2018-02-27 01:19:26,SolarMelt,,1,0,1,"$ACAD Acadia is bumping up against overhead resistance at $33 with Earnings out tomorrow. Acadia has one approved product, Nuplazid, aka Pimavanserin, in Parkinson's Disease Psychosis with four ongoing trails (three P2 and one P3) covering four other indications for Pimavanserin.",,,,968294470117724160,https://twitter.com/SolarMelt/status/968294470117724160
2018-02-26 12:16:00,TheLancetNeuro,,0,1,2,"Pimavanserin Phase 2 Trial Data Published https://www.alzforum.org/news/research-news/pimavanserin-phase-2-trial-data-published",,,,968097314123538433,https://twitter.com/TheLancetNeuro/status/968097314123538433
2018-02-26 02:05:03,Design4agedcare,,0,0,0,"Research news - Pimavanserin: relief from psychosis in dementia, without devastating side-effects - University of Exeter http://ow.ly/edeb30iBIcy #dementia #alzheimers #mentalhealth #medication #health #healthcare #pharmacy #agedcare #nursing",,,#dementia #alzheimers #mentalhealth #medication #health #healthcare #pharmacy #agedcare #nursing,967943562678689793,https://twitter.com/Design4agedcare/status/967943562678689793
2018-02-24 23:31:01,Alzheimerebook,,0,0,0,"Pimavanserin Phase 2 Trial Data Published https://www.alzforum.org/news/research-news/pimavanserin-phase-2-trial-data-published",,,,967542411923771392,https://twitter.com/Alzheimerebook/status/967542411923771392
2018-02-24 16:05:47,TheADDF,,0,11,16,"Pimavanserin Phase 2 Trial Data Published via @Alzforum https://www.alzforum.org/news/research-news/pimavanserin-phase-2-trial-data-published",,@alzforum,,967430365244809218,https://twitter.com/TheADDF/status/967430365244809218
2018-02-24 00:22:41,i_zekel,,0,0,0,"Pimavanserin Phase 2 Trial Data Published",,,,967193027532947460,https://twitter.com/i_zekel/status/967193027532947460
2018-02-23 02:31:11,ATP_CME,,0,0,0,"Top story: Pimavanserin May Hold Promise for Alzheimer's Psychosis https://www.medscape.com/viewarticle/892876?src=soc_tw_180222_mscpedt_news_mdscp_alzheimers&amp;faf=1, see more http://tweetedtimes.com/ATP_CME?s=tnp",,,,966862975163404294,https://twitter.com/ATP_CME/status/966862975163404294
2018-02-22 09:34:27,Spanishcountry,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis https://www.medscape.com/viewarticle/892876?src=wnl_edit_tpal&amp;uac=236010BZ?src=soc_tw_share via @medscape",,@Medscape,,966607106664206336,https://twitter.com/Spanishcountry/status/966607106664206336
2018-02-21 23:36:32,angelnieto_,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis http://dlvr.it/QHJlcg",,,,966456634137440256,https://twitter.com/angelnieto_/status/966456634137440256
2018-02-21 18:50:22,TheADDF,,0,1,6,"Pimavanserin May Hold Promise for Alzheimer's Psychosis via @medscape https://www.medscape.com/viewarticle/892876",,@Medscape,,966384620781625344,https://twitter.com/TheADDF/status/966384620781625344
2018-02-21 11:29:07,jason_peck,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis http://www.medscape.com/viewarticle/892876?src=medscapeapp-android&amp;ref=carouselarticle?src=soc_tw_share via @medscape",,@Medscape,,966273576675528705,https://twitter.com/jason_peck/status/966273576675528705
2018-02-21 01:32:39,lanina881,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis http://dlvr.it/QH9Y4x",,,,966123470777073664,https://twitter.com/lanina881/status/966123470777073664
2018-02-21 00:02:39,JamesPratty,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422%2818%2930039-5.pdf#.Woy3CybPPCM.twitter",,,,966100818465189888,https://twitter.com/JamesPratty/status/966100818465189888
2018-02-20 21:13:04,doctorsaad,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis http://dlvr.it/QH8JLY",,,,966058141598167040,https://twitter.com/doctorsaad/status/966058141598167040
2018-02-20 20:55:06,aghoury79,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis http://wb.md/2CA0NPr",,,,966053620805447681,https://twitter.com/aghoury79/status/966053620805447681
2018-02-20 20:51:58,usmolecular,,0,0,0,"Pimavanserin May Hold Promise for Alzheimer's Psychosis https://goo.gl/fb/qanAng",,,,966052832972607488,https://twitter.com/usmolecular/status/966052832972607488
2018-02-20 17:30:01,Innov_Clin_Neur,,0,0,0,"Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis http://bit.ly/2nOzQSS",,,,966002011769483265,https://twitter.com/Innov_Clin_Neur/status/966002011769483265
2018-02-19 20:57:07,HeidiiHarley,,0,0,0,"Antipsychotic drugs relieve Alzheimer's symptoms, study shows http://ift.tt/2ENsNEE A new antipsychotic drug has been found to relieve frightening symptoms suffered by millions of people with Alzheimer's disease. According to new research, pimavanserin significantly improve…",,,,965691740278738945,https://twitter.com/HeidiiHarley/status/965691740278738945
2018-02-19 20:56:20,HeidiiHarley,,0,0,0,"A new antipsychotic drug has been found to relieve frightening symptoms suffered by millions of people with Alzheimer's disease. According to new research, pimavanserin significantly improves psychosis symptoms in sufferers of the condition, without the unpleasant side-effe… ",,,,965691543309967363,https://twitter.com/HeidiiHarley/status/965691543309967363
2018-02-19 20:15:48,drugnewsin,,0,0,0,"Pimavanserin may Treat Psychosis in Patients With Alzheimers Disease - https://www.drugnews.in/2018/02/19/pimavanserin-may-treat-psychosis-in-patients-with-alzheimer%c2%92s-disease/",,,,965681342863302656,https://twitter.com/drugnewsin/status/965681342863302656
2018-02-19 18:19:03,AnneCauvin,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects https://buff.ly/2Epr3Oo #Dementia #UnitedAgainstDementia @ScienceDaily",,@ScienceDaily,#Dementia #UnitedAgainstDementia,965651964343222274,https://twitter.com/AnneCauvin/status/965651964343222274
2018-02-19 15:55:09,zenbrainest,,0,1,5,"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis:effect at 6 but not 12 weeks.... https://www.ncbi.nlm.nih.gov/pubmed/29452684",,,,965615747492794370,https://twitter.com/zenbrainest/status/965615747492794370
2018-02-19 13:16:53,BrainBoxNic,,0,0,0,"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, rand... - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/29452684",,,,965575920487686145,https://twitter.com/BrainBoxNic/status/965575920487686145
2018-02-19 12:29:02,Medindia,,0,0,0,"Pimavanserin may Treat Psychosis in Patients With Alzheimer’s Disease http://www.medindia.net/news/healthwatch/pimavanserin-may-treat-psychosis-in-patients-with-alzheimers-disease-177123-1.htm",,,,965563876723933184,https://twitter.com/Medindia/status/965563876723933184
2018-02-19 10:12:03,CindyBirck,,0,0,0,"Researchers published data from Phase 2 study investigating the safety, tolerability, and efficacy of pimavanserin in participants with Alzheimer's disease psychosis http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2818%2930039-5/fulltext#.WoqioLxdNoY.twitter",,,,965529406763667457,https://twitter.com/CindyBirck/status/965529406763667457
2018-02-18 23:45:01,wjdeardorff,,1,0,1,"Phase 2 data for pimavanserin in #Alzheimer's disease psychosis (MMSE ~10). Small likely not clinically meaningful benefit at wk 6 but not wk 12. Not much benefit on secondary outcomes. Not sure why placebo got worse at wk 6. http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422(18)30039-5.pdf",,,#Alzheimer,965371609069613057,https://twitter.com/wjdeardorff/status/965371609069613057
2018-02-18 13:11:21,MedPipeline,,0,0,0,"Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis - http://Drugs.com MedNews",,,,965212137865056261,https://twitter.com/MedPipeline/status/965212137865056261
2018-02-17 04:05:14,medicalnewser,,0,0,0,"Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis - http://www.medicalnewser.com/2018/02/17/pimavanserin-might-be-safer-alternative-to-ease-dementia-psychosis.html\",,,,964712316481757184,https://twitter.com/medicalnewser/status/964712316481757184
2018-02-17 00:48:53,socialworkCOM,,0,0,0,"New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the devastating side effe... http://ow.ly/HrUX50gwLRX",,,,964662903847735297,https://twitter.com/socialworkCOM/status/964662903847735297
2018-02-17 00:33:04,DrHubaEvaluator,,0,0,1,"PsychCentral: New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the devasta... ",,,,964658921595068417,https://twitter.com/DrHubaEvaluator/status/964658921595068417
2018-02-17 00:04:07,panicstoppers,,0,0,0,"New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the devastating side effe... http://ow.ly/CoTm50gwFhg",,,,964651639503192065,https://twitter.com/panicstoppers/status/964651639503192065
2018-02-16 18:15:58,mentalwellmru,,0,0,0,"New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the devastating side effe... http://ow.ly/TSxO50gws34",,,,964564021520359424,https://twitter.com/mentalwellmru/status/964564021520359424
2018-02-16 16:51:30,AtlantaHypnosis,,0,0,1,"Enjoy this tweet, then check out my Atlanta hypnosis site: http://ift.tt/28TgdBD New Antipsychotic May Relieve Psychosis in Dementia Patients A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis i… ",,,,964542767644004353,https://twitter.com/AtlantaHypnosis/status/964542767644004353
2018-02-16 15:30:36,lindamusakwa,,0,0,0,"New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the devastating side effe... http://ow.ly/h0iJ50gwlzO",,,,964522405279469568,https://twitter.com/lindamusakwa/status/964522405279469568
2018-02-16 15:23:00,hautahbuhgee,,0,0,0,"Pimavanserin: Relief from Psychosis in Dementia, Without Devastating Side-Effects - Science &amp; Technology Research News https://apple.news/AT-LMcPxdQtiKhZxwyCUtvg",,,,964520493582761985,https://twitter.com/hautahbuhgee/status/964520493582761985
2018-02-16 15:00:50,thementalcloud,,0,0,1,"#mentalhealth #news #mentalillness #mental New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’... http://ow.ly/KGo250gwkwk",,,#mentalhealth #news #mentalillness #mental,964514916450304000,https://twitter.com/thementalcloud/status/964514916450304000
2018-02-16 14:30:35,nyctherapy,,0,0,0,"#psychology #news New Antipsychotic May Relieve Psychosis in Dementia Patients - A new atypical antipsychotic, known as pimavanserin (Nuplazid), has been shown to help relieve the terrifying symptoms of psychosis in Alzheimer’s disease without the dev... http://ow.ly/hesk50gwjqX",,,#psychology #news,964507304891740161,https://twitter.com/nyctherapy/status/964507304891740161
2018-02-16 14:28:02,scitechresnews,,0,0,0,"Pimavanserin: Relief from Psychosis in Dementia, Without Devastating Side-Effects http://www.scienceandtechnologyresearchnews.com/pimavanserin-relief-psychosis-dementia-without-devastating-side-effects/",,,,964506661141565440,https://twitter.com/scitechresnews/status/964506661141565440
2018-02-16 12:56:06,DrNeelamKrBohra,silverinnings,0,0,3,"It looks promisi Published in the Lancet Neurology, the trial of pimavanserin offers particular hope to those with advanced psychosis, which doctors often describe as the most distressing symptom of Alzheimer’s. Currently people with dementia rely on mainstream antipsychotic",,,,964483526757437441,https://twitter.com/DrNeelamKrBohra/status/964483526757437441
2018-02-16 11:07:25,HeidiiHarley,,0,0,0,"A new antipsychotic drug has been found to relieve frightening symptoms suffered by millions of people with Alzheimer's disease. According to new research, pimavanserin significantly improves psychosis symptoms in sufferers of the condition, without the unpleasant side-effe… ",,,,964456175239680000,https://twitter.com/HeidiiHarley/status/964456175239680000
2018-02-16 11:07:19,HeidiiHarley,,0,0,0,"Antipsychotic drugs relieve Alzheimer's symptoms, study shows http://ift.tt/2ENsNEE A new antipsychotic drug has been found to relieve frightening symptoms suffered by millions of people with Alzheimer's disease. According to new research, pimavanserin significantly improve…",,,,964456149314605057,https://twitter.com/HeidiiHarley/status/964456149314605057
2018-02-16 06:20:37,mattotcha,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects | EurekAlert! Science News http://bit.ly/2EHwITj",,,,964384001333936129,https://twitter.com/mattotcha/status/964384001333936129
2018-02-15 18:45:45,BeDiseaseAware,,0,0,0,"Pimavanzserin Cuts Alzheimer’s Psychosis at Six Weeks - Significantly greater reduction in NPI-NH psychosis score at 6 weeks versus placebo, but not at 12 weeks THURSDAY, Feb. 15, 2018 (HealthDay News) — Pimavanserin is efficacious at six weeks for pa... http://ow.ly/P6GD50gvDyu",,,,964209131950309377,https://twitter.com/BeDiseaseAware/status/964209131950309377
2018-02-15 17:04:56,CEADWNY,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects: A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer's disease worldwide https://www.sciencedaily.com/releases/2018/02/180213183620.htm",,,,964183757828784128,https://twitter.com/CEADWNY/status/964183757828784128
2018-02-15 16:57:11,igncioruiz,,0,1,3,"New Alzheimer's drug Pimavanserin (Nuplazid) offers hope for end to 'terrifying' psychosis affecting half of all patients http://www.telegraph.co.uk/science/2018/02/13/new-alzheimers-drug-offers-hope-end-terrifying-psychosis-affecting/?WT.mc_id=tmg_share_tw vía @TelegraphSci",,@TelegraphSci,,964181809687924739,https://twitter.com/igncioruiz/status/964181809687924739
2018-02-15 16:55:28,gladeolie,,0,0,0,"Pimavanserin is new drug that controls symptoms of Alzheimer's disease psychosis ",,,,964181378278608896,https://twitter.com/gladeolie/status/964181378278608896
2018-02-15 16:12:07,NewScientistZon,,0,0,0,"New Alzheimer's drug, pimavanserin, significantly improve psychosis symptoms without the normal... https://goo.gl/dNcQ8K",,,,964170465362239488,https://twitter.com/NewScientistZon/status/964170465362239488
2018-02-15 15:53:25,SimpleStepsMobi,,0,0,0,"RT @LEAD_Coalition: Study: #Pimavanserin significantly improves #psychosis symptoms in people with severe #dementia, without the detrimental side effects of currently used #antipsychotics: https://medicine.exeter.ac.uk/news/articles/pimavanserinrelieffrompsy.html MT @Clive_Ballard #neuroscience #dement…",,@LEAD_Coalition @Clive_Ballard,#Pimavanserin #psychosis #dementia #antipsychotics #neuroscience #dement,964165762347945985,https://twitter.com/SimpleStepsMobi/status/964165762347945985
2018-02-15 15:46:00,LEAD_Coalition,,1,6,9,"Study: #Pimavanserin significantly improves #psychosis symptoms in people with severe #dementia, without the detrimental side effects of currently used #antipsychotics: https://medicine.exeter.ac.uk/news/articles/pimavanserinrelieffrompsy.html MT @Clive_Ballard #neuroscience #dementia #caregiving",,@Clive_Ballard,#Pimavanserin #psychosis #dementia #antipsychotics #neuroscience #dementia #caregiving,964163895651983362,https://twitter.com/LEAD_Coalition/status/964163895651983362
2018-02-15 15:45:08,UofE_Research,,0,0,2,"RT @ExeterMed: Research led by our world-leadng #dementia expert, Prof @Clive_Ballard, is getting fantastic coverage in the @Telegraph: #Pimavanserin offers new hope for #AlzheimersDisease #Psychosis: http://bit.ly/2sqHYyA #ExeterDementia",,@ExeterMed @Clive_Ballard @Telegraph,#dementia #Pimavanserin #AlzheimersDisease #Psychosis #ExeterDementia,964163675249618944,https://twitter.com/UofE_Research/status/964163675249618944
2018-02-15 15:20:30,TheADDF,,0,7,20,"Researchers report encouraging results from trial of pimavanserin for #dementia psychosis. Though this drug won't slow disease progression, it could significantly improve quality of life for patients and their caregivers. http://wb.md/2o0vY1P from @WebMD",,@WebMD,#dementia,964157479037931520,https://twitter.com/TheADDF/status/964157479037931520
2018-02-15 11:43:08,medicaldialogs,,0,0,0,"Pimavanserin is new drug that controls symptoms of Alzheimer's disease psychosis https://speciality.medicaldialogues.in/pimavanserin-is-new-drug-that-controls-symptoms-of-alzheimers-disease-psychosis/",,,,964102777050992641,https://twitter.com/medicaldialogs/status/964102777050992641
2018-02-15 11:15:18,tomhathaway01,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects: A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer's disease worldwide https://www.sciencedaily.com/releases/2018/02/180213183620.htm",,,,964095771065896960,https://twitter.com/tomhathaway01/status/964095771065896960
2018-02-15 09:35:04,UofE_Research,,0,0,1,"RT @clive_ballard: Our @TheLancetNeuro paper found #pimavanserin significantly improves #psychosis symptoms in ppl w/ severe #dementia, without the detrimental side effects of currently used #antipsychotics: http://bit.ly/2EHpfUg #ExeterDementia #DementiaResearch",,@Clive_Ballard @TheLancetNeuro,#pimavanserin #psychosis #dementia #antipsychotics #ExeterDementia #DementiaResearch,964070548539133954,https://twitter.com/UofE_Research/status/964070548539133954
2018-02-15 09:15:00,AgeUKexeter,,0,0,0,"Relief from psychosis in dementia, without devastating side-effects. New research led by the @uniofexeter Medical School, and published in @TheLancetNeuro found that Pimavanserin significantly improves psychosis symptoms in people with the condition http://www.exeter.ac.uk/news/featurednews/title_639602_en.html#.WoVOnTzbjqk.twitter",,@UniofExeter @TheLancetNeuro,,964065496227368961,https://twitter.com/AgeUKexeter/status/964065496227368961
2018-02-15 03:46:03,123buttons,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://dlvr.it/QGQ4Cv",,,,963982715241472000,https://twitter.com/123buttons/status/963982715241472000
2018-02-15 00:00:05,HaeGarciaDDS,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://dlvr.it/QGPCnp",,,,963925848997822464,https://twitter.com/HaeGarciaDDS/status/963925848997822464
2018-02-14 21:59:45,MedPipeline,,0,0,0,"Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis - http://Drugs.com MedNews",,,,963895562889191425,https://twitter.com/MedPipeline/status/963895562889191425
2018-02-14 21:51:46,mazlat10,,0,0,0,"Pimavanserin significantly improves psychosis symptoms | ACAD Message Board Posts ",,,,963893553150734336,https://twitter.com/mazlat10/status/963893553150734336
2018-02-14 21:48:33,ZekHealth,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects",,,,963892747441549318,https://twitter.com/ZekHealth/status/963892747441549318
2018-02-14 21:48:32,zekelhealthcare,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects",,,,963892743566082048,https://twitter.com/zekelhealthcare/status/963892743566082048
2018-02-14 21:37:09,paragpaleja,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://dlvr.it/QGNVrB",,,,963889875492597760,https://twitter.com/paragpaleja/status/963889875492597760
2018-02-14 21:30:51,GymRewards,,0,0,0,"http://GYMRewards.io News: Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://ift.tt/2BrVDbr http://ift.tt/eA8V8J",,,,963888290926678018,https://twitter.com/GymRewards/status/963888290926678018
2018-02-14 21:26:03,JDTekEngRecruit,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://dlvr.it/QGNS2P",,,,963887085256978432,https://twitter.com/JDTekEngRecruit/status/963887085256978432
2018-02-14 21:06:06,Myway500,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects - http://goo.gl/alerts/nZ5r4 #GoogleAlerts",,,#GoogleAlerts,963882060942159872,https://twitter.com/Myway500/status/963882060942159872
2018-02-14 20:58:00,Innov_Clin_Neur,,0,0,0,"Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis http://bit.ly/2nOzQSS",,,,963880024519540736,https://twitter.com/Innov_Clin_Neur/status/963880024519540736
2018-02-14 20:55:04,4rxcard,,0,0,0,"Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis http://dlvr.it/QGNFSB",,,,963879284577255424,https://twitter.com/4rxcard/status/963879284577255424
2018-02-14 20:43:39,drugnewsin,,0,0,0,"Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis - http://www.drugnews.in/2018/02/14/pimavanserin-might-be-safer-alternative-to-ease-dementia-psychosis/",,,,963876412351565825,https://twitter.com/drugnewsin/status/963876412351565825
2018-02-14 19:51:32,Drugscom,,0,0,1,"#Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis - ",,,#Pimavanserin,963863298881015808,https://twitter.com/Drugscom/status/963863298881015808
2018-02-14 19:34:25,adamfeuerstein,jrkl88,0,0,0,"The $ACAD pimavanserin study being discussed is in Alzheimer’s related psychosis — an unapproved indication for the drug. Please, keep up.",,,,963858988139008001,https://twitter.com/adamfeuerstein/status/963858988139008001
2018-02-14 19:08:07,raj_psyc,,0,0,0,"Promising placebo-controlled, double-blind RCT of safety, tolerability, & efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2818%2930039-5/fulltext?elsca1=etoc#.WoSI2P8z-zZ.twitter",,,,963852372765224961,https://twitter.com/raj_psyc/status/963852372765224961
2018-02-14 16:38:00,gpjgijzen,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects https://medicalxpress.com/news/2018-02-pimavanserin-relief-psychosis-dementia-devastating.html via @medical_xpress",,@medical_xpress,,963814591657594881,https://twitter.com/gpjgijzen/status/963814591657594881
2018-02-14 15:54:09,WompotoWill,,0,0,0,"New Alzheimer's drug, pimavanserin, significantly improve psychosis symptoms without the normal side-effects. http://ift.tt/2Es3DYr",,,,963803558591246336,https://twitter.com/WompotoWill/status/963803558591246336
2018-02-14 15:30:02,westlondonnhs,,0,0,0,"A promising study published in @TheLancetNeuro says that antipsychotic drug pimavanserin significantly improves #psychosis symptoms for those with #Alzheimer's without any damaging side effects.",,@TheLancetNeuro,#psychosis #Alzheimer,963797487571025920,https://twitter.com/westlondonnhs/status/963797487571025920
2018-02-14 15:04:24,JRBneuropsiq,,0,0,2,"Pimavanserin for patients with Alzheimer's disease psychosis http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30052-8/fulltext?elsca1=etoc",,,,963791037419241475,https://twitter.com/JRBneuropsiq/status/963791037419241475
2018-02-14 14:31:12,ExeterMed,,0,11,8,"Research led by our world-leadng #dementia expert, Prof @Clive_Ballard, is getting fantastic coverage in the @Telegraph: #Pimavanserin offers new hope for #AlzheimersDisease #Psychosis: http://bit.ly/2sqHYyA #ExeterDementia",,@Clive_Ballard @Telegraph,#dementia #Pimavanserin #AlzheimersDisease #Psychosis #ExeterDementia,963782683410214912,https://twitter.com/ExeterMed/status/963782683410214912
2018-02-14 13:16:23,DrK_W1984,,1,0,2,"The Antipsychotic Pimavanserin shows promise in #Dementia, for its tolerability. http://bit.ly/2o69HiC",,,#Dementia,963763854634254343,https://twitter.com/DrK_W1984/status/963763854634254343
2018-02-14 12:59:04,JordiSM_,,0,1,1,"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2818%2930039-5/fulltext?elsca1=etoc#.WoQylsbESX4.twitter",,,,963759495330574337,https://twitter.com/JordiSM_/status/963759495330574337
2018-02-14 12:46:37,adamfeuerstein,bio_clouseau,6,3,7,". @LonSchneiderMD says pimavanserin sucks. $ACAD",,@LonSchneiderMD,,963756365100605440,https://twitter.com/adamfeuerstein/status/963756365100605440
2018-02-14 12:45:12,FCC_UK,,0,0,0,"New Alzheimer's drug pimavanserin may prevent hallucinations and paranoia for many living with the condition #Dementia #AlzheimersResearch #SocialCare http://ow.ly/xmaN30iomiP",,,#Dementia #AlzheimersResearch #SocialCare,963756009276739584,https://twitter.com/FCC_UK/status/963756009276739584
2018-02-14 12:31:23,LonSchneiderMD,,2,0,3,"Disappointing views follow disappointing outcomes. Pimavanserin with no effect whatsoever on any outcome in 2/3s of the sample. Then only...",,,,963752529640095744,https://twitter.com/LonSchneiderMD/status/963752529640095744
2018-02-14 11:23:36,KieranWalshMPSI,TheLancetNeuro,0,0,1,"Pimavanserin, an atypical antipsychotic, showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition. Promising phase 2 results but larger scale RCT required ",,,,963735471049322496,https://twitter.com/KieranWalshMPSI/status/963735471049322496
2018-02-14 11:16:21,medicaleur,,0,0,0,"Mixed Results with PD Drug in Alzheimer's Psychosis (CME/CE): (MedPage Today) -- Six-week improvement with pimavanserin didn't endure at 12 weeks https://goo.gl/z4WEqU",,,,963733645323395073,https://twitter.com/medicaleur/status/963733645323395073
2018-02-14 11:16:20,rxeur,,0,0,0,"Mixed Results with PD Drug in Alzheimer's Psychosis (CME/CE): (MedPage Today) -- Six-week improvement with pimavanserin didn't endure at 12 weeks https://goo.gl/z4WEqU",,,,963733645189107713,https://twitter.com/rxeur/status/963733645189107713
2018-02-14 10:52:56,portefeuillefun,,0,1,1,"Comment - #Pimavanserin for patients with Alzheimer's disease psychosis http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30052-8/fulltext. $ACAD #AD",,,#Pimavanserin #AD,963727752632373248,https://twitter.com/portefeuillefun/status/963727752632373248
2018-02-14 10:51:14,portefeuillefun,,0,1,2,"Evaluation of the safety, tolerability, and efficacy of #pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30039-5/fulltext. $ACAD",,,#pimavanserin,963727327057338369,https://twitter.com/portefeuillefun/status/963727327057338369
2018-02-14 09:25:57,Clive_Ballard,,1,11,21,"Our @TheLancetNeuro paper found #pimavanserin significantly improves #psychosis symptoms in ppl w/ severe #dementia, without the detrimental side effects of currently used #antipsychotics: http://bit.ly/2EHpfUg #ExeterDementia #DementiaResearch",,@TheLancetNeuro,#pimavanserin #psychosis #dementia #antipsychotics #ExeterDementia #DementiaResearch,963705863679741952,https://twitter.com/Clive_Ballard/status/963705863679741952
2018-02-14 09:03:06,returnofserve,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects http://dlvr.it/QGHdgH",,,,963700114849087488,https://twitter.com/returnofserve/status/963700114849087488
2018-02-14 08:50:50,byron_creese,,0,0,2,"#pimavanserin for #psychosis in AD: particularly important as these symptoms appear to be less amenable to treatment with psychosocial interventions. https://twitter.com/clive_ballard/status/963689168953069570",,,#pimavanserin #psychosis,963697028948791297,https://twitter.com/byron_creese/status/963697028948791297
2018-02-14 07:45:36,ThePodcastRadio,,0,0,0,"http://www.sino.uk Alzheimer's drug reduces psychosis symptoms without side effects - Pimavanserin is an antipsychotic which alleviates symptoms such as paranoia or delusions and works by blocking a very specific nerve receptor in the brain.Cruci... http://ow.ly/1LW650gumLi",,,,963680612157714432,https://twitter.com/ThePodcastRadio/status/963680612157714432
2018-02-14 07:02:26,PatsCSW,SkyNews,0,0,0,"""Pimavanserin is an antipsychotic which alleviates symptoms such as paranoia or delusions and works by blocking a very specific nerve receptor in the brain. Crucially it does not produce the side effects ..."" ",,,,963669745273921536,https://twitter.com/PatsCSW/status/963669745273921536
2018-02-14 06:30:52,LNC_MKC,,0,0,0,"Mixed Results with PD Drug in Alzheimer's Psychosis (CME/CE) - (MedPage Today) -- Six-week improvement with pimavanserin didn't endure at 12 weeks http://ow.ly/klJp50gukIx",,,,963661802637799424,https://twitter.com/LNC_MKC/status/963661802637799424
2018-02-14 05:47:19,wearegorgeousfm,,0,0,0,"A new drug has been found to relieve some of the worst symptoms of Alzheimer's disease. Pimavanserin is an... https://fb.me/Vhio94bC",,,,963650844825653249,https://twitter.com/wearegorgeousfm/status/963650844825653249
2018-02-14 05:46:18,wi_john,,0,0,1,"pimavanserin offers particular hope to those with advanced psychosis, which doctors often describe as the most distressing symptom of Alzheimer’s. http://www.telegraph.co.uk/science/2018/02/13/new-alzheimers-drug-offers-hope-end-terrifying-psychosis-affecting/?WT.mc_id=tmg_share_tw via @TelegraphSci",,@TelegraphSci,,963650585886158849,https://twitter.com/wi_john/status/963650585886158849
2018-02-14 02:50:49,PabloOk47,,0,0,0,"Pimavanserin: Relief from psychosis in dementia, without devastating side-effects https://medicalxpress.com/news/2018-02-pimavanserin-relief-psychosis-dementia-devastating.html via @medical_xpress",,@medical_xpress,,963606424310792192,https://twitter.com/PabloOk47/status/963606424310792192
2018-02-14 01:30:39,DaytimeNews,,0,0,0,"Drug used for psychosis victims could be used for dementia - Researchers from Exeter University believe the new drug Pimavanserin could be offered to half of the 850,000 patients with dementia in the UK. http://ow.ly/ydml50guetg",,,,963586249884880903,https://twitter.com/DaytimeNews/status/963586249884880903
2018-02-14 01:00:46,HarrysExeter,,0,0,0,"News from @UniofExeter : Pimavanserin: relief from psychosis in dementia, without devastating side-effects - A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer’s disea... http://ow.ly/89O250gue28",,@UniofExeter,,963578729799864320,https://twitter.com/HarrysExeter/status/963578729799864320
2018-02-14 00:48:27,UXHealth,,0,0,0,".@medpagetoday Mixed Results with PD Drug in Alzheimer's Psychosis (CME/CE) - (MedPage Today) -- Six-week improvement with pimavanserin didn't endure at 12 weeks http://ow.ly/o1ne50gudqQ",,@medpagetoday,,963575632264355842,https://twitter.com/UXHealth/status/963575632264355842
2018-02-14 00:22:43,visitor_z,,0,0,0,"#Pimavanserin : #Relief from #psychosis in #dementia , without devastating side-effects http://bit.ly/2sxs7hM",,,#Pimavanserin #Relief #psychosis #dementia,963569155311009792,https://twitter.com/visitor_z/status/963569155311009792
